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ABSTRACT 
 
Staphylococcus aureus is a commensal and pathogen of humans and other 
animals. Disease with S. aureus is complicated by dissemination of antimicrobial 
resistance, including methicillin resistance. Methicillin resistant S. aureus (MRSA) is a 
significant burden on the health care industry (HA-MRSA); however, in recent years, 
public health concern has arisen from isolates harbored in the community (CA-MRSA) 
and livestock species (LA-MRSA). Concerns with LA-MRSA isolates are the direct 
impact of infection with livestock isolates and indirect impacts of genetic transfer of 
virulence or antimicrobial resistance genes from LA-MRSA isolates. The prototypical 
LA-MRSA strain, sequence type (ST) 398, is considered less virulent than HA- and CA-
MRSA isolates. Reduced virulence of LA-MRSA ST398 isolates is attributed to loss of 
human specific virulence factors and reduced colonization and transmission in humans. 
While LA-MRSA ST398 isolates are common in European swine, LA-MRSA isolates in 
the United States are diverse including ST398, ST9, and ST5. LA-MRSA ST5 elevated 
public health concerns, because, unlike MRSA ST398 and ST9, MRSA ST5 is a globally 
disseminated and highly pathogenic lineage.  
To better understand direct and indirect impact of swine associated LA-MRSA 
ST5, this thesis investigated the genetics of swine associated and clinical MRSA ST5 
isolates. Phylogenetic analysis revealed LA-MRSA ST5 isolates are genetically distinct 
from clinical MRSA ST5 isolates, which was confirmed by differences in virulence and 
antimicrobial resistance genes harbored on mobile genetic elements. LA-MRSA ST5 
isolates lacked immune evasion genes harbored by the β-hemolysin converting 
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bacteriophage and resistance genes differed between swine associated and clinical MRSA 
ST5 isolates, which indicated genetic exchange was unlikely between the screened 
populations. Resistance genes were consistent with selective pressures from antimicrobial 
use in the swine industry and hospital environment. Finally, swine associated and clinical 
MRSA ST5 isolates adhered equivalently to human keratinocytes, although LA-MRSA 
ST5 isolates lacked virulence factors contributing to colonization. These results indicate 
the isolates screened were distinct with no evidence of mobile genetic element transfer 
between subsets. The virulence of LA-MRSA ST5 isolates is expected to be reduced as 
compared to clinical MRSA ST5 isolates due to the absence of genes that contribute to 
disease in humans. 
 
1 
 
CHAPTER 1. GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
General Biology of Staphylococcus aureus 
Staphylococcus aureus is a Gram positive, facultative anaerobe that grows in 
clusters of coccoid shaped cells. It has been characteristically thought of as non-motile; 
however, a form of spreading motility was recently reported that involves production of 
dendrites that enable movement of cells from the primary colony [1]. Though S. aureus is 
non-spore forming, it is highly resistant to various environmental conditions. It is able to 
grow at a wide range of temperatures, from 7.0-48.5°C with an optimum growth 
temperature of 30-37°C [2]. S. aureus is also tolerant of osmotic stress and highly salt 
resistant, as it can withstand salt at concentrations of 15% NaCl and readily grows at 
concentrations up to 10% NaCl [3]. Additionally, it is tolerant to a pH range of 4.2-9.3, 
with an optimum pH of 7.0-7.5 [4]. These characteristics allow S. aureus to grow in a 
variety of substrates, including various food products and epidermal tissue. 
Isolates grow readily on standard laboratory media such as trypticase soy agar and 
blood agar plates. The colonies are smooth, raised, and translucent [5]. They have a 
cream to golden color due to the production of staphyloxanthin, a carotenoid pigment that 
functions in the detoxification of reactive oxygen species [6]. Isolates typically show 
beta-hemolysis on blood agar plates, which is associated with the production of one of 
four hemolysins: alpha (α), beta (β), delta (δ), or gamma (γ) [7]. In addition to 
physiological traits, S. aureus is identified using biochemical tests. Staphylococcus 
species are differentiated from Streptococcus and Micrococcus species using catalase and 
oxidase testing, in which Staphylococcus species are positive and negative, respectively 
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[8]. The coagulase test is further used to differentiate S. aureus from other 
Staphylococcus species, also termed coagulase-negative Staphylococci [5]; however, not 
all S. aureus isolates are coagulase positive [8].  
S. aureus Classification and Genetics 
Isolates of S. aureus are classified in a variety of ways including restriction 
fragment length polymorphisms (RFLP), multi-locus sequence typing (MLST), and spa 
typing. RFLP uses digestion with a selected restriction enzyme, typically SmaI in S. 
aureus, and pulse field gel electrophoresis (PFGE) to resolve a RFLP pattern [9]. This 
pattern can be compared between isolates to determine similarity and understand the 
epidemiology of a disease outbreak; however, it is not as sensitive or specific in 
determining isolate relatedness as genome sequencing techniques.  
MLST and spa typing are genetic mechanisms of classification. MLST is used to 
classify S. aureus into sequence types and clonal complexes. Sequence types (STs) are 
defined by sequencing and denoting the specific allele for seven housekeeping genes: 
carbamate kinase (arcC), shikimate dehydrogenase (aroE), glycerol kinase (glp), 
guanylate kinase (gmk), phosphate acetyltransferase (pta), triosephosphate isomerase 
(tpi), and acetyl coenzyme A acetyltransferase (yqiL) [10]. The specific combination of 
alleles is compared to the MLST database and used to assign a ST to the isolate. Clonal 
complexes (CCs) are composed of isolates with a specific ST along with STs that harbor 
at least 5 of 7 matching alleles and are used to group similar STs [11]. Additionally, 
lineages defined by a ST or CC generally possess similar characteristics, some of which 
contribute to the success of these lineages as commensals and pathogens [12].  
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Another common method to classify S. aureus isolates is spa typing, which 
involves sequencing the short sequence repeat region (SSR or X region) of the protein A 
gene (spa) [13]. This region contains a variable number of 24 bp repeats that accumulate 
diversity through duplication, deletion, and point mutations [14]. This diversity can be 
utilized to define the spa type for the isolate through sequencing of the X region and 
comparison to the database of identified spa types. The spa type of an isolate often 
correlates with a specific ST; however, defining MLST based on spa types can be 
difficult [15-17]. The classifications described here are often used in epidemiologic 
investigations to determine the relatedness of isolates and detect an isolate’s source.  
S. aureus is taxonomically classified within the phylum Firmicutes, the class 
Cocci, the order Bacillales, and the family Staphylococcaceae. Similar to other members 
of the Firmicutes phylum, S. aureus contains a genome with a low G+C content, which 
ranged from 32.7-32.9% in 16 evaluated S. aureus isolates with closed genomes [18]. 
The S. aureus genome size in the evaluated isolates ranged from 2,742,531 bp to 
2,937,129 bp [18]; however, many S. aureus isolates carry a diverse array of plasmids 
that harbor virulence factors and/or antimicrobial resistance genes that impact genome 
size [19].  
The genome of S. aureus can be divided into three segments: the core genome, 
core variable genes, and mobile genetic elements (MGEs) [20-22]. The core genome is 
highly conserved among all isolates; however, minor variability occurs as single 
nucleotide polymorphisms (SNPs) that arise from mutations. The core variable genes are 
lineage associated and will vary between different STs and CCs. Core variable genes with 
known functions include primarily surface proteins and their associated regulatory genes 
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[21]. MGEs are the most variable portion of the S. aureus genome and comprise around 
25% of all genetic material in S. aureus isolates [23, 24]. MGEs enable the transfer of 
fragments of DNA between cells or from the surrounding environment through horizontal 
gene transfer (HGT).  
HGT mechanisms employed by S. aureus include transformation, transduction, 
and conjugation. Transformation occurs in naturally competent bacteria that possess the 
machinery involved in the uptake of free DNA from the surrounding environment [25]. 
Transformation is a less common form of HGT in S. aureus due to a low level of natural 
competency that requires induction [26, 27]. Transduction involves bacteriophage 
mediated transfer of DNA between cells [28]. Bacteriophages can encode virulence 
genes, such as the immune evasion genes harbored on the β-hemolysin converting 
bacteriophage [29], and become integrated into the bacterial chromosome as a component 
of the prophage during the lysogenic cycle [28]. They can also transmit bacterial genetic 
material from the host cell through generalized transduction, where host genetic material 
is packaged into the phage capsid rather than the phage genome [28]. Finally, conjugation 
is the transfer of genetic material from one bacterial cell to another through cellular 
contact and is the predominant mechanism by which plasmids are transferred [28]. 
Plasmids are common in S. aureus and are known to harbor antimicrobial resistance 
genes, genes involved in metabolic pathways, and virulence genes including toxins [30-
32] 
A multitude of MGEs are found in S. aureus. These include plasmids, insertion 
sequences, transposons, pathogenicity islands, genomic islands, chromosomal cassettes, 
and bacteriophages. These elements often encode virulence genes or antimicrobial 
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resistance genes that contribute to the success of S. aureus in specific environments [24, 
30]; however, they are not without cost and isolates tend to exhibit a reduced fitness 
when selection pressures for MGE maintenance are not present [33-35]. While MGEs are 
generally widespread in S. aureus, it seems some MGEs have strain specificity and are 
restricted to specific STs or CCs, which is thought to contribute to the success of the 
lineage [20, 24, 36, 37]. The acquisition of MGEs plays an important role in the evolution 
of bacteria through large and rapid changes in genomic content that provide a greater 
degree of genome plasticity and a better chance of improved fitness and organism 
survival than chromosomal mutation alone [38, 39]. More specifically, for S. aureus they 
have enabled adaptation to a variety of host species, encode virulence factors that 
contribute to the wide range of disease associated with S. aureus, and harbor 
antimicrobial resistance genes that complicate treatment of clinical infections with S. 
aureus (see below) [24, 30].  
S. aureus Colonization and Disease 
S. aureus is a commensal bacterium in a wide range of animal species, 
particularly mammals, although it has been isolated from birds and reptiles [40]. Humans 
most commonly carry S. aureus in the nasal cavity and on the skin, especially that of the 
hands and perineum [41]. In the United States, the colonization rate in humans during 
cross sectional studies is around 30% [42, 43]; however, colonization rate varies based on 
age, socioeconomic status, health status, and geographic location [44, 45]. 
Colonization of S. aureus in humans is categorized into non-carriers, intermittent 
carriers, and persistent carriers [46, 47]. Non-carriers are resistant to colonization with S. 
aureus and make up around 50% of the population [41]. Humans defined as intermittent 
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carriers make up about 30% of the population [41]. Intermittent carriers are transiently 
colonized by S. aureus strains they are exposed to [48]. They also tend to have a lower S. 
aureus burden than persistent carriers and consequently shed the bacteria at a lower rate, 
reducing the risk of infection as compared to persistent carriers [49, 50]. Persistent 
carriers comprise around 20% of the population [41].They are consistently colonized with 
the same S. aureus strain and shed the bacteria at a much higher rate [48, 50]. To some 
extent, an individual’s propensity for colonization is intrinsic, with the majority of 
experimentally S. aureus exposed humans returning to their original carrier state or the 
original strain in the case of persistent carriers [51]. 
Although S. aureus is a commensal member of the human nasal microbiome, it 
has become evident that colonization is a major risk factor for clinical infection with S. 
aureus [52, 53]. This has been seen with both community acquired infections and 
hospital acquired infections [54-56]. The diseases associated with S. aureus range from 
mild, localized disease to severe, systemic infections. The majority of S. aureus 
infections are mild skin and soft tissue infections that include styes, impetigo, boils, and 
furunculosis [57, 58]. More severe infections include septicemia, osteomyelitis, 
endocarditis, meningitis, and necrotizing pneumonia [8]. S. aureus also causes toxin 
mediated diseases including toxic shock syndrome, staphylococcal scalded skin 
syndrome, and enterotoxicosis [59-61]. Disease caused by S. aureus tends to be more 
severe in persons with comorbidities, such as chronic infections, traumatic injuries, 
immunosuppression, or indwelling medical devices [8]. This has contributed to the 
prevalence and prominence of S. aureus as a cause of nosocomial infections [62, 63]. The 
estimated burden of S. aureus infections in 2005 was over 400,000 infections requiring 
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hospitalization in the United States which equated to 1.38% of hospitalized patients 
receiving a S. aureus related diagnosis [64]. 
S. aureus Virulence Factors and Pathogenesis 
Diseases associated with S. aureus are caused by a complex and coordinated 
series of events mediated by virulence factors encoded within the S. aureus genome or 
obtained through HGT of MGE. These virulence factors are associated with adherence to 
host tissues, biofilm formation, nutrient acquisition, tissue invasion and destruction, toxin 
production, and evasion of the host immune response. Many virulence factors possess 
multiple functions and could be placed into several of the above categories, such as the 
isd proteins, which contribute to adherence to host tissues but also play a major role in 
iron acquisition [65-68]. The following section outlines major virulence genes that 
contribute to the pathogenesis of S. aureus disease. 
Adhesion to host tissues 
Infection with S. aureus requires bacterial-host interaction that begins with 
adherence. Adherence genes are cell wall anchored proteins that, as a group, are essential 
for interaction with host tissues and function in the early stages of infection [69]. Proteins 
involved in adherence are produced in a coordinated manner and this production is 
influenced by growth conditions and cell density [65, 70]. The regulation of adherence 
genes by cell density is controlled by the agr autoinducer system, such that production of 
adherence genes occurs under low cell densities and is downregulated to allow for 
dispersion at higher cell densities [71-74]. The large degree of functional redundancy in 
adherence genes means the contribution of individual genes to adherence is difficult to 
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discern; however, the individual contribution of genes such as isdA, clfB, sdrC, and sdrD 
to colonization has been elucidated [75-78]. 
The genes associated with adherence in S. aureus can be grouped into four main 
categories: microbial surface component recognizing adhesive matrix molecules 
(MSCRAMM), near iron transporter motif (NEAT motif), three-helical bundle, and G5-E 
repeat family (Table 1.1). MSCRAMMs of S. aureus are defined by a structure 
containing immunoglobulin-like subdomains and domains used in ligand binding [75, 
79]. The primary function of MSCRAMMs is for attachment to components of the 
extracellular matrix (ECM) including fibrinogen, fibronectin, and bone sialoprotein [80]; 
however, many of these genes have additional functions including immune evasion, 
biofilm production, and others [81-84]. The NEAT motif family of proteins bind to 
fibrinogen, fibronectin, cytokeratin 10, GPIIb/IIIa receptor, and haptoglobin [67, 68, 85, 
86]. Outside of their role of adherence, the NEAT motif proteins also function in iron 
uptake through heme transfer and aid in survival in iron depleted environments within the 
host [65, 66]. The adherence factors classified as three-helical bundle proteins are named 
for their structure and contain modules formed by three helical bundles, which function in 
ligand binding [87]. Protein A, the major member of this group, is ubiquitous in S. aureus 
and functions in binding to von Willebrand factor [88]. Protein A also binds to the 
conserved region of the immunoglobulin IgG, which contributes to immune evasion 
through inhibition of phagocytosis and complement fixation [87].  G5-E repeats, the final 
group of S. aureus adhesion genes, is characterized by domains of five glycine residues 
separated by E regions and the main member is sasG [89]. The sasG gene has been 
identified to function in adherence to nasal epithelium and biofilm formation [90, 91] 
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Many additional adherence genes are structurally uncharacterized (Table 1.1). These 
proteins have been associated with a variety of functions including binding to ECM 
components (emp, aaa, eap), platelet interaction (sraP) and biofilm formation (bap, isaB) 
[84, 92-96].  
Table 1.1: Adherence genes in S. aureus. 
Adherence gene Ligand  Reference 
Microbial surface component recognizing adhesive matrix molecules (MSCRAMM) 
clfA and clfB Fibrinogen  [97] 
sdrC β-neurexin  [98] 
sdrD Not yet determined [99] 
sdrE Factor H  [81] 
bbp Bone sialoprotein  [100] 
fnbpA and fnbpB Fibronectin  [101] 
cna Collagen  [102] 
Near iron transport motif (NEAT motif) 
isdA Fibrinogen, fibronectin, cytokeratin 10  [67, 85] 
isdB GPIIb/IIIa (platelet receptor)  [86] 
isdH Haptoglobin  [68] 
Three-helical bundle 
spa Von Willebrand factor, immunoglobulin  [87, 88] 
G5-E repeat 
sasG Not yet determined [91, 103]  
Structurally uncharacterized adherence genes 
sasX Not yet determined [104] 
sraP N-acetylneuramic acid  [95, 105] 
sasC Not yet determined [82] 
sasB, sasD, sasF, sasJ, 
sasK, sasL 
Not yet determined [91] 
bap GP96  [84, 96] 
vwb von willebrand factor [106] 
emp Fibrinogen, fibronectin, collagen, 
vitronectin  
[93] 
isaB Nucleic acid  [107] 
aaa Fibrinogen, fibronectin  [92] 
eap ECM and plasma protein (broad 
specificity) 
[94] 
ebps Elastin  [108] 
ebh Fibronectin  [109] 
efb Fibrinogen  [110] 
eno Laminin  [111] 
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Biofilm formation 
Biofilm formation is an additional, important factor contributing to adherence of 
S. aureus to host tissues and fomites, including medical devices [112]. Biofilm formation 
is a coordinated series of events involving initial attachment, maturation, and later 
dispersal [113]. S. aureus attaches using the protein adhesion molecules described above 
[114, 115]. Maturation of the biofilm occurs through cell aggregation followed by 
structural changes that lead to the formation of a three-dimensional structure [112]. 
Aggregation of S. aureus is predominantly mediated by the ica operon, which encodes 
production of polysaccharide intercellular adhesin (PIA) [116]. Biofilms function in 
adherence and persistence of S. aureus in many environments and have a protective role 
through resistance to desiccation, phagocytosis, antimicrobials, and disinfectants [112]. 
Nutrient acquisition 
Within the host, nutrients such as iron are not readily available and therefore limit 
bacterial growth. Because of the necessity of iron in bacterial proliferation, S. aureus has 
evolved two mechanisms to increase iron availability within the host. The first 
mechanism of iron acquisition is the production of siderophores. S. aureus produces 
staphyloferrin A and B siderophores that remove iron from host transferrin molecules 
[117]. S. aureus also obtains iron using the isd proteins to transport hemoglobin and heme 
across the cell wall [65]. These proteins promote iron acquisition within hosts, which 
allows S. aureus to proliferate and survive within host tissues.  
Invasion and tissue destruction 
Invasion and tissue destruction follow the proliferation of S. aureus during 
infection. The production of exoproteins involved in this stage of infection is regulated by 
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growth phase and cell density, which limits their production until S. aureus has reached 
high cell densities found in late exponential phase [71-74]. Exoproteins produced by S. 
aureus enable invasion of deeper tissues and results in destruction of surrounding tissue 
[118-121]. The enzymes involved in this process are proteases, lipases, and nucleases 
[122-124]. Protease activity is conferred by serine proteases, cysteine proteases, and 
metalloproteases [122], which play a role in tissue damage and dissemination of S. 
aureus [122]. Lipases contribute to abscess formation and the survival and proliferation 
of S. aureus in organs, such as the liver and kidney [123]. Finally, nucleases are 
important in surviving within abscesses and evading neutrophil extracellular traps (NETs) 
[124]. S. aureus is also capable of cellular invasion, which is directed by the adhesion 
genes isdB, fnbpA, and fnbpB [125-128].  
Toxin mediated disease 
S. aureus produces many toxins that are an important component of the disease 
process. These toxins function in cellular cytotoxicity or directly cause clinical signs 
through cell activation or protease activity. The cytolytic toxins cause the release of 
nutrients from host cells, such as iron, and function in immune evasion through the lysis 
of immune cells [7, 129]. The mechanism of action and cell specificity of the cytolytic 
toxins can be found in Table 1.2.  
12 
 
Table 1.2: Toxins produced by S. aureus and their function.  
Toxin gene Mechanism of action Cell type affected Reference 
Cytolytic toxins 
α-hemolysin Pore formation through heptamer integration 
in membrane 
Erythrocytes, macrophages, lymphocytes [130-133] 
β-hemolysin Membrane disruption through 
sphingomyelinase activity 
Erythrocytes [132] 
γ-hemolysin Bi-component leukocidin – pore formation by 
four slow and four fast proteins  
Leukocytes [134, 135] 
δ-hemolysin Peptides cause membrane disruption at high 
density 
Non-specific – erythrocytes, leukocytes [136, 137] 
Phenol soluble 
modulin 
Peptides cause membrane disruption at high 
density 
Non-specific – erythrocyte, leukocytes [138, 139] 
Panton Valentine 
leukocidin 
Bi-component leukocidin – pore formation by 
four slow and four fast proteins  
Leukocytes [134, 140] 
LukED, LukGH Bi-component leukocidin – pore formation by 
four slow and four fast proteins  
Leukocytes [141-143] 
Non-cytolytic toxins 
Toxic shock 
syndrome toxin 
(TSST-1) 
Non-specific binding to the major 
histocompatibility complex molecule 
CD4 T cells [144] 
Enterotoxin Induction of emesis and diarrhea, 
gastrointestinal inflammation, non-specific 
binding to the major histocompatibility 
complex molecule 
Epithelium of the gastrointestinal tract, 
CD4 T cells 
[145-147] 
Enterotoxin-like 
proteins 
Non-specific binding to the major 
histocompatibility complex molecule 
CD4 T cells [148-150] 
Exfoliative toxins Serine protease targeting the desmosomal 
proteins involved in cell-cell adhesion within 
the skin 
Keratinocyte  [120, 151, 152] 
1
2
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Non-cytolytic toxins produced by S. aureus include toxic shock syndrome toxin 1 
(TSST-1), the enterotoxins and enterotoxin-like proteins, and exfoliative toxins (Table 
1.2). TSST-1 is the primary mediator of toxic shock syndrome (TSS), a disease 
characterized by fever, rash, organ failure, shock, and death [153]. TSST-1 is a 
superantigen that acts through a non-antigen-specific mechanism to activate of 5-30% of 
CD4 T cells within the host [144, 154]. The activation of CD4 T cells causes the release 
of cytokines, which stimulate vasoactivation and lead to shock [144, 155]. Enterotoxins, 
another group of non-cytolytic toxins, cause vomiting and diarrhea associated with 
foodborne intoxication due to S. aureus [156]. Enterotoxins and enterotoxin-like proteins, 
similar to TSST-1, are superantigens and also activate T cells in a non-antigen-specific 
manner [157, 158]; however, enterotoxins are also capable of inducing emesis and 
gastrointestinal inflammation [145-147], while enterotoxin-like proteins either lack the 
ability to induce vomiting or are untested for this ability [159]. Finally, exfoliative toxins 
are the cause of staphylococcal scalded skin syndrome (SSSS). Clinical signs of SSSS 
include fever, lethargy, and skin exfoliation that begins with large blisters that rupture, 
removing the epidermal layer [160]. The exfoliative toxins, eta and etb, are serine 
proteases that degrade desmosomal proteins in the skin with a high degree of specificity 
[120, 151, 152]. Desmosome degradation causes a loss of cell-cell adhesion within the 
skin leading to the formation of blisters [161, 162]. Toxin production in S. aureus, similar 
to exoproteins, is regulated by cell density and they are produced in late exponential 
phase when cell densities peak [71-74].  
14 
 
Immune evasion 
S. aureus subverts the host immune response through the production of many 
immune evasion factors. These act through cell lysis, promoting dysfunction of the 
cellular immune response, inhibition of complement and antibody mediated actions, and 
detoxification of lethal compounds (Table 1.3). As described, S. aureus produces a 
variety of toxins that disrupt the cellular immune response through the lysis of innate and 
adaptive immune cells (Table 1.2). Additionally, the adaptive cellular immune response 
is subverted by S. aureus through the superantigen toxins described above [144, 155, 
158], which cause aberrant T cell activation and prevent a coordinated response to S. 
aureus. Immune evasion proteins from S. aureus are also able to act on the cells of the 
innate immune system to prevent leukocyte migration (eap, chp) and reduce uptake and 
killing by phagocytes (capsule, asdA) [163-167]. The humoral immune response is 
inhibited by S. aureus through genes that disrupt the action of complement (sak, scn, ecb) 
or bind IgG to the cell surface, preventing complement activation and receptor mediated 
phagocytosis (opsonization) (sbi, spa) [168-175]. Finally, S. aureus possess mechanisms 
to detoxify lethal compounds produced by the host including reactive oxygen species 
(katA, aphC, sod), defensins (aur), and polyamines (speG) [176-179]. Immune evasion 
genes of S. aureus act to evade both the innate and adaptive arms of the immune system 
and ensure S. aureus is able to survive and proliferate within a host. 
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Table 1.3: Immune evasion genes in S. aureus.  
Immune evasion gene Function Reference 
eap (extracellular adhesion protein) Prevents neutrophil migration by binding receptors on endothelial cells [163, 164] 
chp (chemotaxis inhibitory protein) Prevents neutrophil migration through blockade of the C5a receptor and 
formyl receptor 
[165] 
fll  (FPR-like1 inhibitory protein) Prevents neutrophil migration through blockade of the formyl receptor [180] 
asdA (adenosine synthetase A) Adenosine synthesis – prevents killing by neutrophils [167, 181] 
Capsule Polysaccharide capsule production – prevents deposition of complement 
and antibody, antiopsonic  
[166] 
flr (FPR-like1 inhibitor protein-like) Interrupts of the complement cascade [172] 
ecb (extracellular complement-binding 
protein) 
Interrupts of the complement cascade [171, 172] 
efb (extracellular fibrinogen-binding 
protein) 
Interrupts of the complement cascade [173] 
scn (staphylococcal complement 
inhibitor) 
Interrupts of the complement cascade [168] 
sak (staphylokinase) Binds defensins preventing cell membrane disruption, promotes degradation 
of the opsonins IgG and C3b reducing phagocytosis 
[169, 170] 
sbi (S. aureus binder of IgG) Sequesters IgG through binding to the constant region, disrupts the 
complement cascade 
[173, 174] 
spa (protein A) Sequesters IgG through binding to the constant region [175]  
ACME – arc gene cluster Arginine deaminase – raises pH enabling survival on the skin, depletes 
arginine available for nitric oxide production in phagocytes 
[182, 183] 
ACME – speG  Polyamine degradation – enables survival on the skin  [176] 
aur (auerolysin) Zinc metalloprotease – degrades defensins [177] 
katA (catalase), aphC (alkyl 
hydroperoxide reductase 
Detoxification of hydrogen peroxide [178] 
sod (superoxide dismutase) Detoxification of superoxide radicals [179]  
Staphyloxanthin Carotenoid pigment – resistance to reactive oxygen species [6] 
1
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Drug Resistance in S. aureus 
Prior to the introduction of penicillin, invasive S. aureus infections had a 
mortality rate exceeding 80% [184]. The discovery and application of antibiotics has 
significantly reduced the mortality rate associated with invasive infections; however, 
mortality for S. aureus septicemia currently ranges from 15-50% depending on the 
original location of the infection [185, 186]. The burden of S. aureus is complicated by 
inappropriate antimicrobial selection and treatment failures due to antimicrobial 
resistance (AMR) [187, 188]. Treatment failures worsen clinical prognosis and cause 
increased health care costs [187, 188].  
Antibiotics are considered bacteriostatic, which inhibit bacterial replication, or 
bactericidal, which cause bacterial cell death [189]. They act by disrupting critical cell 
functions including: cell wall synthesis, protein synthesis, nucleic acid synthesis (DNA or 
RNA), folic acid synthesis, and cell membrane integrity [190]. AMR mechanisms prevent 
or inhibit the effects of antibiotics and can be intrinsic to the organism or acquired 
through mutation of chromosomal genes or acquisition of MGEs through HGT [191]. 
Intrinsic or innate resistance provides resistance to an entire class of antibiotics [191]. An 
example of this form of resistance is the ineffectiveness of metronidazole as a treatment 
for infections with facultative anaerobes, such as S. aureus [192]. Metronidazole causes 
cellular damage through toxic intermediates that are generated during reduction of the 
drug; however, this process requires metabolic pathways that are present predominantly 
in anaerobic bacteria and absent in S. aureus [193]. Alternatively, acquired resistance 
develops through the use of antibiotics. Antimicrobial exposure applies selective 
pressures that encourage the development of AMR through mutation or acquisition of 
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AMR genes harbored on MGE [191]. As a subpopulation of resistant organisms 
develops, continued use of the antibiotic allows only resistant organisms to proliferate, 
generating a dominant population of resistant organisms.  Acquired AMR mechanisms 
can be divided into four categories: reduced antibiotic uptake, increased antibiotic efflux, 
antibiotic modification, and target replacement or modification [191]. Examples of these 
categories follow below and a more complete collection of genes conferring AMR in S. 
aureus listed in Table 1.4. 
AMR associated with reduced antibiotic uptake is more common in Gram 
negative organisms due to their cell envelope structure and is commonly associated with 
changes in porin structure or selectivity [194, 195]. An example of this resistance 
mechanism in S. aureus is involved in intermediate vancomycin resistance. Vancomycin 
intermediate S. aureus (VISA) produce a peptidoglycan layer with reduced cross linking 
that generates an irregular and thickened cell wall with increased exposure of the 
vancomycin target, D-alanine-D-alanine [196]. Vancomycin binds the exposed residues 
that reduces the concentration of antibiotic reaching the cell membrane and contributes to 
survival of VISA with vancomycin exposure [196]. 
A second mechanism for resistance works through active removal of antibiotics 
from the cell. Efflux pumps are employed to increase antibiotic extrusion from the cell 
and protect intracellular targets. Acquired mechanisms of increased antibiotic efflux are 
due to mutation of chromosomally encoded efflux pumps or acquisition of novel efflux 
pumps through HGT. In S. aureus, low level fluoroquinolone resistance is associated 
with induction of the chromosomally encoded efflux pump norA [197, 198]. Mutations in 
the promoter or operator region found upstream of norA increases protein expression, 
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which increases efflux of fluoroquinolones from the cell [197, 199-201]. Alternatively, 
antibiotic efflux genes can be acquired through HGT of MGE encoding efflux pumps, 
such as the tetracycline resistance genes tetK and tetL [202].  
The third mechanism of resistance involves altering the antibiotic to reduce its 
effect on the cell. Enzymes modifying or degrading antibiotics are widespread in S. 
aureus isolates. Prominent examples of such enzymes are the beta-lactamase, blaZ, and 
aminoglycoside modifying enzymes. The bla operon is found in 90% of S. aureus 
isolates [203], which explains the widespread prevalence of penicillin resistance. It 
inactivates beta-lactam antibiotics through hydrolysis of the beta-lactam ring [204]. This 
gene and its regulatory elements are often found on plasmids that also encode resistance 
to other compounds, such as disinfectants, dyes, heavy metals, or other antibiotics [205-
207]. The beta-lactamase operon has also been identified on a transposon integrated into 
the chromosome [208]. Another example of antibiotic alteration is the aminoglycoside 
modifying enzymes, which change antibiotic structure and therefore prevent the 
antibiotic-target interaction. These enzymes act through acetylation, adenylation, or 
phosphorylation and are deemed aminoglycoside acetyltransferases (AAC), 
aminoglycoside nucleotidyltransferases (ANT), and aminoglycoside phosphotransferases 
(APH), respectively [209]. Nomenclature for aminoglycoside modifying enzymes is 
based on their mechanism of action with alphanumeric modifiers that indicate the 
location of modification and resistance profile, for example APH(3’)-IIIa is a 
phosphorylase acting on the hydroxyl group present on the carbon at position 3’ of the 
antibiotic [210, 211].  
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Table 1.4: AMR genes of interest identified in S. aureus and their mechanism of action 
Antibiotic Class Resistance Gene Mechanism of Action Type of 
Resistance 
Transmission Reference 
Glycopeptide vanA Catalyzes formation of D-alanine-
D-lactate bridges 
Target 
replacement 
Plasmid [212, 213] 
Unknown VISA 
induction 
Alteration in cell wall structure – 
binding of vancomycin 
Reduced 
uptake 
Chromosomal [196] 
Fluoroquinolone norA Induction of chromosomal efflux 
pump 
Antibiotic 
efflux 
Chromosomal [197, 199, 201] 
parC, gyrA, parE, 
gyrB mutation 
Alteration in the fluoroquinolone 
binding site  
Target 
modification 
Chromosomal [214] 
Beta-lactam blaZ Beta-lactam hydrolysis Antibiotic 
degradation 
Chromosomal 
or plasmid 
[204, 205, 208] 
mecA, mecC Alternative penicillin binding 
protein 
Target 
replacement 
Chromosomal [215, 216] 
Tetracycline Ribosomal 
protection – tetM, 
tetO 
Interaction with ribosomal protein 
and allosterically blocking the 
antibiotic binding site 
Target 
modification 
Chromosomal 
or plasmid 
[217-219] 
Antibiotic efflux – 
tetK, tetL 
Removal of antibiotic from the cell Antibiotic 
efflux 
Chromosome or 
plasmid  
[202, 218] 
Streptogramin A Acetyltransferase – 
vat 
Acetylation of antibiotic preventing 
interaction with target 
Antibiotic 
modification 
Plasmid [220, 221] 
Streptogramin B Lactonase – vgb Hydrolysis of the lactone ring  Antibiotic 
degradation 
Plasmid [220, 222] 
Trimethoprim / 
Sulfonamide 
Mutation in 
dihydropteroate 
synthase 
Changes in protein sequence that 
alter drug binding 
Target 
modification 
Chromosomal [223] 
Dihydrofolate 
reductase – dfr  
Alternative dihydrofolate reductase 
with reduced binding to 
trimethoprim 
Target 
replacement 
Chromosomal 
or plasmid 
[224] 
1
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Table 1.4 Continued 
Antibiotic Class Resistance Gene Mechanism of Action Type of 
Resistance 
Transmission Reference 
Carbolic acid 
(mupirocin) 
mupA and mupB Alternative isoleucyl-tRNA 
synthetase 
Target 
replacement 
Plasmid [225, 226] 
ileS mutation Mutation alters ability of antibiotic 
to bind 
Target 
modification 
Chromosomal [227] 
Aminoglycoside Aminoglycoside 
acetyltransferase 
Acetylation of antibiotic preventing 
interaction with target 
Antibiotic 
modification 
Chromosomal 
or plasmid 
[209] 
Aminoglycoside 
nucleotidyltransferae 
Adenylation of antibiotic 
preventing interaction with target 
Antibiotic 
modification 
Chromosomal 
or plasmid 
[209] 
Aminoglycoside 
phosphotransferase 
Phosphorylation of antibiotic 
preventing interaction with target 
Antibiotic 
modification 
Chromosomal 
or plasmid 
[209] 
Phenicol fexA Removal of antibiotic from the cell Antibiotic 
efflux 
Chromosomal [228, 229] 
Chloramphenicol 
acetyltransferases 
(CAT) 
Acetylation of antibiotic preventing 
interaction with target 
Antibiotic 
modification 
Plasmid [230] t 
Lincosamide lnuA, lnuB Transfer of a nucleotide to the 
antibiotic preventing interaction 
with target (nucleotidyltransferase) 
Antibiotic 
modification 
Chromosomal 
or plasmid 
[231, 232] 
Macrolide msrA, msrB Removal of antibiotic from the cell Antibiotic 
efflux 
Plasmid [233] 
mphC Phosphorylation of antibiotic 
preventing interaction with target 
Antibiotic 
modification 
Plasmid [234] 
 
  
2
0
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Table 1.4 Continued 
Antibiotic Class Resistance Gene Mechanism of Action Type of 
Resistance 
Transmission Reference 
Multi-drug resistance genes 
Phenicol, 
lincosamide, 
oxazolidinone, 
pleuromutilin, 
streptogramin A 
cfr rRNA methylation to prevent 
antibiotic interaction 
Target 
modification 
Plasmid [235, 236] 
Macrolide, 
lincosamide, 
streptogramin B 
erm genes rRNA methylation to prevent 
antibiotic interaction 
Target 
modification 
Chromosomal 
or plasmid 
[237, 238] 
Lincosamide, 
pleuromutilin, 
streptogramin A 
lsaE Removal of antibiotic from the cell Antibiotic 
efflux 
Plasmid  [239] 
Lincosamide, 
pleuromutilin, 
streptogramin A 
vga genes Removal of antibiotic from the cell Antibiotic 
efflux 
Chromosomal 
or plasmid 
[240, 241] 
2
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The fourth and final mechanism of AMR is target replacement or modification, 
which is a widespread mechanism of resistance employed for many antibiotic classes. In 
S. aureus, the most well-known example is methicillin resistance encoded by the mecA 
gene (described in the Methicillin resistance section); however, this form of resistance is 
also employed in resistance to vancomycin, fluoroquinolones, and other antibiotics. 
Target modification is also the mechanism by which the multi-drug resistance gene cfr 
confers AMR. Vancomycin resistant S. aureus (VRSA) is mediated by the vanA gene, 
which is harbored on a plasmid highly similar to that found in vancomycin resistant 
Enterococcus species [242]. The vanA gene encodes production of D-alanine-D-lactate 
cross bridges, to which vancomycin is unable to bind [212, 213]. Alternatively, 
fluoroquinolone resistance is acquired through chromosomal mutation to the quinolone 
resistance determining region (QRDR) of DNA gyrase or DNA topoisomerase IV [197, 
214]. Mutations in the QRDR reduce the ability of fluoroqinolones to bind to their target 
and alter the binding stability of the fluoroquinolone-target interaction [243, 244]. The cfr 
gene is another example of target modification conferring AMR in S. aureus. It encodes 
an rRNA methylase that modifies the adenine found at position 2503 in the 23S rRNA 
[235]. This causes multi-drug resistance by preventing ribosomal binding of antibiotics 
from the lincosamide, streptogramin A, phenicol, pleuromutalin, and oxazolidinone 
classes [236]. 
As discussed, selective pressures associated with antimicrobial exposure 
contribute to the development or acquisition of AMR genes. This has been seen in the 
health care industry where the use of penicillin and methicillin rapidly led to the presence 
and prevalence of blaZ and mecA in the hospital setting [245, 246]. These genes are 
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further disseminated generating “waves” of resistance that begin in the health care setting 
and spread into the community [247]. More recently, livestock production has been 
identified as a potential reservoir for AMR genes including mecA (see LA-MRSA 
characteristics section) and uncommon AMR genes, such as cfr and vgaC [248-251]. The 
diversity of AMR genes identified in S. aureus isolates from livestock species has 
triggered public health concerns surrounding antimicrobial use in the livestock industry 
and has encouraged continued monitoring for the development and dissemination of 
additional AMR genes [252, 253].  
Methicillin Resistance 
S. aureus isolates expressing resistance to methicillin are termed methicillin 
resistant S. aureus or MRSA. Resistance to methicillin was first reported in S. aureus in 
1961 in an English hospital [246]. Clones of MRSA disseminated within the health care 
setting and over the next 30 years became a global burden for the health care industry that 
continues today [247]. In the time since its discovery, the impact of MRSA has 
broadened beyond the hospital setting and now causes community acquired infections as 
well as hospital acquired infections (see MRSA Epidemiology). 
Methicillin resistance in Staphylococcus species is conferred through the 
acquisition of the Staphylococcal Cassette Chromosome mec (SCCmec) element, a MGE 
harboring the mecA gene [254]. SCCmec elements vary in size, which range from 21-67 
kb, and composition through the presence of additional MGEs within the element 
including transposons and plasmids encoding other resistance genes [255]. The defining 
features of the SCCmec element are the ccr genes that function in recombination and the 
mec gene complex, which functions in methicillin resistance. These components are used 
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to classify SCCmec elements into 12 currently identified types (Table 1.5), with subtypes 
defined by the joining regions (J1-J3) oriented between chromosomal DNA, the mec gene 
complex, and the ccr genes (Figure 1.1) [256].  
Table 1.5: Identified SCCmec elements and their associated ccr gene complex and mec gene compex. 
(Adapted from http://www.sccmec.org/) 
SCCmec 
type 
ccr gene 
complex 
mec gene 
complex 
I Type 1 Class B 
II Type 2 Class A 
III Type 3 Class A 
IV Type 2 Class B 
V Type 5 Class C2 
VI Type 4 Class B 
VII Type 5 Class C1 
VIII Type 4 Class A 
IX Type 1 Class C2 
X Type 7 Class C1 
XI Type 8 Class E 
XII Type 9 Class C2 
 
 
 
Figure 1.1: Structure of the SCCmec element. The SCCmec element is composed of the mec gene 
complex and the ccr genes. The ccr genes function to integrate the SCCmec element into the chromosome 
at orfX and the mec gene complex encodes the alternate penicillin binding protein (mecA) and the 
associated regulatory elements (mecR1 and mecI). SCCmec elements are typed based on the ccr genes and 
the mec gene complex, with subtype of each being defined by the joining regions (J1-J3) indicated below. 
J1 is the region between the chromosome and the ccr genes. J2 is located between the ccr genes and the 
mec gene complex. J3 is the sequence found between the mec gene complex and the chromosome.  
 
The ccr genes are present in the SCCmec element either as a combination of 
ccrA/ccrB alleles or ccrC allele alone (Table 1.6). They generate proteins that are 
involved in integration and excision of the SCCmec element in a site specific manner at 
the orfX gene [254]. The mec gene complex is composed of one or two insertion 
sequence(s), mecA, a complete or partial mecR1, and mecI in class A mec gene 
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complexes (Table 1.7). The mecA gene encodes an alternate penicillin binding protein 
(PBP2a), which has a lower binding affinity for β-lactam antibiotics and a reduced rate of 
inactivation through β-lactam mediated acetylation [215, 216]. PBP2a catalyzes the 
formation of cell wall cross bridges but is not inactivated by methicillin or other 
penicillin class antibiotics, preventing the bactericidal effects of these antibiotics [257, 
258].  
Table 1.6: Identified ccr gene complexes and their associated ccr alleles. (Adapted from 
http://www.sccmec.org/) 
ccr gene complex ccr genes 
Type 1 A1B1 
Type 2 A2B2 
Type 3 A3B3 
Type 4 A4B4 
Type 5 C1 
Type 6 A5B3 
Type 7 A1B6 
Type 8 A1B3 
Type 9 C2 
 
 
Table 1.7: Identified mec gene complexes and their composition. (Adapted from 
http://www.sccmec.org/) 
mec gene complex Genes composing 
Class A IS431-mecA-mecR1-mecI 
Class B IS431-mecA-ΔmecR1-IS1272 
Class C1 IS431-mecA-ΔmecR1-IS431 a  
Class C2 IS431-mecA-ΔmecR1-IS431 b 
Class D IS431-mecA-ΔmecR1  
Class E blaZ-mecALGA251- mecR1LGA251- mecILGA251 
c 
a – IS431 in Class C1 are oriented in the same direction 
b – IS431 in Class C2 are oriented in opposing directions 
c – mecALGA251 is also known as mecC 
 
Production of mecA is regulated by mecI and mecR1, the transcriptional repressor 
and signal transduction protein encoded in the mec complex, respectively (Figure 1.2). 
The mecI gene is constitutively produced and binds to a 30 bp target found upstream of 
the mecA gene [259]. Through binding, mecI causes steric hindrance and prevents 
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polymerase access to the mecA gene, which results in marked reductions in transcription 
and translation [260]. The mecR1 gene is a signal transduction protein that detects β-
lactam antibiotics in the environment surrounding the cell. It is a homolog of and 
functions similarly to blaR1, the signal transduction protein associated with the β-
lactamase gene blaZ [261]. The extracellular domain of the signal transducer is acetylated 
through contact with β-lactam antibiotics [261], which activates the cytoplasmic protease 
domain resulting in autocatalytic cleavage [204]. The proteolytic activity results in 
downstream cleavage of the transcriptional repressor, mecI, and releases the repression of 
the mecA gene [204]. Deletion of the mecI gene is seen in the Class B, Class C1, Class 
C2, and Class D mec gene complexes (Table 1.7). For these classes, mecA transcription is 
regulated by the repressor (blaI) and signal transducer (blaR1) from the β-lactamase 
operon or, if the blaZ locus is absent, constitutive expression of mecA is seen [260, 262]. 
Figure 1.2: Regulation of the mecA gene. The transcriptional repressor, MecI, binds upstream of the 
mecA gene in the absence of methicillin. Through this binding, MecI provides steric hindrance preventing 
RNA polymerase from accessing the mecA gene. When methicillin is present, MecR1 is activated through 
acetylation and cleaves MecI. In the absence of intact MecI, RNA polymerase can bind the promoter 
allowing transcription of mecA and the expression of phenotypic methicillin resistance. 
 
 
More recently, a novel mecA homologue conferring methicillin resistance has 
been discovered in livestock isolates [263]. This gene has been named mecALGA251 or 
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mecC and was found to be 70% identical to the traditional mecA gene [263]. It is 
harbored by the class E mec gene complex, which is found within the type XI SCCmec 
element (Table 1.5 and 1.7).  
The SCCmec element is hypothesized to have originated in coagulase negative 
Staphylococcus species, such as Staphylococcus scuri or Staphylococcus haemolyticus 
[264, 265]. Isolates of S. scuri were found to harbor a close homologue of the mecA gene, 
which is phenotypically silent in these isolates [264]. Evidence implicating S. 
haemolyticus as the source of SCCmec is associated with IS1272, an insertion sequence 
found in the Class B mec gene complex (Table 1.7), which is widely distributed in S. 
haemolyticus isolates [265]. Although the origin of the SCCmec element in S. aureus has 
not been definitively determined, the findings of these studies suggest that methicillin 
resistance originated in coagulase negative Staphylococcus species and was later 
transferred to S. aureus through acquisition of the SCCmec element.  
MRSA Epidemiology  
MRSA, similar to methicillin susceptible S. aureus (MSSA), is also found to 
colonize humans, although in most instances at a much lower rate than that seen for 
MSSA colonization. In 2008, the colonization rate of MRSA in the general population in 
the United States was 1.5% [42]; however, subsets of the population are at increased risk 
for colonization, such as healthcare workers, livestock caretakers and others (Table 1.8) 
[183]. There is evidence that MRSA isolates are able to take over the niche currently 
occupied by MSSA isolates, which has been noted as an increase in MRSA colonization 
with an associated decrease in MSSA colonization over time [266]. 
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Table 1.8: Populations at risk for MRSA colonization. (Adapted from David and Daum, 2010 [183]) 
At risk individuals Reference 
Neonates and children [267, 268] 
Athletes (especially contact sports) [269, 270] 
Incarcerated individuals [271] 
Indigenous individuals [272] 
Military personnel [273] 
Veterinarians and livestock caretakers [248, 274] 
Individuals of low socieoeconomic status [275] 
HIV or AIDS affected individuals – intervenous drug users, 
men with male partners 
[276-278] 
Patients with cystic fibrosis [279] 
Household contacts of MRSA patients [140, 280] 
Emergency room patients [281] 
Health care professionals [282] 
 
MRSA isolates are classified based on epidemiologic characteristics into hospital 
acquired (HA-MRSA), community acquired (CA-MRSA), and livestock associated (LA-
MRSA). The predominant characteristic that defines each subset is the location from 
which the isolate is obtained, such that HA-MRSA isolates are obtained from contact 
with health care settings, CA-MRSA isolates are associated with sources outside of the 
health care setting, and LA-MRSA isolates are acquired from livestock species. The 
epidemiologic classifications are an important aide in the selection of antimicrobial 
therapy and play a role in understanding the virulence capacity of the isolate [283]. 
However, traditional definitions have blurred in recent years with HA-MRSA isolates 
circulating in the community and CA-MRSA isolates causing outbreaks in the health care 
setting [183]. This has led to a new scheme to define isolates based on other 
characteristics including: location of infection onset, recent health care exposure, risk 
factors associated with CA-MRSA colonization, genetic characteristics, AMR profile, 
and MRSA associated clinical syndrome [183, 284]. These characteristics are defined for 
each subset in Table 1.9. 
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Table 1.9: General characteristics of HA-, CA-, and LA-MRSA isolates 
Characteristic HA-MRSA isolates CA-MRSA isolates LA-MRSA isolates 
Location of disease onset Health care setting Outside of health care setting Outside of health care setting 
Recent health care exposure Yes No No 
Risk factors associated with 
CA-MRSA 
No Yes – see Table 1.8 Yes – livestock contact 
Health status of patient Comorbidities present Normal, healthy individual Often possess comorbidities – such 
as an open wound 
Virulence factors Limited – PVL negative, 
ACME negative 
More commonly harbor 
multiple virulence factors 
(PVL, ACME) 
Typically lack human specific 
virulence factors (PVL, β-
hemolysin converting 
bacteriophage, enterotoxins) 
Antimicrobial resistance profile Resistant to many non-
β-lactam antibiotics 
Susceptible to the majority of 
non-β-lactam antibiotics 
Commonly resistant to tetracycline 
class antibiotics 
SCCmec element Type I-III Type IV-V Type III-V and many untypable 
Common clinical syndrome  Severe, invasive 
infections 
Skin and soft tissue infections Skin and soft tissue infections 
2
9
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Another method that can aid in differentiating these subsets is MLST. As 
previously mentioned, MLST is an important tool used to define genetic lineages. 
Specific lineages have found success in different settings and some STs seem to possess 
characteristics that better enable them to adapt to their environment through the 
acquisition of MGE [12]. One example of this is the ST8 strain identified as USA300. 
The success of this CA-MRSA clone has been attributed to some of the MGEs it 
acquired, specifically the acquisition of ACME [182]. There are additional STs that have 
adapted to unique settings, such as the predominance of ST398 and ST9 in livestock 
species; however, there are also lineages that can persist in any environment and are 
found to thrive in both the hospital and community settings, such as the ST5 lineage [12, 
285].  
MRSA was first identified in the hospital setting in 1961 and developing strains 
of MRSA remained confined to this setting until the 1980s [246, 286, 287]. While 
initially discovered in Britain, dissemination occurred rapidly and the first outbreak of 
HA-MRSA in the United States was reported in 1968 [288]. HA-MRSA isolates were 
initially localized within the health care setting and were predominantly detected in 
patients with comorbidities [183, 289]. These patients tend to develop more severe 
disease associated with S. aureus, which is attributed to the immunocompromised state of 
many of these patients and the use of indwelling medical devices, such as intravenous 
catheters, that increase the risk of invasive infections [290]. The prevalence of MRSA in 
health care settings has increased since its introduction in both number of infections and 
as a percent of the total S. aureus infections, with over 60% of all S. aureus isolates 
reported in hospitals in 2004 [291, 292]. HA-MRSA isolates are characterized by 
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harboring the larger SCCmec elements (types I-III) and displaying phenotypic AMR to a 
wider range of antibiotics outside the β-lactam class [183, 293, 294]. Though HA-MRSA 
isolates tend to cause more severe clinical syndromes, they often lack virulence factors 
such as PVL and ACME [183].  
The first reports of CA-MRSA were sporadic outbreaks in the 1980s and early 
1990s [286, 287, 295-297]. CA-MRSA isolates have disseminated in the community 
setting since the mid-1990s and it is currently thought that around 90% of diagnosed 
MRSA infections are community onset [183, 298, 299]. In contrast to HA-MRSA, CA-
MRSA infections occur in people with no recent exposure to the health care setting and 
tend to present as skin and soft tissue infections in healthy, younger individuals [300, 
301]. CA-MRSA isolates are characterized by smaller SCCmec elements (type IV and V) 
and are generally susceptible to most of the non-β-lactam antibiotics [183]. Due to their 
ability to cause disease in otherwise healthy individuals, CA-MRSA isolates are 
considered more virulent and tend to harbor additional virulence factors found on MGE 
such as PVL and ACME [182, 183, 302]. These isolates have been detected in both urban 
and rural settings [268, 303, 304], but they tend to be maintained in locations with high 
density populations or where close contact between individuals occurs. Known CA-
MRSA reservoirs include prisons, athletic centers, schools, and daycare centers [269, 
305, 306]. It appears that CA-MRSA has added to the health care burden of S. aureus 
because the dissemination of CA-MRSA has been associated with a concomitant increase 
in doctor visits for abscesses, cellulitis, and other skin and soft tissue infections [307].  
LA-MRSA is often considered a subset of CA-MRSA, since by definition CA-
MRSA infections are those diagnosed in the community setting or within 48 hours of 
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hospital admission [308]. These isolates possess unique characteristics that enable them 
to be defined as a distinct subset of MRSA (Table 1.9). The discovery and 
characterization of these isolates are discussed more thoroughly below. 
LA-MRSA Characteristics 
The first reports of MRSA associated with livestock species were published in 
1972 and detailed clinical mastitis in a Belgian dairy cow [309]. However, MRSA in 
livestock remained largely unreported until 2005, when the first report associated MRSA 
with swine in the Netherlands [248]. The connection with swine was discovered during a 
patient’s pre-operative MRSA screening, which revealed the patient was colonized with 
MRSA [248]. Decolonization was attempted; however, routine decolonization procedures 
were ineffective [248]. The patient’s history indicated no known risk factors for MRSA 
colonization and familial screening discovered the patient’s parents were also colonized. 
Further testing indicated the swine on the farm where they lived served as the source of 
MRSA [248]. Furthermore, all of the identified isolates were unable to be typed using 
RFLP analysis. This was due to a novel restriction modification system that methylates 
DNA in the SmaI restriction site preventing digestion with SmaI [248, 310]. MLST later 
revealed the isolates were of the ST398 lineage, which became the prototypical LA-
MRSA lineage [311].  
Initial screening indicated MRSA was widespread in European swine [312-314]; 
however the prevalence varied depending on the study. Variable MRSA prevalence has 
been attributed to variable MRSA colonization rates as well as study design. One factor 
playing a major role in prevalence is location. For example, in Norway the prevalence of 
MRSA on swine farms was 0.6%, while studies in Germany found a MRSA prevalence 
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of 80% on swine farms [315, 316]. Differences in prevalence on farms have also been 
attributed to the age of pigs tested, the farm size and stocking density, and use of 
antimicrobials on farm [317-320]. While most studies look at prevalence as a snapshot, 
some longitudinal studies have been completed and they indicate that not all swine are 
permanently colonized with LA-MRSA [321, 322]. Because of the transient nature of 
colonization, the prevalence of LA-MRSA in individual animals on farms varies and herd 
level prevalence is a better indicator of the incidence of LA-MRSA in swine [316].  
The discovery of LA-MRSA ST398 stimulated concerns within the public health 
community over the potential for swine to act as a reservoir for MRSA in humans. 
However, though LA-MRSA ST398 isolates are suspected to be derived from an 
ancestral human MSSA lineage [323], LA-MRSA ST398 isolates appear to present a 
reduced medical importance as compared to other lineages routinely found in the hospital 
or community but unassociated with livestock [320]. The majority of reported disease 
with LA-MRSA ST398 are skin and soft tissue infections and, rarely, severe invasive 
infections are noted, predominantly in patients with concurrent disease [324]. Reduced 
virulence is suspected to be due to the adaptation of the LA-MRSA ST398 lineage to 
colonizing animals, which caused the loss of virulence factors and led to a reduced 
capacity for causing disease in humans [323, 325-329]. The reduced pathogenicity and 
severity of disease associated with LA-MRSA ST398 isolates as compared to HA- and 
CA-MRSA isolates has been attributed to the absence of virulence factors that contribute 
to disease in humans and reduced adherence capacity and colonization capability. 
Additionally, AMR patterns differ in LA-MRSA isolates as compared to isolates from the 
hospital and community setting, which can alter treatment efficacy [330-332]. 
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Comparisons of the virulence genes from LA-MRSA ST398 and MRSA isolates 
from the hospital or community settings have revealed differences in the complement of 
virulence genes harbored by the isolates [12, 323, 330]. The immune evasion cluster 
harbored by the β-hemolysin converting bacteriophage, while present in over 90% of 
human clinical isolates [29], is largely absent in LA-MRSA ST398 isolates [12, 323, 
330]. Similarly, LA-MRSA ST398 isolates often lack enterotoxin genes commonly 
associated with foodborne illness and enterotoxin-like genes that function as 
superantigens [12, 323, 330, 333]. Many other exotoxins have also been absent or 
infrequent in screened LA-MRSA ST398 isolates including: leukocidin (lukD and lukE), 
PVL (lukF-PV and lukS-PV), and toxic shock syndrome toxin (tst) [12, 330, 334]. The 
absence of virulence genes is thought to contribute to the reduced pathogenicity exhibited 
by LA-MRSA ST398 and may represent an adaptation to colonizing animal hosts.  
Investigation of humans in contact with swine that harbor LA-MRSA ST398 
indicates carriage is common following interaction with swine [248, 318, 335-338]; 
however, colonization, when followed over time, appears to be dependent on animal 
contact and, without contact, it is rapidly lost [335, 336, 339]. Furthermore, 
epidemiologic analysis of LA-MRSA ST398 isolates indicates LA-MRSA isolates are 
less transmissible than HA-MRSA isolates within the hospital setting and fewer 
secondary contacts become positive with LA-MRSA isolates [340-342]. This also 
appears to be true in the community setting where colonization of household members 
and their contacts is less frequent than that seen in non-LA-MRSA isolates [338, 342, 
343]. Reduced transmission and duration of colonization has been attributed to a 
demonstrated reduction in the capacity to adhere to human cells in vitro [344]. Genetic 
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analysis revealed mutations causing truncations of adhesion genes, such as the fibrinogen 
and fibronectin binding proteins (clfA, clfB, and fnbpB) as well as the absence of some 
adhesion genes in LA-MRSA ST398, such as srdE, which were thought to contribute to 
the differential adherence capability of these isolates in vitro [344].  
Finally, LA-MRSA ST398 isolates are more variable in their resistance patterns 
than CA-MRSA isolates and they are typically resistant to more than the β-lactam 
antibiotic class [320]. These isolates are ubiquitously resistant to tetracycline class 
antibiotics and have variable resistance to many other classes including fluoroquinolone 
antibiotics (7-64%) and macrolide and lincosamide antibiotics (33.6-85%) [330-332, 
345]. LA-MRSA ST398 isolates are under different selection pressures than HA-MRSA 
and CA-MRSA isolates, which promote the retention of different AMR genes. For 
example, LA-MRSA ST398 isolates often harbor SCCmec elements that are non-typeable 
or have smaller type IV and V elements [12, 320]. The type V element is common in LA-
MRSA ST398 and may contribute to the fitness of the ST398 lineage in swine because it 
can harbor the czrC gene, a zinc and cadmium resistance gene, which provides resistance 
in the face of widespread zinc chloride use in the swine industry [323, 346-349]. LA-
MRSA ST398 isolates also have the potential to act as a reservoir for diverse and 
uncommon AMR genes, including the multidrug resistance genes cfr, vgaC, and vgaE 
[249-251]. The prevalence of resistance genes beyond mecA and the identification of 
resistance genes uncommonly found in HA- and CA-MRSA isolates raises concerns 
about the potential for LA-MRSA isolates to disseminate AMR genes outside of the 
livestock setting. 
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While LA-MRSA ST398 isolates have been well studied since their discovery, 
more recent evaluation of LA-MRSA isolates worldwide indicates lineages associated 
with livestock are more complex than ST398 alone [335, 350-355]. While LA-MRSA 
ST398 is considered the predominant lineage in European swine, there are reports of 
other lineages as well including CC97 and CC30 [350, 351]. MRSA screening in Asian 
swine indicate LA-MRSA ST9 isolates predominate [354, 356-359]. This differs from the 
epidemiology of LA-MRSA in the United States, in which there is not a single prevalent 
lineage but a mix of ST398 and ST5 isolates with sporadic ST9 isolates detected [335, 
360-362].  
LA-MRSA in the United States was first detected in 2009 [318]. This report 
indicated LA-MRSA ST398 was widespread and found a prevalence of 50% in swine 
herds in Iowa and Illinois [318]; however, further investigation indicated the high 
prevalence was likely due to a sampling bias. It now appears that LA-MRSA is far less 
prevalent than this initial report, with later reports finding a prevalence of 2.8-30% [317, 
335, 361, 363, 364]. These studies also indicated the lineages of LA-MRSA in the United 
States were more diverse than initially reported and isolates of the ST398, ST9, and ST5 
lineages were detected [335, 361, 362, 365, 366].  
Aims and Significance of Research 
The prevalence of LA-MRSA ST398 revealed in initial investigations made it 
clear that swine had the potential to serve as the largest reservoir of MRSA outside of the 
hospital setting, making LA-MRSA a significant public health threat [333]. This threat is 
associated with direct risks of MRSA infection through human contact with animals 
harboring LA-MRSA and indirect risks through the dissemination of AMR genes and 
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virulence factors that LA-MRSA may harbor. While these risks have been well 
elucidated for LA-MRSA ST398 and investigated in LA-MRSA ST9, LA-MRSA ST5 
has not been similarly evaluated. This is cause for concern because, unlike the MRSA 
ST398 and ST9 lineages, the ST5 lineage is a globally disseminated and widely 
successful cause of S. aureus infections in both the community and hospital settings [12]. 
The success of the ST5 lineage has been attributed to its ability to rapidly adapt to its 
environment through the acquisition of MGEs harboring virulence factors and AMR 
genes, many of which are widespread throughout the ST5 lineage [12].  
The overarching goal of this dissertation was to address the public health concerns 
surrounding LA-MRSA ST5 isolates. More specifically, this dissertation aimed to 
evaluate the genetic background of LA-MRSA ST5 isolates as compared to clinical 
MRSA ST5 isolates from humans with no swine contact, determine the potential 
virulence of LA-MRSA ST5 isolates, and evaluate the antimicrobial resistance patterns of 
LA-MRSA ST5 isolates as compared to human clinical MRSA ST5 isolates. To address 
these aims, 82 swine-associated LA-MRSA ST5 isolates and 71 clinical MRSA ST5 
isolates from humans with no swine contact were sequenced using the Illumina MiSeq 
platform (Illumina, San Diego, CA) (Appendix A-F). The resulting draft genome 
sequences were used for single nucleotide polymorphism (SNP) and phylogenetic 
analysis to detect the relatedness of LA-MRSA ST5 and human clinical MRSA ST5 
isolates (Chapter 2). The genome sequences were also evaluated for MGEs encoding 
virulence factors and AMR genes, which were used to detect the potential for genetic 
exchange between these populations (Chapter 3-5). Finally, adherence capacity for these 
isolates was evaluated, including a genetic comparison of known adherence genes and a 
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phenotypic screen of a subset of isolates (Chapter 6). The results of genotypic and 
phenotypic analyses were used to determine the potential direct and indirect implications 
of LA-MRSA ST5 isolates on human health.  
Organization of Dissertation 
This dissertation is organized in journal format with 6 chapters. Chapter 1 
contains a literature review of S. aureus. Each of chapters 2-5 contain a manuscript that is 
published, has been submitted for publication, or will be submitted for publication. 
Chapter 2 contains a core genome analysis of LA-MRSA ST5 and human clinical MRSA 
ST5 isolates in which SNPs were identified and used in a phylogenetic analysis to 
determine the relatedness of the subsets of isolates. Chapter 3 addresses the prevalence of 
the β-hemolysin converting bacteriophage, an integrating bacteriophage containing 
virulence genes involved in evasion of the host immune response, in both LA-MRSA and 
human clinical MRSA ST5 isolates. Chapter 4 and 5 evaluate the prevalence of AMR 
genes and compare the specific AMR genes found in both subsets of isolates. Chapter 6 
examines the genetic potential and in vitro capacity for LA-MRSA ST5 and human 
clinical MRSA ST5 isolates to adhere to human keratinocytes. Finally, Chapter 7 
contains a general conclusion that summarizes the studies contained within this 
dissertation and examines future directions for this research. References and Appendices 
are found following Chapter 7. 
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CHAPTER 2. SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS 
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Abstract 
Livestock associated MRSA (LA-MRSA) are lineages adapted to livestock species. 
LA-MRSA can be transmitted to humans and public health concerns exist because 
livestock may be the largest MRSA reservoir outside of hospital settings. Although the 
predominant European (ST398) and Asian (ST9) lineages of LA-MRSA are considered 
livestock adapted, North American swine also harbor ST5, a globally disseminated and 
highly pathogenic lineage. This study applied whole genome sequencing and single 
nucleotide polymorphism (SNP) typing to compare the population structure and genetic 
relatedness between swine associated and clinical MRSA ST5 isolates. The established 
high-resolution phylogenomic framework revealed that LA-MRSA and clinical MRSA 
ST5 are genetically distinct. LA-MRSA isolates were found to be clonal within farms, 
while greater genome plasticity was observed among sampled clinical MRSA ST5. 
Collectively, our data indicate LA-MRSA and clinical MRSA ST5 isolates are distinct and 
agricultural sources pose minimal significance as a source of clinical MRSA ST5 
infections. 
Introduction 
Staphylococcus aureus is a commensal organism found in the nasopharynx and on 
the skin of humans and other mammals. It can also cause infections in these hosts and 
cause a range of diseases from mild skin and soft tissue infections to severe systemic 
infections. The treatment of S. aureus infections is hampered by the development of 
antimicrobial resistance in these isolates, such as the acquisition of the SCCmec element, 
which confers methicillin resistance. These isolates are designated as methicillin resistant 
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S. aureus (MRSA) and have become a significant burden for the health care system [367, 
368]. 
MRSA isolates are classified based on epidemiologic characteristics into hospital 
acquired MRSA (HA-MRSA), community acquired MRSA (CA-MRSA), and livestock 
associated MRSA (LA-MRSA) [22]. These subsets are defined by the source of the 
isolate and the isolates within each subset tend to share genotypic and phenotypic 
characteristics, such as degree of antimicrobial resistance and virulence factors. Specific 
lineages or sequence types (STs) tend to predominate within each group, although there 
are regional variations. For example, in the United States, ST5 and ST8 are major HA-
MRSA and CA-MRSA clones, respectively [369]. 
LA-MRSA became a significant public health concern in 2005, when the first 
report linked MRSA ST398 to swine production facilities [248]. Further investigations 
indicated swine may serve as the largest reservoir for MRSA outside of hospital settings 
and motivated considerable research into the potential health risks associated with LA-
MRSA. Subsequent research showed the most prevalent lineage of LA-MRSA varied 
based on geographic location. In European swine populations, ST398 is the most 
common lineage [312], while the ST9 lineage predominates in swine in most Asian 
countries [357]. In the United States, the swine population was found to harbor more 
diverse sequence types with isolates of the ST398, ST9, and ST5 lineages [335, 361, 
362]. The presence of MRSA ST5 isolates in US swine herds raised particular public 
health concerns because the ST5 lineage, unlike the ST398 and ST9 lineages, was not 
thought to be livestock adapted but is a highly successful and globally disseminated 
MRSA lineage among human clinical cases [12, 329, 370]. The widespread success of 
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the ST5 lineage has been partially attributed to its capacity to acquire mobile genetic 
elements (MGEs) that harbor virulence factors or antimicrobial resistance genes [12]. 
Phylogenetic studies employ whole genome sequencing (WGS) technology and 
data analysis to better understand the epidemiology, origin, and evolution of bacteria 
[323, 344, 355, 371]. In the case of LA-MRSA, these techniques have been used to assess 
the relatedness of isolates from the ST398 lineage. LA-MRSA ST398 isolates clustered 
separately from human ST398 isolates and are suspected to have evolved from an 
ancestral methicillin susceptible ST398 clade in humans [323]. Similar investigations into 
the CC97 lineage indicated that isolates causing clinical disease in humans comprise a 
sub-clade of the LA-MRSA isolates that may have developed an increased capacity for 
infecting and causing disease in humans [372]. WGS analysis can be used to assess 
isolate relatedness or determine genetic characteristics that define subsets of isolates, 
including information about the MGEs harboring virulence factors or antimicrobial 
resistance genes. Through SNP discovery within the core genome, the accuracy and 
resolution power is available to determine phylogenetic relationships and distinguish 
isolates within highly homogenous lineages, which provides insight in epidemiological 
investigations [355, 371, 373, 374].  
Although previous reports have examined the relatedness of MRSA isolates from 
livestock species and humans within the ST398 and CC97 lineages [323, 372], to date 
there are no reports using WGS data to evaluate the relatedness of MRSA ST5 isolates 
obtained from swine and humans. In this study, we used SNP analysis of the core genome 
to evaluate the genetic relatedness of LA-MRSA ST5 isolates from a variety of swine 
associated sources and clinical MRSA ST5 isolates from humans with no swine contact 
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to investigate the potential for dissemination of LA-MRSA ST5 outside of the 
agricultural setting. 
Methods 
Isolate Acquisition 
Swine associated LA-MRSA ST5 isolates were collected by Iowa State 
University (ISU) from swine nasal swabs (n = 38), the environment within swine 
facilities (n = 26), and healthy veterinary students after visiting a swine farm (n = 9) 
[335]. Isolates from healthy practicing swine veterinarians who have long term contact 
with pigs (n = 9) were provided by the University of Minnesota (UMN). MRSA ST5 
isolates from humans with no swine contact were obtained from medical centers 
associated with the University of California Irvine (UCI) (n = 64) [375] and the 
University of California San Francisco (UCSF) (n = 8). Isolates were characterized for 
MLST and Spa typed prior to acquisition [335, 375]. Isolate information can be found in 
Appendix A.  
Whole Genome Sequencing 
Draft genomes were generated as previously described [376-381]. Briefly, total 
genomic DNA was extracted from isolates grown in Trypticase Soy Broth (BD 
Biosciences, Sparks, MD) using a High Pure PCR Template Preparation Kit (Roche 
Applied Science, Indianapolis, IN). The Nextera XT DNA sample preparation and index 
kit (Illumina, San Diego, CA) was used to generate paired-end DNA libraries with 250-
bp read length that were sequenced using the MiSeq v2 500 Cycle reagent kit on the 
Illumina MiSeq platform (Illumina, San Diego, CA). Sequence reads were assembled 
with MIRA v. 4.0.2 (http://mira-
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assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html) and annotated using the 
NCBI Prokaryotic Genome Annotation Pipeline 
(https://www.ncbi.nlm.nih.gov/genome/annotation_prok/). Draft genomes and sequence 
reads have been submitted to GenBank and the Sequence Read Archive (SRA). 
Accession numbers are provided in Appendix A. 
Core Genome SNP Discovery  
For reference based SNP discovery we used a custom developed pipeline 
implemented on Galaxy [382], that was successfully applied for the high resolution 
genomic epidemiology profiling of various microbial human pathogens [371, 373, 374]. 
Strategies and phylogenetic principles have been described in detail in Rusconi et al., 
2016 [374]. The MRSA core genome in this study is defined in the samples as the set of 
genic and intragenic regions that are not repeated and do not contain mobile genetic 
elements (which evolve at different rates and are not indicative of evolutionary 
relationships), such as phages, IS elements, genomic islands or plasmids. These excluded 
regions were determined for the reference genome Mu50 as follows: NUCmer was used 
to detect repeat regions by running the reference against itself [383], integrated 
bacteriophages were identified using PHAST [384], ISFinder was used for detection of 
insertion sequences [385], and antibiotic resistance cassettes were detected with 
ResFinder [386]. The SNP discovery and verification pipelines are implemented on 
Galaxy, and contain the following modules: (i) SNP discovery and typing, (ii) SNP 
curation, (iii) SNP annotation, (iv) SNP distribution, and (v) SNP phylogeny. 
SNP discovery and typing: Illumina reads of the 72 MRSA ST5 isolates from 
humans with no swine contact and 82 LA-MRSA ST5 were uploaded into Galaxy along 
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with two ST5 representative closed genomes: a HA-MRSA isolate from Japan (Mu3) and 
a representative poultry-adapted MRSA ST5 isolate (ED98) [325, 387]. For read-based 
SNP discovery, reads were aligned with Bowtie2 to the reference genome Mu50 [388]. 
The resulting alignments were processed with Freebayes using the following threshold 
settings: mapping quality 30, base quality 20, coverage 30, and allelic frequency 0.9 
[389]. The two closed representative genomes, Mu3 and ED98, were analyzed using the 
contig-based workflow. Briefly, a panel of SNPs for each genome was obtained by 
aligning the genome against the reference strain, Mu50, using NUCmer. SNPs were 
called with delta-filter and show-snps distributed with the MUMmer package [383]. 
SNP curation: Several SNP curation strategies were used to correct for false 
positive calls [371, 373]. First, reads were mapped against the reference genome Mu50 
and false positives identified by Freebayes with the settings described. If reads were 
unavailable (Mu3 and ED98), the post-assembly workflow generated a reference-based 
NUCmer alignment and extracted SNPs as described above with filtering of false SNPs. 
SNPs located within excluded regions (repeat regions, bacteriophages, resistance 
cassettes, and IS elements) were removed. SNPs were further curated by extracting the 40 
nucleotides surrounding each predicted SNP in the reference genome and completing a 
nucleotide BLAST against the query genomes [390]. Finally, resulting alignments were 
parsed to remove SNP locations derived from ambiguous hits (≥2), low alignment quality 
or misalignments, non-uniformly distributed regions, and InDels, as previously described 
[371, 373, 391]. Also, multinucleotide insertions and deletions of polymorphic bases 
were not considered SNPs and were excluded.  
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SNP annotation: The curated catalogued SNPs from each query genome were 
merged into a single SNP panel that reported the allele, genic/intergenic status, SNP 
position, and annotation [344, 372, 374]. This SNP discovery and validation pipeline 
allows for rapid typing of strains of unknown provenance by interrogating the captured 
allelic states from established SNP panels [373].  
SNP distribution: From the distribution of SNPs along the Mu50 chromosome, 
potential mutational hotspots and genes under positive selection could be identified using 
custom scripts implemented on Galaxy [382, 391, 392].  
SNP phylogeny: The identified curated SNP panel was used for phylogenetic 
reconstruction by maximum parsimony with PAUP v4.0a146 with 100 bootstrap 
replicates [393]. The SNP tree was visualized in Geneious (vR9) and the majority 
consensus tree was built in Mesquite [394, 395]. Tree decorations were added using 
Evolview [396]. Calculation of the consistency index for each SNP allowed for 
identification of parsimony informative SNPs and flag homoplastic SNPs, as described in 
our previous works [371, 374]. 
Mobile genetic element analysis 
Mobile genetic elements harboring antimicrobial resistance genes and virulence 
factors were detected as described previously and verified using Geneious 9.0.5 [397-
399]. Antimicrobial resistance genes detected with ResFinder were verified through draft 
genome analysis [399]. The SCCmec type was determined using PCR and confirmed in 
silico [397]. Immune evasion genes associated with the β-hemolysin converting 
bacteriophage were identified in these isolates using PCR and confirmed in silico [398]. 
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Results 
Isolate provenance and sequence information 
Swine associated LA-MRSA ST5 isolates were obtained from nasal swabs of 
healthy pigs or humans, none of which exhibited signs of MRSA infection, or from swabs 
of the environment within swine facilities. Clinical MRSA ST5 isolates were obtained 
from patients with MRSA related disease at two urban, university affiliated hospitals in 
California where the likelihood that patients had contact with swine was considered 
negligible. Draft genomes confirmed the MLST data indicating all isolates were ST5. 
Single nucleotide polymorphism typing 
For reference based SNP discovery, genomes were aligned to the closed genome 
of reference strain Mu50, a vancomycin resistant HA-MRSA isolate from Japan [387]. 
The core genome was determined by excluding identified mobile genetic elements and 
repeats. Core genome SNP discovery identified 759 SNPs comprised of: 150 intergenic, 
186 synonymous, and 423 non-synonymous SNPs (Table 2.1). Further evaluation of non-
synonymous SNPs indicated that eight were shared by swine associated LA-MRSA ST5 
isolates and not present in isolates from humans with no swine contact, as listed in Table 
2.2. There were also two SNPs found only in MRSA ST5 isolates from humans with no 
swine contact (Table 2.2) that were specific to clinical isolates. The genes harboring the 
non-synonymous SNPs distinct to each subset of isolates have not been implicated in 
virulence of S. aureus and are unlikely to contribute to the pathogenicity of these isolates. 
SNPs were distributed throughout the Mu50 reference genome and no mutational 
hotspots were observed (Figure 2.1).   
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Table 2.1. SNP discovery results. 
 Total Number 
of Genes 
NSYN SYN INT Genic 
SNPs 759 362 423 186 150 609 
Non-Informative 514 279 287 134 93 421 
Parsimony Informative 245 166 136 52 57 188 
Stop Gain 25 22 25 0 0 25 
Stop Loss 2 2 2 0 0 2 
Hypothetical Proteins 150 87 106 44 0 150 
Transition 509 280 264 150 95 414 
Transversion 250 166 159 36 55 195 
Multiallelic 0 0 0 0 0 0 
NSYN – nonsynonymous 
SYN – synonymous 
INT – intergenic 
 
 
Table 2.2. Non-synonymous SNPs unique to LA-MRSA ST5 isolates or MRSA ST5 isolates from 
humans with no swine contact.  
Number of 
Swine 
Associated 
Isolates 
Number of 
Isolates from 
Humans with No 
Swine Contact 
SNP 
Positiona 
Gene Productb 
82/82 0/72 160799 2'-3'-cyclic-nucleotide 2'-
phosphodiesterase 
82/82 0/72 292343 sorbitol dehydrogenase homologue 
82/82 0/72 806489 putative transporter 
82/82 0/72 848820 putative P-loop-containing kinase 
82/82 0/72 1012841 similar to ATP-dependent nuclease 
subunit A 
82/82 0/72 1928498 O-succinylbenzoic acid-CoA ligase 
82/82 0/72 2695325 ferrous iron transport protein B 
homolog 
82/82 0/72 2720180 regulatory protein 
0/82 69/72 192929 hypothetical protein 
0/82 69/72 2277937 conserved hypothetical protein 
a SNP position indicates the location of the SNP in the reference genome of Mu50 
b Gene product represents the protein produced by the gene containing the SNP of interest 
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Figure 2.1: Genomic distribution of SNPs. The position of the 759 identified SNPs were plotted on the 
Mu50 chromosome using a sliding window of 1000 bp. SNPs were distributed throughout regions included 
in the analysis and did not indicate any locations for mutational hotspots. Regions lacking SNP predictions 
are associated with locations of mobile genetic elements and repeat regions that were excluded from the 
SNP discovery and encode elements such as the SCCmec element and the β-hemolysin converting 
bacteriophage. 
 
Phylogenetic analysis 
A phylogenetic hypothesis was constructed from the identified core genome SNPs 
and rooted using the MRSA ST5 isolate Mu50. This tree depicts the evolutionary 
relationships between the 154 MRSA ST5 isolates and the reference isolates Mu3 and 
ED98 (Figure 2.2). The tree topology shows that swine associated LA-MRSA ST5 
isolates cluster together and are separated from MRSA ST5 isolates from humans with no 
swine contact. These groups will be referred to as Clades I and II, representing MRSA 
ST5 isolates from humans with no swine contact and LA-MRSA ST5, respectively. A 
single MRSA ST5 isolate (UCSF14436) from a human with no swine contact was 
contained within Clade II. This isolate was the most distantly related of the Clade II 
isolates, harboring 24 unique/strain-specific SNPs. USCF14436 harbors a type IV 
SCCmec element and two antimicrobial resistance genes (mecA and blaZ), which is a 
strong indication this isolate is a CA-MRSA strain (Figure 2.3).  
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MRSA ST5 isolates from humans with no swine contact (Clade I) are divided into 
subclades Ia and Ib. The SNP-level plasticity between MRSA ST5 isolates from humans 
with no swine contact is greater than that from LA-MRSA ST5 isolates. Despite the 
northern and southern geographic regions represented by the two groups of California 
isolates, the tree topology shows that UCSF isolates were found interspersed throughout 
Clade I and did not cluster by geographic location. 
The swine associated isolates within Clade II formed four subclades, IIa-d. Each 
subclade represents a subset of isolates from a specific farm or farms; such that, Clade IIa 
represents isolates from Farm 10, Clade IIb represents isolates from Farm 24, Clade IIc 
represents isolates from Farm 46, and Clade IId represents isolates from Farm 38-42. 
Isolates originating from individual farms were genetically homogenous, possessing 
fewer than 5 SNPs (distinguishing them from other isolates from the same farm). These 
results suggest that LA-MRSA ST5 populations residing on farms are clonal and 
intermingling/transfer of isolates among farms or reintroduction of MRSA ST5 onto 
farms had likely not occurred. This was true for all swine associated isolates except those 
from farms 38-42 (Clade IId). The high degree of genetic relatedness of the isolates 
within Clade IId suggests these farms are likely from a single production system or share 
a common genetic source, with exposure of pigs to LA-MRSA ST5 early in the 
production system (farrowing unit) and disseminated throughout the later stages as pigs 
are moved (finishing barns). High resolution profiling provides important phylogenetic 
signals for strain attribution [371, 374]. In this case, isolates from humans with short-term 
contact with swine farms could be traced back to a specific farm or production system. 
For example, isolates ISU886-ISU889 were traced to Farm 24, through SNP analysis.   
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Figure 2.2: Maximum parsimony SNP tree of ST5 MRSA isolates. Comparison of 156 genomes yielded 
a total of 759 SNPs, of which 245 were parsimony informative. The tree shown is a majority-consensus tree 
of 4440 equally parsimonious trees with a consistency index of 0.9428. Trees were recovered using a 
heuristic search in Paup 4.0b10 [393]. This tree is broken into clades, with Clade I representing clinical 
MRSA ST5 isolates from humans with no swine contact representing and Clade II representing LA-MRSA 
ST5 isolates. Clade IIa-d are subsets of LA-MRSA ST5 isolates and each subclade represents an individual 
farm or production system.  
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These isolates possessed the unique pattern of SNPs present on that farm or within that 
production system (Clade IIb, IIc, and IId), indicating exposure to the farm harboring that 
specific clone. The remaining isolates in Clade II include the isolates from humans with 
long-term swine contact and UCSF14436. Isolates from humans with long term swine 
contact did not cluster with isolates from the tested farms (Figure 2.2). This is consistent 
with the source of these isolates as it was unlikely the swine veterinarians sampled had 
contact with the specific farms sourcing the other swine associated isolates in this study. 
Though these isolates were distinct from the isolates obtained from swine, swine 
facilities, and humans with short term swine contact, they clustered together within Clade 
II and were representative of the livestock associated ST5 genotype.  
Mobile genetic element analysis 
The draft genomes of both LA-MRSA ST5 isolates and clinical MRSA ST5 
isolates from humans with no swine contact were evaluated for mobile genetic elements. 
LA-MRSA ST5 isolates could also be distinguished from clinical MRSA ST5 isolates by 
the antimicrobial resistance genes and virulence factors they harbored (Figure 2.3). For 
LA-MRSA ST5 isolates, the SCCmec elements were of type III, IV, or untypable. 
Alternatively, clinical MRSA ST5 isolates harbored predominantly type II SCCmec 
elements and two type IV elements. Evaluation of the antimicrobial resistance genes 
revealed the primary macrolide resistance gene was ermA in clinical MRSA ST5 isolates, 
while LA-MRSA ST5 isolates harbored ermC. Additionally, tetracycline resistance genes 
were found exclusively in LA-MRSA ST5 isolates. Virulence factors harbored by the 
subsets were also different, with the majority (65/72, 90.3%) of clinical MRSA ST5 
isolates harboring innate immune evasion genes within the β-hemolysin converting 
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bacteriophage and none of the LA-MRSA ST5 isolates harboring these genes. This 
analysis revealed that MGE were not commonly shared between the two subsets of 
isolates.  
 
Figure 2.3: Maximum parsimony SNP tree of ST5 MRSA isolates with MGE analysis. The SNP tree 
developed for Figure 2.2 was decorated using Evolview [396, 400]. The tree shows the MGE complement 
of these isolates, specifically describing the SCCmec element, the β-hemolysin converting bacteriophage 
(harboring virulence factors involved in innate immune evasion), and antimicrobial resistance genes 
involved in tetracycline resistance (tetT/tetL) and macrolide resistance (ermA and ermC).  
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Discussion 
MRSA in livestock species was first identified in the 1970s [309]; however, 
discovery of a high prevalence of MRSA ST398 in  swine in 2005, and subsequently in 
other livestock, brought debate over its public health implications to the forefront [248]. 
Previous studies investigating LA-MRSA ST398 demonstrated these isolates have 
adapted to livestock hosts. This was represented by the absence of human specific 
virulence factors, such as the β-hemolysin converting bacteriophage [323], and reduced 
adherence and transmission among humans [339, 344]. LA-MRSA ST9 isolates, similar 
to ST398, are thought to be livestock adapted, and clinical cases appear to be rare and 
attributed to animal contact [401]. While the ST5 lineage in humans is globally 
distributed and successful in both the hospital and community settings [12], there are 
currently no reports of MRSA ST5 related disease occurring due to contact with livestock 
species; however, the genetic potential for swine isolates to adhere, invade, and cause 
disease in humans has not been investigated.  
Here, we examined the phylogenetic relatedness applying high resolution core 
genome SNP profiling strategies on MRSA ST5 isolates from swine associated sources 
and humans with no swine contact to determine if distinct subpopulations of ST5 isolates 
exist within different host populations, which may provide evidence of host adaption. 
Similar analyses have been conducted for the ST398 lineage, where researchers identified 
that the studied LA-MRSA ST398 isolates were within the same clade and that clade 
appeared to have evolved from an ancestral human methicillin susceptible S. aureus 
(MSSA) ST398 clade [323].  
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In this study, isolates from humans with no swine contact clustered distinctly 
from swine associated LA-MRSA ST5 isolates. All swine associated LA-MRSA ST5 
isolates were contained within Clade II, while all but one MRSA ST5 from humans with 
no swine contact belonged to Clade I. The MGE complement of this clinical MRSA ST5 
isolate (UCSF14436) suggests that it is likely a CA-MRSA isolate. CA-MRSA isolates 
tend to be genetically distinct from HA-MRSA isolates [22], which may explain why 
UCSF14436 is found within the LA-MRSA clade. The separation of LA-MRSA ST5 
isolates from clinical MRSA ST5 isolates based on their core genome relatedness 
supports our previous work, which indicated that swine associated LA-MRSA ST5 
isolates harbor different MGEs containing virulence and resistance genes than MRSA 
ST5 from humans with no swine contact [397-399]. The data reported here further 
demonstrate the phylogenetic distinction of isolates into different groups and may reflect 
the adaptation of LA-MRSA ST5 isolates to colonization of swine. Furthermore, similar 
to LA-MRSA ST398, evaluation of known virulence genes provides evidence that swine 
associated LA-MRSA ST5 may be less capable of causing disease in humans (Figure 3) 
[398].  
Our results indicate frequent introduction of MRSA ST5 onto swine farms is 
unlikely and dominant clones of MRSA ST5 circulated within each farm at the time of 
sampling. A high degree of genetic relatedness was identified among swine-associated 
isolates. As expected, the population of isolates found on individual farms were 
dominated by clonal populations. This indicates either a single introduction of LA-MRSA 
ST5 onto a farm or dominance of a single variant that precludes colonization with 
alternative isolates introduced by human caretakers. However, multiple S. aureus 
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lineages and spa types often occur simultaneously on swine farms and in individual pigs 
[402], so the diversity of S. aureus in these animals may be underrepresented when 
looking specifically at MRSA ST5 isolates. This clonality was not present in isolates 
from humans with no swine contact, where genome plasticity was greater and individual 
isolates showed more diversity than that observed among LA-MRSA ST5 isolates. 
While the evidence here suggests the populations of LA-MRSA ST5 and MRSA 
ST5 from humans with no swine contact are distinct, the isolates used in this analysis 
were sourced from geographically limited regions to ensure the clinical isolates were 
from patients with no swine contact. Because of the unlikelihood of these populations 
mingling, the SNPs identified can be attributed to the geographic separation or the host 
species of the isolates. In the future, the inclusion of clinical MRSA ST5 isolates from the 
hospital and community setting in areas of swine production could further elucidate the 
distribution and impact of LA-MRSA ST5 isolates outside of the livestock setting and the 
potential of swine associated isolates to cause disease in humans. As evidenced in this 
study, WGS followed by high resolution SNP profiling is a powerful molecular genomic 
epidemiology approach to gain insights into the population structure and transmission 
dynamics of LA-, CA-, and HA-MRSA and can provide important phylogenetic signals 
for strain attribution. 
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Abstract 
Livestock associated methicillin-resistant Staphylococcus aureus (LA-MRSA) 
draws concern from the public health community because in some countries these 
organisms may represent the largest reservoir of MRSA outside hospital settings. Recent 
studies indicate LA-MRSA strains from swine are more genetically diverse than the first 
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reported sequence type ST398. In the US, a diverse population of LA-MRSA is found 
including organisms of the ST398, ST9, and ST5 lineages. Occurrence of ST5 MRSA in 
swine is of particular concern since ST5 is among the most prevalent lineages causing 
clinical infections in humans. The prominence of ST5 in clinical disease is believed to 
result from acquisition of bacteriophages containing virulence or host-adapted genes 
including the immune-evasion cluster (IEC) genes carried by β-hemolysin converting 
bacteriophages, whose absence in LA-MRSA ST398 is thought to contribute to reduced 
rates of human infection and transmission associated with this lineage. The goal of this 
study was to investigate the prevalence of IEC genes associated with β-hemolysin 
converting bacteriophages in MRSA ST5 isolates obtained from agricultural sources, 
including swine, swine facilities, and humans with short- or long-term swine exposure. 
To gain a broader perspective, the prevalence of these genes in LA-MRSA ST5 strains 
was compared to the prevalence in clinical MRSA ST5 strains from humans with no 
known exposure to swine. IEC genes were not present in any of the tested MRSA ST5 
strains from agricultural sources and the β-hemolysin gene was intact in these strains, 
indicating the bacteriophage’s absence. In contrast, the prevalence of the β-hemolysin 
converting bacteriophage in MRSA ST5 strains from humans with no exposure to swine 
was 90.4%. The absence of β-hemolysin converting bacteriophage in LA-MRSA ST5 
isolates is consistent with previous reports evaluating ST398 strains and provides genetic 
evidence indicating LA-MRSA ST5 isolates may harbor a reduced capacity to cause 
severe disease in immunocompetent humans. 
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Introduction 
Staphylococcus aureus is a gram positive coccus that forms part of the normal 
nasal microflora in humans and other animal species. In developed countries, 
approximately one-quarter to one-third of healthy people harbor S. aureus in the nose, but 
prevalence appears to be lower in developing countries [403]. Although considered to be 
a commensal in the nasopharynx, S. aureus is an opportunistic pathogen causing a wide 
range of disease in humans. Skin and soft tissue infections are most commonly reported 
[58], but S. aureus also causes severe, invasive diseases including necrotizing 
pneumonia, bacteremia, osteomyelitis, and toxin mediated diseases such as toxic shock 
syndrome and staphylococcal enterotoxicosis. In 2005, the incidence rate for invasive 
MRSA infections per 100,000 individuals in the US was estimated to be 31.8 infections 
and 6.3 fatalities [367]. 
Resistance to methicillin was first reported in S. aureus in 1961 [246]. It is 
mediated by a mobile genetic element containing the mecA gene that confers resistance to 
methicillin and other β-lactam antibiotics. These isolates are designated methicillin 
resistant S. aureus (MRSA) and are difficult to treat, particularly if they have acquired 
multiple antibiotic resistance elements. Prevalence reports indicate MRSA may colonize 
as much as 1.5% of the healthy US population [42], and caused over 400,000 infections 
and millions of dollars in healthcare costs and lost productivity in 2009 [404]. 
Based on epidemiological characteristics, MRSA isolates are classified into three 
types: hospital-acquired (HA-MRSA), community-acquired (CA-MRSA), and livestock-
associated (LA-MRSA). HA-MRSA isolates are obtained through contact in a healthcare 
setting. CA-MRSA isolates are not associated with a healthcare environment and are 
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more commonly found in younger and healthy persons [58]. They are typically obtained 
from close contact environments, such as dormitories or athletic centers [405, 406]. CA-
MRSA isolates tend to possess fewer antimicrobial resistance elements, but exhibit 
increased virulence compared to HA-MRSA. The association between MRSA and swine 
was first reported in 2005 [248] and these isolates were referred to as LA-MRSA. 
MRSA isolates are typically characterized by their genetic lineage through multi-
locus sequence typing (MLST). MLST involves sequencing seven housekeeping genes 
(arcC, aroE, glpF, gmk, pta, tpi, yqiL) to obtain an allelic profile that defines the isolate’s 
sequence type (ST) [407]. STs present in the human population vary regionally and this 
trend is also true for animal populations, including swine. Initial reports of LA-MRSA 
from swine and other livestock species described isolates which all belonged to a novel 
MLST type (ST398). Subsequent research revealed a more complex epidemiology of S. 
aureus in pigs. The predominant swine-associated LA-MRSA lineage in Europe is ST398 
[312], while in Asia ST9 isolates are most prevalent [357]. However, LA-MRSA isolates 
in the United States are a diverse population containing ST398, ST9, and ST5 isolates 
[335]. The presence of ST5 isolates in swine has raised additional public health concern 
because, in contrast to ST398 and ST9, ST5 is a highly successful and globally 
disseminated MRSA lineage in humans with both HA- and CA-MRSA clones reaching 
pandemic levels [12]. 
The clinical significance of ST5 strains is thought to be due to their ability to 
acquire mobile genetic elements (MGE) containing virulence factors or antibiotic 
resistance genes. Of particular importance is the β-hemolysin converting bacteriophage 
that is commonly acquired by MRSA ST5 isolates [12]. The β-hemolysin converting 
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bacteriophage is a lysogenic phage that integrates into and disrupts the β-hemolysin gene 
of S. aureus. This bacteriophage contains an immune evasion cluster (IEC) encoding a 
combination of 1–4 known virulence factors that enhance the capacity of S. aureus strains 
to colonize, disseminate, and persist within a human host. These genes include: 
staphylococcal complement inhibitor (scn), chemotaxis inhibitory protein (chp), 
staphylokinase (sak), staphylococcal enterotoxin A (sea), and staphylococcal enterotoxin 
P (sep) [29]. These genes have been shown by in vitro assays to disrupt the normal 
function of the human immune system by inhibiting chemotaxis of phagocytes to the site 
of infection or inflammation (chp), preventing receptor-mediated phagocytosis (sak), 
inactivating antimicrobial peptides (sak), and inhibiting the complement cascade (scn) 
[165, 168, 169]. These proteins allow S. aureus to survive and replicate within host 
tissues causing local disease. Staphylokinase also acts through plasminogen activation to 
break down the extracellular matrix enabling bacterial dissemination from the initial site 
of infection [170]. Each of these proteins has been shown to be highly specific for human 
immune cells and serum proteins and are therefore considered human-specific virulence 
factors [165, 168, 408]. The toxin genes (sea and sep) are less specific to humans; 
however, they are important virulence determinants in disease. The enterotoxin proteins 
are superantigens, which when introduced systemically, non-specifically activate large 
populations of T cells in the host and cause dysregulation of the host’s adaptive immune 
response [409]. This limits the host’s ability to form an adaptive response specific to S. 
aureus antigens, preventing bacterial elimination [410]. While not all IEC genes are 
present within an individual prophage, the presence of a combination of several IEC 
genes confers increased virulence to an individual isolate. Previous studies indicate that 
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prophage integration was present in 90.5% of human clinical isolates [29]; however, 
because not all genes are present on a given bacteriophage, the prevalence of individual 
genes differs. 
In spite of the pathogenicity attributed to HA- and CA-MRSA ST5 isolates and 
detection of LA-MRSA ST5 in the nasal cavity of persons with swine contact, there are 
currently no known reports of clinical infection with ST5 isolates being attributed to 
animal contact. Epidemiological data has indicated that LA-MRSA ST398 isolates have 
reduced person-to-person transmission rates and are less virulent than their HA- and CA-
MRSA counterparts [339, 411]. Studies from pig dense regions in Europe suggest low 
risks of clinical infection with ST398 MRSA and there are few reports of severe clinical 
infections with LA-MRSA in people with animal contact despite high levels of exposure 
[412, 413]. Previous studies focusing on ST398 isolates have demonstrated the absence 
of MGE associated virulence factors, including the IEC genes described here which is 
believed to contribute to the decreased pathogenicity and zoonotic potential of LA-
MRSA isolates [323, 414, 415]. Reports showing a comparatively low prevalence of β-
hemolysin converting bacteriophages in swine-associated ST398 isolates along with the 
lack of reports implicating swine exposure in MRSA ST5 related disease have led to the 
hypothesis that swine-associated LA-MRSA ST5 isolates would similarly have a low 
prevalence of prophage integration compared to their counterparts causing human clinical 
infections. 
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Methods 
Strain acquisition 
Swine associated isolates were obtained from Iowa State University [335] and the 
University of Minnesota. Sources for these isolates were swine (38 isolates), the 
environment within swine facilities (26 isolates), humans with short-term contact with 
swine (9 isolates), and swine veterinarians representing humans with long-term contact 
with swine (9 isolates). Clinical isolates from humans with no swine contact, representing 
both HA- and CA- S. aureus isolates, were obtained from the University of California 
Irvine (64 MRSA isolates) [375] and the University of California San Francisco (7 
MRSA and 1 MSSA isolates). All isolates were MLST and Staphylococcal protein A 
(spa) typed prior to acquisition. Spa types can be found in Supplemental Table 1 
(available at https://doi.org/10.1371/journal.pone.0142832.s001) and Appendix A. ATCC 
strains Mu3 (ATCC #700698), Mu50 (ATCC #700699), Newman (ATCC #25904) were 
obtained for use as controls for the IEC genes, and a ST398 isolate from Iowa State 
University was used as a control for a strain encoding an intact β-hemolysin gene. 
DNA isolation 
Strains were grown overnight on Trypticase Soy Agar (BD Biosciences, Sparks, 
MD) at 37°C to obtain isolated colonies. Individual colonies were selected to start an 
overnight culture of Trypticase Soy Broth (BD Biosciences, Sparks, MD). After 12–18 
hours of growth, 750 μl of the liquid culture was pelleted and the supernatant was 
removed. The pelleted cells were stored at -80°C until DNA extraction. To isolate DNA, 
each pellet was resuspended in 200 μl 1× Phosphate Buffered Saline with 0.2 M EDTA. 
To lyse the cells, the following were added to each suspension: 12 μl of Lysozyme 
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solution (Sigma, St. Louis, MO), 1 μl RNase (Roche, Mannheim, Germany), 7.5 μl 
Lysostaphin solution (Sigma, St. Louis, MO), and 7.5 μl Mutanolysin solution (Sigma, 
St. Louis, MO). The cells were then incubated for 1 hour at 37°C. Forty microliters of 
Proteinase K (Roche, Mannheim, Germany) was added and the suspension was incubated 
overnight at 55°C. The following day, a Roche High Pure PCR Template Preparation Kit 
(Roche, Mannheim, Germany) was used to isolate DNA according to the manufacturer’s 
protocol. The Elution Buffer containing DNA samples was centrifuged for 5 minutes at 
8000xg to remove visible debris. The supernatant was transferred into a clean 1.5 mL 
tube and stored at 4°C until further analysis. 
PCR reactions 
The primers, reaction conditions, and expected product size are listed in Table 3.1 
[29, 182, 326, 416]. Primers were designed based on a multiple sequence alignment of 
Mu3, Mu50, and Newman. PCR screening was conducted in 50 uL reaction volume using 
either AmpliTaq (Applied Biosystems, Carlsbad, CA) or AccuPrime Taq (Invitrogen, 
Carlsbad, CA) depending on the primer set. An MJ Research PCT-200 DNA Engine 
thermocycler (GMI, Ramsey, MN) was used for amplification using the following 
settings: 30 cycles of 30 second denaturation at 94°C, 30 seconds annealing at the 
temperature listed, 1 minute extension at 72°C (AmpliTaq) or 68°C (AccuPrime). PCR 
products were run on a 1% agarose gel, stained with ethidium bromide, and visualized 
using UV light. Nucleotide sequence determination of PCR products was completed by 
Sanger sequencing methods. 
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Table 3.1: Primer sets with reaction components, expected product size and primer source. 
 
 
Primer 
 
 
Sequence 
 
Annealing 
Temp 
DNA 
Polymerase 
Used 
Expected 
Product 
Size 
 
Primer Source 
Int-F GCTTTGAAATCAGCCTGTAGAGTC  
54º 
 
 
AmpliTaq 
 
499 bp 
 
This study 
Hlb-R3 GTTGATGAGTAGCTACCTTCAGT Jarraud et al [416] 
Scn-F4 TGAGGCACAAGCTAGCACAAGCT  
63º 
 
 
AccuPrime 
 
224 bp 
 
This study 
Scn-R4 TGAAGTTGATATTTTGCTTCTGACATTTTC This study 
Sak-F2 TGAGGTAAGTGCATCAAGTTCA  
53º 
 
 
AmpliTaq 
 
403 bp 
 
Sung et al [326] 
Sak-R2 CCTTTGTAATTAAGTTGAATCCAGG Sung et al [326] 
Chp-F TTTACTTTTGAACCGTTTCCTAC  
51.5º 
 
 
AccuPrime 
 
404 bp 
 
van Wamel et al [29] 
Chp-R2 TGCATATTCATTAGTTTTTCCAGG Sung et al [326] 
Sea-F5 GGTTATCAATGTGCGGGTGG  
54º 
 
 
AmpliTaq 
 
322 bp 
 
This study 
Sea-R4 CAAATAAATCGTAATTAACCGAAGGTTC Jarraud et al [416] 
Sep-F2 GACCTTGGTTCAAAAGACACC  
54º 
 
 
AmpliTaq 
 
275 bp 
 
Diep et al [182] 
Sep-R2 TGTCTTGACTGAAGGTCTAGC Diep et al [182] 
Hlb-TNF1 TATGTTATCGACCGTGTTGTATCC  
58º 
 
 
AmpliTaq 
 
766 bp 
 
This study 
Hlb-TNR1 ATCCCATGGCTTAGGTTTTTCAGT This study 
6
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Southern blotting 
Genomic DNA (500ng) was digested overnight with BamH1 in a 25 uL reaction 
volume and run on a 1% agarose gel. Each gel was depurinated in 0.2M HCl for 10 
minutes and rinsed with distilled water. It was then placed in denaturing solution for 1 
hour followed by neutralizing solution for 1 hour. Each gel was set up for transfer via 
capillary action to a nylon membrane overnight. The DNA was crosslinked in UV light to 
the membrane. Prehybridization was done at 42°C for 2 hours and hybridized at 42°C 
overnight using a DIG labeled probe (Roche, Mannheim, Germany). The membrane was 
washed with 2× and 0.5× wash solution and blocked for 1 hour with maelic acid solution 
containing 5% powdered milk. It was then probed with anti-DIG antibody (Roche, 
Mannheim, Germany) at 1:10,000 in 5% powdered milk in maelic acid solution. The 
membrane was washed in washing buffer to remove excess antibody and CSPD (Roche, 
Mannheim, Germany) was added for visualization. Imaging was done using a 
myECLImager (Life Technologies, Grand Island, NY) or x-ray film development. 
Phage typing 
Phage types were designated based on the complement of IEC genes present in 
the isolate as determined by PCR results. The typing scheme employed is the same as 
previously reported by van Wamel and colleagues [29]. Briefly, type A included isolates 
carrying the genes sea, sak, chp, and scn. Isolates containing sak, chp, and scn were 
designated type B. Type C comprised isolates containing chp and scn. Those isolates 
carrying sea, sak, and scn were labeled type D. Isolates harboring sak and scn were 
designated type E. Type F were isolates containing sep, sak, chp, and scn. Those isolates 
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containing sep, sak, and scn were designated type G. Type H isolates were those 
containing only the scn gene as reported by Price and colleagues [323]. 
Statistical analysis 
The prevalence results were analyzed with a two-tailed Fisher’s exact test using 
the program GraphPad Prism (GraphPad Software, La Jolla, CA). A P value of 0.05 was 
used as the cutoff for statistical significance. 
Results 
IEC gene prevalence 
PCR screens of the ST5 isolates were used to detect the presence of each of the 
five IEC genes known to be carried by β-hemolysin converting bacteriophages. Results of 
all screening tests are listed in Table 3.2. The staphylococcal complement inhibitor (scn) 
gene was not found in any of the swine-associated ST5 isolates (0/82). It was detected in 
90.3% (65/72) of the isolates from humans with no swine contact (p < 0.0001). 
The gene for the chemotaxis inhibitory protein (chp) was absent in the swine-
associated isolates (0/82), but was detected in 88.9% (64/72) of isolates from humans 
with no swine contact (p < 0.0001). The staphylokinase (sak) gene was also lacking in all 
of the swine-associated isolates (0/82), but found to be present in 90.3% (65/72) of 
isolates from humans with no swine contact (p < 0.0001). The gene encoding 
staphylococcal enterotoxin-like P (sep) was absent from all swine-associated isolates 
(0/82), but detected in 37.5% (27/72) of isolates from humans with no swine contact (p < 
0.0001). The staphylococcal enterotoxin A (sea) gene was not found in any of the swine-
associated isolates (0/82), and the prevalence of this gene was also low (1.4%, 1/72) in 
isolates from humans with no swine contact (p = 0.4675).
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Table 3.2: Immune-evasion complex and β-hemolysin converting bacteriophage screening results for all isolates. 
 Gene Tested 
Isolate Source scn chp sak sea sep int Intact hlba 
Agricultural 
Human: short-
term contact 
0 (0/9)b 0 (0/9) 0 (0/9) 0 (0/9) 0 (0/9) 0 (0/9) 100 (9/9) 
Human: long-
term contact 
0 (0/9) 0 (0/9) 0 (0/9) 0 (0/9) 0 (0/9) 0 (0/9) 100 (9/9) 
Pig 0 (0/38) 0 (0/38) 0 (0/38) 0 (0/38) 0 (0/38) 0 (0/38) 100 (38/38) 
Environment 0 (0/26) 0 (0/26) 0 (0/26) 0 (0/26) 0 (0/26) 0 (0/26) 100 (26/26) 
Clinical 
90.3 
(65/72) 
88.9 
(64/72) 
90.3 
(65/72) 
1.4  
(1/72) 
37.5 
(27/72) 
90.3 
(65/72) 
9.7  
(7/72) 
a Data reported represents the results from Southern blotting.  
b Data reported as percent of isolates positive for each gene tested. Number of positive isolates is noted in parenthesis. 
 
Table 3.3: Phage types in human clinical isolates. 
Phage Type Genes van Wamel et al [29] Price et al [323] This Study 
A sea—sak—chp—scn a12.2 (11) 0 (0) 1.4 (1) 
B           sak—chp—scn  26.7 (24) 31.6 (6) 50 (36) 
C                    chp—scn 13.3 (12) 52.6 (10) 0 (0) 
D sea—sak—      —scn 15.6 (14) 0 (0) 0 (0) 
E           sak—      —scn 14.4 (13) 0 (0) 1.4 (1) 
F sep—sak—chp—scn 4.4 (4) 0 (0) 37.5 (27) 
G sep—sak—      —scn 3.3 (3) 0 (0) 0 (0) 
H                              scn 0 (0) 10.5 (2) 0 (0) 
None None 10 (9) 5.3 (1) 9.7 (7) 
aData are reported as the percent of isolates of each phage type out of the number of isolates evaluated. The number of isolates found of each phage type is listed 
in parenthesis.  
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β-hemolysin converting bacteriophage prevalence via integrase gene screening 
Although PCR results for the IEC genes indicated the presence or absence of the 
β-hemolysin converting bacteriophage in the tested isolates, PCR analysis for the 
integrase gene insertion site was used to verify the presence of an integrated phage. The 
integrase gene enables lysogenic bacteriophages to integrate into the bacterial genome. 
Due to the high degree of nucleotide sequence conservation of bacteriophage integrase 
genes, the primers used for this PCR analysis were developed to create a product that 
spanned the 3’ end of the integrase gene and the 5’ end of the β-hemolysin gene (Figure 
3.1). This ensured specificity to the integrase gene of the β-hemolysin converting 
bacteriophage. None of the swine isolates were found to contain the integrase/β-
hemolysin gene junction (0/82), while the gene was present in 90.3% (65/72) of the 
isolates from humans with no swine contact (p < 0.0001). 
 
 
 
Figure 3.1. Location of primers used for PCR used to test for the presence of the integrase gene and 
intact β-hemolysin gene. The integrase gene associated with the β-hemolysin converting bacteriophage 
(int CDS) and the 5’ end of the disrupted β-hemolysin gene (truncated beta-hemolysin CDS) are shown 
along with the primer specific for the the integrase gene (Int-F) and the primer specific for the β-hemolysin 
gene (Hlb-R3). The primers used for detection of an intact β-hemolysin gene (Hlb-TNF1 and Hlb-TNR1) 
spanned the disrupted portion of the gene and no product should be generated when the phage has 
integrated. 
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β-hemolysin gene analysis 
To further confirm the absence of the β-hemolysin converting bacteriophage in 
the isolates tested, PCR screening was undertaken using primers Hlb-TNF1 and Hlb-
TNR1 (Figure 3.1). An ST398 strain was used as a control for the absence of the 
bacteriophage and produced a 750 base pair product, while the controls for the presence 
of the bacteriophage, ST8 Newman, ST5 Mu3, ST5 Mu50, produced a 300 base pair 
product. After further analysis, the nucleotide sequence of 300 base pair product 
produced by the control isolates containing the bacteriophage was determined to be a 
portion of bacteriophage DNA at the 5’ end of the integrated sequence. All swine-
associated isolates produced a band 750 base pairs in length (82/82). These results 
demonstrate that the β-hemolysin gene is intact and no bacteriophage is present in these 
strains. Of isolates from humans with no swine contact, 9.7% (7/72) produced a band 750 
base pairs in length. However, only 31.9% (23/72) of the isolates produced a single band 
300 base pairs in length. Many of the isolates (56.9%, 41/72) produced two bands, one at 
750 base pairs and the other at 300 base pairs in length (Figure 3.2). After comparing 
these results with the PCR results for the IEC genes and the integrase gene, it was 
determined that the isolates producing a 300 base pair band, even with the presence of a 
750 base pair band, were carrying a disrupted β-hemolysin gene. One explanation for the 
multiple PCR products is that they may have been produced due to the induction of beta-
converting phage during bacterial culture, subsequently leading to the loss of phage in a 
sub-population of bacterial cells. 
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Figure 3.2.  Agarose gel electrophoresis demonstrating inconclusive banding pattern resulting from 
PCR used to test an intact β-hemolysin gene in isolates obtained from humans with no swine contact. 
Those isolates producing only a 750bp band were found to contain an intact β-hemolysin gene, while 
isolates producing only a 300bp band or both bands were found to contain a disrupted β-hemolysin gene. A 
disrupted β-hemolysin gene is represented by the negative control ST8 Newman (lane 1), which produced a 
band 300bp in size. An intact β-hemolysin gene is represented by the positive control ST398 (lane 2), 
which produced a band 750bp in size. Of the isolates from humans with no swine contact, 9.7% (7/72) 
produced a 750bp band (lane 8) and 31.9% (23/72) produced a 300bp band (lane 4, 7). However, 56.9% 
(41/72) of the isolates produced both a 750bp and a 300bp band (lane 3, 5, 6, 9–13). 
 
Due to the inconclusive banding pattern, Southern blotting was used to confirm 
whether the β-hemolysin gene was intact or disrupted using a probe derived from the 
750bp PCR product of ST398 and the Hlb-TNF1 and Hlb-TNR1 primers. The restriction 
enzyme BamH1 was selected to digest the genomic DNA because no restriction sites 
were present within the β-hemolysin gene or any of the bacteriophage genes (confirmed 
using Newman, Mu3, and Mu50 genomes in GenBank accession numbers NC_009641, 
NC_009782, NC_002758 respectively). The genome fragments produced by BamH1 
digestion of isolates with an intact and disrupted β-hemolysin genes were approximately 
20kb and 65kb respectively and were readily distinguished during analysis of the 
Southern blots (Figure 3.3). Intact genes produced a distinct band around 20kb, while 
disrupted genes showed background extending beyond 48kb with no distinct band. The 
lack of a distinct band seen with the disrupted genes was attributed to reduced annealing 
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strength of the probe to the disrupted β-hemolysin gene and the reduced transfer rate seen 
with larger band sizes. Southern blotting was able to confirm β-hemolysin gene 
disruption in 90.3% (65/72) of the isolates from humans with no swine contact. The β-
hemolysin gene was intact in 9.7% (7/72) of isolates from humans with no swine contact 
and in 100% (82/82) of the swine-associated isolates (p < 0.0001). 
 
 
 
Figure 3.3.  Southern blot demonstrating the presence of an intact or disrupted β-hemolysin gene. 
Isolates containing an intact β-hemolysin gene produced a distinct band (20kb) as seen with the control 
isolate ST398 that lacked the bacteriophage (lane 1). Isolates containing a disrupted β-hemolysin gene did 
not produce a distinct band at 20kb and background extended in the lanes to a size greater than 40kb, as 
seen with the control ST8 Newman (lane 2). Swine-associated MRSA ST5 isolates are represented by lanes 
3–5 and MRSA ST5 from humans with no swine contact are represented by lanes 6–17. Lanes 13 and 17 
contained isolates from humans with no swine contact bearing an intact β-hemolysin gene.. 
 
Phage typing 
The different combinations of the immune evasion complex genes carried by the 
β-hemolysin converting bacteriophage have been previously defined into seven types (A-
G) by van Wamel and colleagues [29]. A novel phage type was discovered by Price and 
colleagues and will be referred to here as type H [323]. The phage types found in both 
studies can be found in Table 3.3 along with the prevalence rate found in the isolates 
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from humans with no swine contact analyzed in this study. The ST5 isolates evaluated in 
this study were found to contain primarily type B (50%, 36/72) and type F (37.5%, 27/72) 
prophages. 
Discussion 
It has long been known that S. aureus commonly colonizes many mammalian and 
avian species and particular lineages are more adapted to different host species [417]. The 
recent recognition that livestock may represent a substantial reservoir of MRSA and 
people having regular contact with animals were commonly colonized with LA-MRSA 
isolates represented a shift in MRSA epidemiology and raised urgent questions about the 
public health significance of these organisms. Fundamental questions remain about the 
ability of S. aureus lineages adapted to animals to both colonize and cause disease in 
humans. The capacity of ST398 LA-MRSA to cause clinical disease in humans is 
established, but reports of severe infections in people with occupational exposure to 
livestock remain uncommon, despite continued exposure to these organisms. There is 
increasing evidence that ST398 MRSA isolates of animal origin are less likely to be 
transmitted between people and are less likely to be associated with severe infections 
than are human adapted variants. Genomic studies have indicated that distinct livestock 
and human variants are identifiable even within a given sequence type and spa type, such 
as ST398/t571 and ST1/t127 [344, 418]. More specifically, the absence of MGE 
associated virulence factors, including IEC genes has been linked to host adaptation and 
loss of virulence in ST398 LA-MRSA [323, 414, 415]. 
The MRSA lineages ST398 and ST9, which predominate in swine populations in 
Europe and Asia respectively, do not appear to have a significant impact on human health 
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in the US. Unlike in Europe and Asia where ST5 MRSA have only rarely been reported, 
several studies indicated that ST5 S. aureus (both MRSA and MSSA) are relatively 
common in the North American swine industry [335, 353, 362, 402, 419]. Because the 
ST5 lineage is a major contributor to both hospital and community associated MRSA and 
MSSA infections in this country and worldwide [12, 420], it is important to address the 
question about the potential contribution, if any, of the swine reservoir to the burden of 
clinical disease associated with ST5 S. aureus. 
At this time, no human disease due to swine-associated LA-MRSA ST5 isolates 
has been reported. This may be due to differences in the composition of the accessory 
genome seen in LA-MRSA versus HA- and CA-MRSA isolates, similar to that 
previously noted in ST398 isolates [323, 415]. HA- and CA-MRSA ST5 isolates are 
known to carry several MGE that enhance their virulence and antibiotic resistance, which 
have contributed to their dissemination and pathogenicity [12]. 
This is the first report examining β-hemolysin converting bacteriophage 
prevalence within human clinical MRSA ST5 isolates specifically. The incidence of 
prophage integration in ST5 isolates obtained from humans with no swine contact was 
consistent with that found in previous reports of human clinical S. aureus isolates, both 
MRSA and methicillin-susceptible [29, 323, 415]. Additionally, this is the first study 
investigating the prevalence of the β-hemolysin converting bacteriophage in LA-MRSA 
ST5 isolates. The results obtained in this study are consistent with previous publications, 
and comparative statistical analysis showed no significant difference (p = 0.3987) in the 
prevalence of β-hemolysin converting bacteriophages between LA-MRSA ST5 isolates 
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evaluated in this study (0/82) and LA-MRSA ST398 isolates evaluated previously (1/63) 
by Price and colleagues [323]. 
Due to the restricted host specificity of the most prevalent genes (sak, scn, chp), it 
has been suggested that this prophage may be absent in MRSA isolates after adapting to a 
livestock niche [323]. These genes would not confer an advantage during colonization or 
disease development in livestock species and are therefore unnecessary to retain within 
the genome of LA-MRSA isolates. The loss of these important virulence factors is likely 
one of the reasons LA-MRSA isolates are rarely known to cause invasive disease in 
immunocompetent humans. The absence of IEC genes carried by β-hemolysin converting 
bacteriophages in LA-MRSA ST398 and ST5 strains parallels the findings for poultry 
adapted ST5 strains in that the human-specific IEC genes were lost and subsequently 
replaced by genes encoding avian-specific factors after the human-to-poultry transition 
[325]. However, unlike poultry adapted ST5 strains, swine-associated LA-MRSA ST398 
and ST5 strains harbor an intact β-hemolysin gene, indicating that the bacteriophage is 
absent from these strains rather than being replaced by genes encoding swine-specific 
factors. 
There were several interesting differences noted between the prevalence of phage 
types found in the human clinical isolates evaluated in this study compared to those 
previously reported by van Wamel and colleagues (Table 3.3). Their initial investigation 
and description of the β-hemolysin converting bacteriophage types was completed using 
85 clinical S. aureus isolates from several hospitals in the Netherlands and 5 S. aureus 
reference strains [29]. These isolates were not characterized using MLST typing and are 
therefore thought to have a more diverse genetic background than the isolates evaluated 
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here. Specifically, the enterotoxin A (sea) and enterotoxin-like P (sep) gene prevalence 
varied considerably between these investigations. In this study, significantly more (p < 
0.0001) isolates were found to harbor the sep gene and significantly less (p < 0.0001) 
isolates were found to harbor the sea gene compared to the prevalences previously 
reported. The results reported here correlate with a decrease in the prevalence of phage 
types A and D and an increase in phage type F. This was surprising in that sea is 
considered to be the most common enterotoxin involved in staphylococcal food borne 
illness [409]. The increased prevalence of sep seen in this study may indicate a larger role 
in the development of clinical disease than previously described. Additionally, 
significantly more isolates were found to harbor the chp gene (p < 0.0001) and the sak 
gene (p = 0.0352) in this study. These results correlate with an increase in prevalence of 
the type B and F prophages that contain the three innate immune evasion genes. 
Variability in phage types seen within this population of clinical MRSA ST5 isolates 
indicates multiple acquisitions of the β-hemolysin converting bacteriophage even within a 
regional population. The differences in phage prevalence reported in this study compared 
to the van Wamel study may be due to the sample populations evaluated. The isolates 
evaluated previously were clinical isolates from several hospitals in the Netherlands and 
no MLST types were indicated. In contrast, the isolates evaluated in this study comprised 
of 73 clinical ST5 isolates from University of California associated medical facilities. 
The differences in phage prevalence reported could be attributed to the disease profile of 
the isolates, the narrowed genetic background of the isolates evaluated, or a regional 
difference (California versus the Netherlands) not previously noted. 
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ST5 S. aureus appear to be widespread in the North American swine population 
and have likely been endemic in this reservoir for some time, yet livestock contact has 
not been identified as a risk factor for clinical staphylococcal disease [361]. This 
investigation identified clear genomic differences between ST5 MRSA isolates linked to 
swine and isolates from human clinical infections. These differences parallel previous 
observations with ST398 isolates. We hypothesize that the genetic changes observed may 
reflect general processes related to host adaptation of S. aureus to pigs. More extensive 
genomic investigations of ST5 S. aureus in pigs are warranted, as is investigation of other 
lineages S. aureus associated with pigs such as ST9. 
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Abstract 
Zinc resistance in livestock-associated methicillin-resistant Staphylococcus 
aureus (LA-MRSA) sequence type 398 (ST398) is primarily mediated by the czrC gene 
colocated with the mecA gene, encoding methicillin resistance, within the type V 
staphylococcal cassette chromosome mec (SCCmec) element. Because czrC and mecA 
are located within the same mobile genetic element, it has been suggested that the use of 
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zinc in feed as an antidiarrheal agent has the potential to contribute to the emergence and 
spread of methicillin-resistant S. aureus (MRSA) in swine, through increased selection 
pressure to maintain the SCCmec element in isolates obtained from pigs. In this study, we 
report the prevalence of the czrC gene and phenotypic zinc resistance in U.S. swine-
associated LA-MRSA ST5 isolates, MRSA ST5 isolates from humans with no swine 
contact, and U.S. swine-associated LA-MRSA ST398 isolates. We demonstrated that the 
prevalence of zinc resistance in U.S. swine-associated LA-MRSA ST5 isolates was 
significantly lower than the prevalence of zinc resistance in MRSA ST5 isolates from 
humans with no swine contact and swine-associated LA-MRSA ST398 isolates, as well 
as prevalences from previous reports describing zinc resistance in other LA-MRSA 
ST398 isolates. Collectively, our data suggest that selection pressure associated with zinc 
supplementation in feed is unlikely to have played a significant role in the emergence of 
LA-MRSA ST5 in the U.S. swine population. Additionally, our data indicate that zinc 
resistance is associated with the multilocus sequence type lineage, suggesting a potential 
link between the genetic lineage and the carriage of resistance determinants. 
Importance 
Our data suggest that coselection thought to be associated with the use of zinc in 
feed as an antimicrobial agent is not playing a role in the emergence of livestock-
associated methicillin-resistant Staphylococcus aureus (LA-MRSA) ST5 in the U.S. 
swine population. Additionally, our data indicate that zinc resistance is more associated 
with the multilocus sequence type lineage, suggesting a potential link between the genetic 
lineage and the carriage of resistance markers. This information is important for public 
health professionals, veterinarians, producers, and consumers 
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Introduction 
Staphylococcus aureus commonly colonizes the skin and mucosal surfaces of 
mammalian and avian species and is present in the anterior nares of 20 to 30% of healthy 
humans [42]. S. aureus is also a major opportunistic human pathogen with diverse 
clinical manifestations, ranging from mild skin and soft tissue infections to severe 
systemic infections and fatal sepsis. Prior to the availability of antibiotics, fatality rates 
for human cases of S. aureus bacteremia were estimated at 80% [186]. Increased access 
to antibiotics has reduced the case fatality rate of S. aureus bacteremia to around 20 to 
30% [186], but the capacity of S. aureus to acquire resistance to antibiotics has made 
multidrug-resistant strains a major public health concern [368].  
Methicillin-resistant S. aureus (MRSA) was first reported in 1961 [246] and 
rapidly became endemic in hospitals (i.e., hospital-associated MRSA [HA-MRSA]) in 
many countries. During the 1990s, an increasing number of MRSA infections occurred in 
persons with no known risk factors for HA-MRSA infection [421]. These infections 
developed in healthy members of the general community and were termed community-
associated MRSA (CA-MRSA). S. aureus is considered a clonal organism, and genotypes 
associated with hospital infections typically differed from those associated with 
community infections, as well as varying geographically [422]. 
Although MRSA was first reported in food animals (dairy cattle) in 1972 [309], 
animal reservoirs were not considered to play a significant role in MRSA epidemiology 
until 2004, when an atypical MRSA variant was detected in three people in the 
Netherlands and was attributed to their residence on a swine farm [248]. These initial 
isolates could not be typed by pulsed-field gel electrophoresis using SmaI restriction 
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digestion, due to a variation in methylation by the type I restriction modification system. 
Multilocus sequence typing (MLST) revealed that these isolates belonged to a novel 
sequence type (ST), ST398 [248]. This genotype was found to be widespread in the 
Dutch pig industry and to be present in other animal species, including cattle, poultry, 
and horses [12, 312, 423, 424]. Subsequent research revealed more complex 
epidemiology, and the predominant genotypes of MRSA found in swine vary 
geographically. In most Asian countries, ST9 variants are most common [357, 359, 425]; 
in the United States and Canada, both ST398 and ST5 MRSA variants appear to be 
relatively common, with ST9 MRSA being detected sporadically [335, 353, 360, 362]. 
Resistance to tetracycline antibiotics has been almost universal in S. aureus 
isolates from pigs. Additionally, a prominent feature of livestock-associated MRSA (LA-
MRSA) ST398 isolates from Europe and North America is the high prevalence (61 to 
74%) of zinc resistance seen in swine-associated isolates [323, 346, 347, 349], relative to 
isolates from veal calves (42%) or humans (48%) [346, 347]. Zinc resistance in these 
MRSA isolates has been attributed to colocalization of the czrC gene (conferring zinc and 
cadmium resistance) on the type V staphylococcal cassette chromosome mec (SCCmec) 
element, which contains the mecA gene (conferring methicillin resistance). A strong 
correlation between phenotypic zinc resistance and the presence of czrC was reported 
previously, with 99% of MRSA ST398 isolates harboring czrC showing phenotypic zinc 
resistance and 96% of isolates exhibiting zinc resistance harboring the czrC gene [346]. 
Dietary zinc supplementation at >2,400 ppm (compared with the minimum nutritional 
requirement of 100 to 165 ppm) for 5 to 10 days is commonly used in weaned pigs to 
control enteric disease [426]. Since czrC and mecA are colocated on the SCCmec 
82 
 
element, it has been suggested that the use of high concentrations of zinc in feed might 
have contributed to the emergence and spread of MRSA in swine, by increasing the 
selection pressure to maintain the SCCmec element in swine-associated ST398 isolates 
[348, 349, 427]. 
While many reports detailing the prevalence of zinc resistance in LA-MRSA 
ST398 and ST9 isolates have been published, little to no information exists regarding the 
prevalence of zinc resistance in LA-MRSA ST5 isolates [346]. Here we report the 
prevalence of zinc resistance in U.S. swine-associated LA-MRSA ST5 isolates and 
compare it with the prevalence in MRSA ST5 isolates obtained from humans with no 
swine contact and that in U.S. swine-associated LA-MRSA ST398 isolates, as well as 
that in previous studies reporting zinc resistance in LA-MRS ST398 isolates. 
Materials and Methods 
Isolate acquisition 
Swine-associated LA-MRSA ST5 cultures were isolated from swine (n = 38), the 
environment within swine facilities (n = 26), and persons with short-term (n = 9) and 
long-term (n = 9) swine contact. These isolates were provided by Iowa State University 
and the University of Minnesota [335]. Clinical isolates from humans with no swine 
contact were obtained from the University of California, Irvine (n = 64) [375], and the 
University of California, San Francisco (n = 7 MRSA and 1 methicillin susceptible S. 
aureus), hospitals servicing urban populations in Orange County (southern California) 
and the San Francisco area (northern California), respectively. Swine-associated LA-
MRSA ST398 cultures obtained from Iowa State University were isolated from swine (n 
= 8) or the environment within swine facilities (n = 6) [335]. Isolates were subjected to 
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MLST and spa typing prior to acquisition [335, 375]. Isolate sources and spa types are 
provided in Supplemental Table 1 (available at https://doi.org/10.1128/AEM.00756-17) 
and in Appendix A. 
Zinc susceptibility testing 
Zinc chloride MICs were determined by agar dilution, as described by Aarestrup 
and Hasman [428]. Briefly, plates of Mueller-Hinton agar with an adjusted pH of 5.5 
were supplemented with zinc chloride in 2-fold dilutions, with concentrations ranging 
from 0.25 to 16 mM. The isolate Salmonella enterica subsp. enterica serovar 
Typhimurium ATCC 14028 was used as a positive control, and S. aureus ATCC 29213 
and ATCC 43300 were used as negative controls. A MIC value of >2 mM was used as 
the cutoff value to designate resistance, in accordance with previously published reports 
and the result for the positive control in this study [346, 347]. 
czrC PCR testing 
The presence of the czrC gene was determined by PCR using previously reported 
primers and protocols [347]. Briefly, PCR was carried out in an MJ Research PCT-200 
DNA Engine thermocycler (GMI, Ramsey, MN) using 50 ng of purified genomic DNA 
from the appropriate strains, the forward primer 5’-TAGCCACGATCATAGTCATG-3’, 
and the reverse primer 5’-ATCCTTGTTTTCCTTAGTGACTT-3’. Reaction mixtures 
included 0.4 μM primers, 1 U of AmpliTaq polymerase (Applied Biosystems, Foster 
City, CA), 2.5 μl of 10× buffer II (100 mM Tris-HCl [pH 8.3], 500 mM KCl), 2.5 mM 
MgCl2, and 200 μM deoxynucleoside triphosphates (dNTPs), in a final volume of 50 μl. 
Cycling conditions were 95°C for 2 min, 30 cycles of 95°C for 15 s, 52°C for 30 s, and 
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72°C for 1.5 min, and a final extension step of 72°C for 7 min. PCR products were run on 
a 1% agarose gel, stained with ethidium bromide, and visualized using UV light. 
SCCmec typing 
SCCmec typing was completed using previously designed primer sets (Table 4.1) 
[429-434]. Briefly, PCR was carried out in a MJ Research PCT-200 DNA Engine 
thermocycler (GMI) using 50 ng of purified genomic DNA from the appropriate strains; 
reaction mixtures included 0.4 μM primers, 1 U of AmpliTaq polymerase (Applied 
Biosystems), 2.5 μl of 10× buffer II (100 mM Tris-HCl [pH 8.3], 500 mM KCl), 2.5 mM 
MgCl2, and 200 μM dNTPs, in a final volume of 50 μl. PCR for the ccrA and ccrB genes 
was a multiplex reaction with cycling conditions of 95°C for 2 min, 10 cycles of 95°C for 
15 s, 65°C for 30 s, and 72°C for 1.5 min, 25 cycles of 95°C for 15 s, 55°C for 30 s, and 
72°C for 1.5 min, and a final extension step of 72°C for 7 min. PCR of the ccrC gene 
used cycling conditions of 95°C for 2 min, 30 cycles of 95°C for 15 s, 58°C for 30 s, and 
72°C for 2 min, and a final extension step of 72°C for 7 min. PCR of the mec element 
genes was completed with cycling conditions of 95°C for 2 min, 30 cycles of 95°C for 15 
s, 50°C for 30 s, and 72°C for 2 min, and a final extension step of 72°C for 7 min. PCR 
products were run on a 1% agarose gel, stained with ethidium bromide, and visualized 
using UV light. 
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Table 4.1: Primer sets used to SCCmec type isolates.  
 
 
Nucleotide Sequence  Expected Product 
(Forward Primer 
Used) 
Source 
ccrB-F ATTGCCTTGATAATAGCCITCT  Ito et al. 2001 [429] 
ccrA1-R AACCTATATCATCAATCAGTACGT 694 (ccrB-F) Ito et al. 2001 [429] 
ccrA2-R TAAAGGCATCAATGCACAAACACT 937 (ccrB-F) Ito et al. 2001 [429] 
ccrA3-R AGCTCAAAAGCAAGCAATAGAAT 1791 (ccrB-F) Ito et al. 2001 [429] 
ccrA4-R GTATCAATGCACCAGAACTT 1287 (ccrB-F) Kondo et al. 2007 [431] 
ccrC-F CGTCTATTACAAGATGTTAAGGATAAT  Kondo et al. 2007 [431] 
ccrC-R CCTTTATAGACTGGATTATTCAAAATAT 518 (ccrC-F) Kondo et al. 2007 [431] 
mecI-F CAAGTGAATTGAAACCGCCT  Okuma et al. 2002 [432] 
mecI-R CAAAAGGACTGGACTGGAGTCCAAA 187 (mecI-F) Okuma et al. 2002 [432] 
mecR1-R GTCTCCACGTTAATTCCATT 1920 (mecI-F) Kobayashi et al. 1996 [433] 
Class B-F TATACCAAACCCGACAAC  Katayama et al. 2001 [430] 
IS1272-R AACGCCACTCATAACATATGGAA 1996 (Class B-F) Okuma et al. 2002 [432] 
Class C-F AACGTTGTAACCACCCCAAGA  Hiramatsu et al. 1992 [434] 
IS431-R TGAGGTTATTCAGATATTTCGATGT 2072 (Class C-F) Katayama et al. 2001 [430] 
8
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Whole-genome sequencing and analysis 
Draft genome sequence data for 14 czrC-carrying isolates (UCI3, UCI9, UCI11, 
UCI19, UCI21, UCI24, UCI27, UCI43, UCI45, UCI46, UCI48, UCI52, UCI56, and 
UCI64) were generated using the Illumina MiSeq platform (Illumina, San Diego, CA) 
[376]. Indexed libraries were generated and run on the MiSeq platform using the 500-
cycle MiSeq v2 reagent kit. The data were assembled using MIRA 4.0.2 (http://mira-
assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html) [435]. Closed genomes 
were obtained for UCI28 and UCI62 as described previously [436]. Briefly, genomic 
DNA was sequenced with a PacBio RSII instrument using a 10-kb insert library and one 
SMRT cell for each isolate. The data were assembled using PacBio SMRT Analysis 2.3.0 
and CANU 1.3 software. The genomes were then polished and error corrected using 
Illumina MiSeq data and Broad Institute Pilon 1.18 software. Whole-genome sequence 
data were analyzed using Geneious 9.0.5 (Biomatters Ltd., Auckland, New Zealand). The 
SCCmec region was extracted from the closed genome sequences of Mu3 (GenBank 
accession number AP009324.1), UCI28 (GenBank accession number CP018768), UCI62 
(GenBank accession number CP018766), and S0385 (GenBank accession number 
AM990992.1); these were compared visually in Geneious, using multiple sequence 
alignments to determine similarity. For the 14 draft genomes, the contig harboring the 
czrC gene was extracted and used for comparison. These regions were analyzed for 
similarity to UCI28 and UCI62 using multiple sequence alignments. 
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Statistical analysis 
Comparisons between isolates from humans with no swine contact and swine-
associated isolates were completed using Fisher’s exact test using GraphPad Prism 
(GraphPad Software, La Jolla, CA). 
Accession numbers  
The whole-genome sequences for isolates UCI28 and UCI62 were deposited in 
DDBJ/ENA/GenBank with the following accession numbers: UCI28, CP018768 and 
CP018769; UCI62, CP018766 and CP018767 [436]. The draft genome sequences 
obtained for 14 S. aureus ST5 isolates were deposited in DDBJ/ENA/GenBank with the 
following accession numbers: UCI3, LKYU00000000; UCI9, LKZA00000000; UCI11, 
LKZC00000000; UCI19, LKZK00000000; UCI21, LKZM00000000; UCI24, 
LKZP00000000; UCI27, LKZS00000000; UCI43, LLAI00000000; UCI45, 
LLAK00000000; UCI46, LLAL00000000; UCI48, LLAN00000000; UCI52, 
LLAR00000000; UCI56, LLAV00000000; UCI64, LLBD00000000 [376]. 
Results 
Prevalence of the czrC gene 
The czrC-specific PCR demonstrated that none of the tested swine-associated 
MRSA ST5 isolates (0/82 isolates) harbored the czrC gene (Table 4.2). In contrast, all 
LA-MRSA ST398 isolates (14/14 isolates) tested harbored the czrC gene. The prevalence 
of czrC in LA-MRSA ST5 isolates associated with swine was significantly lower than 
that in swine-associated LA-MRSA ST398 isolates (P < 0.0001) (Table 4.2) and also was 
lower than that reported for other LA-MRSA ST398 isolates (P < 0.0001) [346]. Over 
one-fifth of MRSA ST5 isolates obtained from humans with no swine contact (16/72 
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isolates [22%]) contained the czrC gene (Table 4.2). The prevalence of the czrC gene 
among MRSA ST5 isolates obtained from humans with no swine contact was 
significantly higher than that among swine-associated ST5 isolates (P < 0.0001) (Table 
4.2). Information on individual isolates is provided in Supplemental Table 1 (available at 
https://doi.org/10.1128/AEM.00756-17). 
Table 4.2: The prevalence of phenotypic zinc chloride resistance and czrC presence in isolates from 
human with no swine contact and swine-associated isolates. 
Characteristic 
Number of Isolates/Total Number of Isolates (%) 
MRSA ST5 from Humans 
with no Swine Contact 
LA-MRSA 
ST5 
LA-MRSA 
ST398 
czrC PCR Prevalence 16/72 (22.2%)a 0/82 (0%) 14/14 (100%)a 
Phenotypic Zinc 
Chloride Resistance 18/72 (25%)a 0/82 (0%) 14/14 (100%)a 
a – Statistical significance (p < 0.0001) as compared to LA-MRSA ST5 
Zinc chloride susceptibility testing 
Susceptibility testing revealed that no swine-associated MRSA ST5 isolates (0/82 
isolates) were resistant to zinc chloride, while phenotypic resistance was seen for all LA-
MRSA ST398 isolates (14/14 isolates). The prevalence of phenotypic resistance to zinc 
among MRSA ST5 isolates obtained from humans with no swine contact was 25% (18/72 
isolates), greater than among swine-associated MRSA ST5 isolates (P < 0.0001) (Tables 
4.2 and 4.3). Two MRSA ST5 isolates obtained from humans with no swine contact 
exhibited phenotypic resistance despite not harboring the czrC gene. Phenotypic zinc 
chloride resistance in the absence of czrC was reported previously for MRSA ST398 and 
non-ST398 isolates by Cavaco et al. [346], which indicates that an alternative mechanism 
for zinc resistance is also present in MRSA ST5 isolates. 
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Table 4.3: Results from phenotypic zinc chloride resistance screen. 
Isolate Type 
Number of isolates with susceptibility of*: 
0.25 
mM 
0.5 
mM 
1 
mM 
2 
mM 
4 
mM 
8 
mM 
16 
mM 
MRSA ST5 from Humans 
with no Swine Contact  
(n = 73) 
7 0 18 29 14 4 0 
LA-MRSA ST5  
(n = 82) 
0 20 53 9 0 0 0 
LA-MRSA ST398 
(n = 14) 
0 0 0 0 14 0 0 
* >2 mM designates resistance 
SCCmec typing 
The swine-associated LA-MRSA ST5 isolates carried SCCmec type III (17/82 
isolates [21%]) or type IV (42/82 isolates [51%]) or could not be typed using the primer 
sets published previously (23/82 isolates [28%]) (Table 4.4). Of the 23 untypeable 
isolates, 20 (24.4% of LA-MRSA ST5 isolates) carried a class D mec gene complex, 
which has not been assigned to a mec type, and 3 carried a class A mec gene complex 
without the traditional ccrA-ccrB gene combination. All LA-MRSA ST398 isolates tested 
harbored SCCmec type V (14/14 isolates). The MRSA ST5 isolates from humans with no 
known swine contact mostly carried SCCmec type II (69/72 isolates [96%]); the others 
were type IV (2/72 isolates [2.8%]) or lacked a SCCmec element (1/72 isolates [1.4%]). 
Table 4.4: SCCmec type and czrC gene prevalence in swine associated LA-MRSA ST5 and ST398 
and MRSA ST5 isolates from humans with no swine contact. 
Isolate type SCCmec type czrC prevalence 
LA-MRSA ST5 
III 0/17 
IV 0/42 
Untypablea 0/23 
MRSA ST5 from Humans with no 
Swine Contact 
II 16/69 
IV 0/2 
None 0/1 
LA-MRSA ST398 V 14/14 
 a – Isolates that are unable to be classified into an SCCmec type due to the presence of a ccr gene or mec 
complex unable to be determined using available primer sets or the presence of a ccr and mec complex 
combination not currently assigned an SCCmec type. 
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czrC localization 
To determine the location of the czrC gene within the genomes of the 16 MRSA 
ST5 isolates obtained from humans with no swine contact that harbored the czrC gene, 
draft genome sequences were obtained, along with the complete genome sequences for 
two of the strains (UCI28 and UCI62) [376, 436]. The gene content and organization of 
the SCCmec region and the surrounding mobile genetic elements for strains UCI28 and 
UCI62, along with strains Mu3 and S0385 for reference, are shown in Figure 4.1. The 
SCCmec region for strains Mu3 and UCI28 contained pUB110 within the J3 region of the 
SCCmec element (Figure 4.1-A and B). Strain UCI28 and 12 other isolates (UCI3, UCI9, 
UCI19, UCI21, UCI28, UCI43, UCI45, UCI46, UCI48, UCI52, UCI56, and UCI64) 
harbored czrC downstream of speG and upstream of pUB110 and the SCCmec element 
(Figure. 4.1-B) [376, 436]. The nucleotide sequences containing speG and czrC located 
between the 23S methyltransferase and the second transposase were observed to be 100% 
identical between strains UCI28 and UCI62. The SCCmec elements of Mu3, UCI28, and 
UCI62 were observed to be 95.8% identical, with nucleotide differences being found in 
the J2 region. Isolate UCI62, as well as UCI11and UCI27, harbored czrC downstream of 
speG and upstream of the arginine catabolic mobile element (ACME) genes and the 
SCCmec element (Figure 4.1-C) [376, 436]. The czrC gene for all 16 clinical isolates, 
even those lacking ACME, was located downstream of speG, a spermidine 
acetyltransferase that functions in the detoxification of spermidine and is often found 
within the ACME composite island. The location of the czrC gene within the SCCmec  
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Figure 4.1. Localization of the czrC gene within the SCCmec region. SCCmec region and surrounding mobile genetic elements for Mu3 (A), UCI28 (B), 
UCI62 (C), and S0385 (D). All regions start at the 23S methyl-transferase (indicated by the blue pentagons ). Insertion sequences are depicted by solid black 
pentagons ( ). The location of the SCCmec elements, czrC, speG, and pUB110 are indicated along with other previously annotated genes of interest. The 
SCCmec element of S0385 (D) is given as a reference for the location of czrC within the type V SCCmec element in LA-MRSA ST398. 
9
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region of these isolates is different than the location of czrC in the LA-MRSA ST398 
reference strain S0385, in which czrC is located downstream of the mecA gene within the 
type V SCCmec (Figure 4.1-D) [333]. 
Discussion 
The recent emergence of MRSA in livestock throughout the world has become a 
focal point in discussions regarding the role of antibiotic use in food animal production 
and the development of antibiotic-resistant clinical infections in humans. However, the 
mechanisms and factors responsible for this emergence, as well as the factors 
contributing to the geographical variations in genotypes of swine-associated MRSA 
found globally, are poorly understood. Although some causal role of antibiotic use in the 
emergence of LA-MRSA is hypothesized and may seem obvious, epidemiological 
evidence of such relationships has not been readily demonstrated [437]. It is clear that 
other factors, including disinfectants and metals, may play selective roles in the 
emergence of particular MRSA clones in humans and animals [349, 438, 439]. 
In this study, zinc resistance mediated by the czrC gene was examined as a 
potential contributor to the prevalence of LA-MRSA ST5 on swine farms in the United 
States. A documented association exists between the presence of czrC and the mecA gene 
in LA-MRSA ST398 isolates obtained from swine farms, with swine-associated isolates 
having a higher prevalence of czrC than LA-MRSA ST398 isolates obtained from veal 
calves or humans [346, 347]. The strong correlation (99%) reported between isolates 
harboring the czrC gene and phenotypic zinc resistance in LA-MRSA ST398 indicates 
that this gene orchestrates the predominant mechanism mediating zinc resistance in this 
lineage [346]. The specific importance of the czrC gene and the physical link between 
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mecA and czrC within the SCCmec element provide a mechanism by which dietary 
supplementation of zinc in swine rations could contribute to the persistence of methicillin 
resistance through coselection [347-349, 427]. Evidence of the practical relevance of this 
mechanism comes from Denmark, where widespread use of zinc in weaned pig diets as 
an alternative to antibiotic therapy for controlling enteric disease followed the banning of 
antibiotics for growth promotion in 2000, approximately a decade before LA-MRSA 
ST398 became highly prevalent in the Danish swine industry [348]. 
Sequencing studies have demonstrated that the czrC gene is located within the 
type V and type VIII SCCmec elements of ST398 MRSA [347, 440]. The majority of 
European LA-MRSA ST398 isolates investigated carried the type V SCCmec element 
containing the czrC gene downstream of the mecA gene [333], but none of the LA-MRSA 
ST5 isolates we examined carried the SCCmec type V element. All of the MRSA ST5 
isolates from humans with no swine contact that carried the czrC gene contained the 
SCCmec type II element (Table 4.4), which has not been previously associated with the 
czrC gene. In those isolates, the czrC gene was located upstream of the SCCmec element 
and possibly transferred with the speG gene, which confers resistance to spermidine and a 
potential selective advantage for isolates colonizing and infecting humans [176]. 
Importantly, the fact that none of the swine-associated LA-MRSA ST5 isolates harbored 
the SCCmec types seen in ST5 MRSA isolates from clinical infections provides further 
evidence that the animal and human reservoirs of ST5 MRSA appear to be 
phylogenetically distinct [398]. 
Previous reports examining czrC in LA-MRSA isolates indicated a higher 
prevalence of this gene in MRSA clonal complex 398 (CC398) isolates (72.5%), 
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compared to all non-CC398 isolates evaluated (25.5%) [346]. An absence of czrC in 
European and Asian LA-MRSA isolates of the CC5 and CC9 lineages has been reported, 
which is consistent with our results evaluating LA-MRSA ST5 isolates from the United 
States. Collectively, our results and previously published data indicate that the czrC gene 
has a lineage association and is prevalent in the ST398 lineage but is absent or rare 
among livestock-associated ST5 and ST9 lineages [346]. An alternate explanation for the 
elevated prevalence of the czrC gene in the ST398 lineage is the selection pressure 
incurred with the use of elevated levels of zinc in feed. However, the prevalence of the 
czrC gene in non-ST398 LA-MRSA isolates from European swine was reported to be 
30% in the tested isolates, while the phenotypic zinc resistance was reported to be 60% in 
the same isolates [346], arguing against selection pressure incurred with the use of 
elevated levels of zinc in feed being the sole factor controlling MRSA prevalence in 
swine, because the majority of these isolates lacked an SCCmec element carrying czrC. 
Although no national data concerning the use of zinc in swine rations exist, the practice is 
thought to be widespread in the United States (M. Tokach, personal communication). 
This appears not to have played the same role in propagating methicillin resistance in 
livestock isolates of S. aureus in the United States, as the majority of herds tested in 
recent studies were MRSA negative [335, 361]. 
Our results reported here, combined with previously reported results [346], open 
new avenues of research to be explored. First, the czrC gene has been identified in two 
methicillin-susceptible S. aureus ST398 isolates [323]. The presence of this gene without 
the SCCmec element should be evaluated to determine whether czrC is a remnant from a 
previously methicillin-resistant isolate or whether the czrC gene has been integrated 
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through a different mechanism. Both LA-MRSA isolates [346] and swine-associated 
methicillin-susceptible S. aureus isolates (J. Sun, R. S. Singer, S. J. Hau, T. L. Nicholson, 
and P. R. Davies, unpublished data) that show phenotypic zinc resistance without 
carrying the czrC gene have been identified. Such isolates should be screened for other 
mechanisms of zinc resistance, to determine the impact of other genes in conferring a 
resistant phenotype. Evaluation of the impact of czrC in non-ST398 LA-MRSA, 
specifically the ability of LA-MRSA ST5 isolates to acquire and to harbor czrC, and the 
impact of zinc in feed on the capability of LA-MRSA ST398 isolates to outcompete other 
lineages in swine also bears further investigation. Ultimately, zinc resistance in LA-
MRSA is more complex than the presence or absence of czrC or the use of zinc in feed as 
an antimicrobial agent to combat disease in livestock. Further investigation is needed to 
determine the mechanisms leading to zinc resistance and to illuminate the impact of 
selective pressure on the emergence of particular MRSA clones in humans and animals. 
Overall, the data reported here indicate that coselection associated with zinc 
supplementation in feed has not contributed to the persistence or prevalence of LA-
MRSA ST5 in the U.S. swine population. This conclusion is contrary to theories 
surrounding the dissemination of LA-MRSA ST398 in Europe and, considering the 
presence of czrC in LA-MRSA ST398 isolates in the United States, indicates a potential 
link between the genetic lineage and the carriage of specific resistance markers, such as 
that seen for qacA resistance in CC22 in the hospital setting [439]. Furthermore, the data 
reported here indicate that multiple mechanisms contribute to fitness and the ability of 
LA-MRSA ST5 and other lineages to compete and to persist in the nasal microbiota of 
pigs. 
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Abstract 
Background 
Antimicrobial resistance is a prominent public health concern and methicillin 
resistant Staphylococcus aureus (MRSA) is a notable example. The discovery of 
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livestock associated MRSA (LA-MRSA) has heightened public health concerns due to 
the potential of LA-MRSA isolates to serve as a reservoir for antimicrobial resistance 
determinants.  
Objectives 
To compare swine associated LA-MRSA ST5 and human clinical MRSA ST5 
isolates for phenotypic antimicrobial resistance and genetic determinants of resistance 
and evaluate for evidence of genetic exchange between swine associated and clinical 
MRSA ST5 isolates. 
Methods 
Minimum inhibitory concentrations for antibiotics were determined using 
microbroth dilution techniques. Genotypic determinants of antimicrobial resistance were 
detected through draft genome analysis.  
Results 
Swine associated LA-MRSA ST5 isolates exhibited resistance to fewer antibiotics 
than clinical MRSA ST5 isolates from humans with no swine contact. Distinct genomic 
antimicrobial resistance elements were harbored by each subgroup, with little overlap in 
shared antimicrobial resistance genes between swine associated LA-MRSA ST5 and 
clinical MRSA ST5 isolates.  
Conclusions 
Phenotypic antimicrobial susceptibilities and genotypic determinants of 
antimicrobial resistance among swine associated LA-MRSA ST5 and clinical MRSA ST5 
isolates are separate and distinct suggesting ST5 MRSA isolates from agricultural sources 
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were not a source of antimicrobial resistance elements for these clinical human ST5 
MRSA isolates.  
Introduction 
Treatment of Staphylococcus aureus infections is complicated by the bacterium’s 
ability to acquire mobile genetic elements (MGEs) encoding antimicrobial resistance 
(AMR). Most notable of these is the SCCmec element harboring mecA (or less commonly 
mecB or mecC) which encodes resistance to the beta-lactamase resistant beta-lactam 
antibiotic methicillin [246]. Methicillin resistant S. aureus (MRSA) are typically 
classified epidemiologically based on their putative source into hospital acquired (HA-
MRSA), community acquired (CA-MRSA), and livestock associated (LA-MRSA); 
however, these designations have become blurred with some MRSA clones being 
identified in multiple settings. 
MRSA infections were limited to hospital settings until the 1990s, when CA-
MRSA isolates were detected in community members with no risk factors for HA-MRSA 
[370]. Although CA-MRSA isolates are considered more virulent than HA-MRSA 
isolates, HA-MRSA isolates typically harbor a greater number of AMR determinants 
[367, 370]. LA-MRSA was first reported in swine in 2004 and raised concerns that swine 
and other livestock may serve as reservoirs for MRSA isolates that can transmit to 
humans [248]. While LA-MRSA are less able to colonize and cause disease in humans 
than HA- and CA-MRSA isolates [274, 338, 344], they often harbor multiple 
antimicrobial resistance genes and can be a source for diverse AMR determinants, such 
as the multidrug resistance gene cfr and the lincosamide, pleuromutilin, and 
streptogramin A resistance genes vgaC and vgaE [249-251].  
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Multi-locus sequence typing (MLST) has been employed to classify S. aureus 
isolates by genetic lineage. The distribution of sequence types (STs) in both human and 
animal populations, including swine, vary regionally. In Europe, ST398 is the 
predominant swine associated LA-MRSA lineage and in Asia, ST9 isolates dominate 
[312, 357]. In contrast, swine herds in North America harbor a mixed population of LA-
MRSA isolates containing ST398, ST9, and ST5 [335, 419]. While ST9 and ST398 
MRSA isolates are considered livestock adapted and are uncommon causes of human 
infections [370, 441], ST5 isolates compose a globally disseminated and highly 
successful lineage with both CA- and HA-MRSA clones reaching pandemic levels [12]. 
The success of the ST5 lineage in and out of a hospital setting is attributed to the capacity 
of these isolates to acquire MGEs containing genes encoding virulence factors and AMR 
determinants [12]. 
MGEs are components of the accessory genome and function in adaption of 
bacteria through genome plasticity [30]. Under selective conditions, these elements 
confer advantageous phenotypes that improve fitness or enable organism survival. The 
selective advantage of MGEs facilitates genome evolution through adaption to 
environmental and host derived selection pressures. This is true for the numerous AMR 
genes carried on MGE including transposons, insertion sequences, and plasmids.  
AMR is a significant public health concern due to the economic and societal cost 
associated with increased morbidity, mortality, and treatment costs [442]. Both ST398 
and ST9 LA-MRSA isolates can harbor diverse resistance elements [249, 443], raising 
concerns over the potential for LA-MRSA isolates to disseminate AMR beyond the 
agricultural setting. In this report, we compared the AMR phenotypes and genetic 
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determinants conferring AMR in MRSA ST5 isolates obtained from swine-associated 
sources and from humans with no known swine contact. 
Materials and methods 
Isolate Acquisition 
Swine associated LA-MRSA ST5 isolates were obtained from swine (n = 38), 
environmental samples from swine facilities (n = 26), humans after short-term swine 
contact (n = 9), and swine veterinarians with long-term contact (n = 9) [335, 444]. 
Clinical MRSA isolates with no known livestock connection were obtained from 
hospitals at University of California San Francisco (n = 7) and University of California 
Irvine (n = 64) [375]. All isolates were determined to be mecA positive and were MLST, 
SCCmec, and spa typed prior to acquisition (Appendix A). 
DNA Sequencing 
As previously described, genomic DNA was extracted from overnight cultures 
using the High Pure PCR Template Preparation Kit (Roche Applied Science, 
Indianapolis, IN) [376-381]. The Nextera XT DNA sample preparation and index kit 
(Illumina, San Diego, CA) was used to generate indexed libraries sequenced on an 
Illumina MiSeq instrument using the MiSeq v2 500 Cycle reagent kit (Illumina, San 
Diego, CA). Sequence reads were assembled using MIRA v. 4.0.2 (http://mira-
assembler.sourceforge.net/) [435]. Genome sequences are available from GenBank under 
accession numbers listed in Appendix A.  
Genomic AMR Analysis 
ResFinder 2.1 from the Center for Genomic Epidemiology 
(http://www.genomicepidemiology.org/) and the Comprehensive Antibiotic Resistance 
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Database (CARD) (https://card.mcmaster.ca/home) [445] were employed for AMR 
determinant identification. Draft genomes were submitted to ResFinder 2.1 using a 
threshold ID of 70% and a minimum length of 60% and CARD using the criteria “default 
– perfect and strict hits only”.  
AMR genetic elements were analyzed using Geneious 9.0.5 (Biomatters Ltd., 
Auckland, New Zealand). Multiple sequence alignments were used to compare sequence 
identity of genes and plasmids. AMR determinants found on transposons were evaluated 
for location of integration. Geneious 9.0.5 was used for image generation. 
Phenotypic AMR Analysis 
Phenotypic antibiotic resistance was determined using the microbroth dilution 
method by standard operating procedures. Each isolate was tested using the Trek 
BOPO6F plate (Thermo Fisher Scientific Inc., Oakwood Village, OH) and the Trek 
GPALL1F plate (Thermo Fisher Scientific Inc., Oakwood Village, OH) and minimum 
inhibitory concentrations (MICs) were determined. MICs were evaluated in accordance 
with Clinical Laboratory Standards Institute (CLSI) recommendations to give resistance 
interpretations for 29 antibiotics in 14 antibiotic (Table 5.1). AMR index, defined as the 
proportion of antibiotics tested to which an isolate exhibited phenotypic resistance, was 
determined for each isolate using the results of the microbroth dilution analysis 
Statistical Analysis 
Statistical analysis was completed using GraphPad Prism 7.01 (GraphPad 
Software, Inc., La Jolla, CA). Phenotypic antimicrobial resistances were compared using 
contingency analyses. Comparisons of AMR index and resistance gene numbers were 
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completed using Mann-Whitney tests. Results were considered significant using a P-
value cutoff of P < 0.05.  
Results 
Phenotypic AMR distribution 
Phenotypic resistance prevalence was determined and compared between swine-
associated and human clinical MRSA ST5 isolates (Table 5.1). Swine associated isolates 
had AMR indices ranging from 0.14-0.66, while clinical isolates had AMR indices 
ranging from 0.21-0.59 (Figure 5.1). Clinical MRSA ST5 isolates had significantly 
higher AMR index (median=0.52) than swine associated LA-MRSA ST5 isolates 
(median=0.38) (P < 0.0001), which equated to isolates exhibiting phenotypic resistance 
to an average of 14.6 and 11.7 (median 15 and 11) antibiotics respectively (Figure 5.1). 
These data indicate AMR was generally less extensive among swine associated LA-
MRSA ST5 isolates than clinical MRSA ST5 isolates. 
Isolates were screened for resistance to vancomycin and linezolid, antibiotics of 
choice for MRSA treatment in a hospital setting. Neither swine associated nor clinical 
MRSA ST5 isolates displayed phenotypic resistance to vancomycin or linezolid (Table 
5.1). Genetic determinants conferring vancomycin resistance and the multidrug resistance 
gene cfr were absent from all isolates.   
Fluoroquinolone Resistance 
Fluoroquinolone resistance was significantly more prevalent among clincail 
MRSA ST5 isolates than swine associated LA-MRSA ST5 isolates (P < 0.0001) (Table 
5.1). Of the fluoroquinolone resistant LA-MRSA ST5 isolates, 13/25 (52.0%) were 
obtained from a single farm and 4/25 (16%) were from humans visiting that farm. The 
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remaining fluoroquinolone resistant isolates (8/25, 32.0%) were distributed on two other 
farms (n = 4), from humans contacting swine on those farms (n = 2), or from humans 
with long term swine contact (n = 2).  
Table 5.1: Antibiotic resistance prevalence for screened antibiotics in LA-MRSA ST5 isolates and 
MRSA ST5 isolates from humans with no swine contact 
Antibiotic 
Class 
Antibiotic 
Swine 
Associated LA-
MRSA ST5 a 
MRSA ST5 
from Humans 
with No Swine 
Contact 
Statistics b 
Penicillin 
Penicillin 82/82 (100%) 71/71 (100%) NS, P = 1.0 
Ampicillin 82/82 (100%) 71/71 (100%) NS, P = 1.0 
Oxacillin  78/82 (95.1%) 71/71 (100%) NS, P = 0.1240 
Cephalosporin 
Cefoxitin  74/82 (90.2%) 71/71 (100%) P = 0.0075 
Ceftiofur  73/82 (89.0%) 67/71 (94.4%) NS, P = 0.2628 
Ceftriaxone  49/82 (59.8%) 60/71 (84.5%) P = 0.0011 
Aminoglycoside 
Gentamicin 22/82 (26.8%) 12/71 (16.9%) NS, P = 0.1735 
Neomycin 69/82 (84.1%) 67/71 (94.4%) NS, P = 0.0689 
Streptomycin 1/82 (1.2%) 1/71 (1.4%) NS, P = 1.0 
Tetracycline 
Chlortetracycline 65/82 (79.3%) 0/71 (0%) P < 0.0001 
Oxytetracycline 65/82 (79.3%) 0/71 (0%) P < 0.0001 
Tetracycline 65/82 (79.3%) 0/71 (0%) P < 0.0001 
Phenicol 
Chloramphenicol 9/82 (11.0%) 1/71 (1.4%) P = 0.0206 
Florfenicol 30/82 (36.6%) 54/71 (76.1%) P < 0.0001 
Macrolide 
Erythromycin 36/82 (43.9%) 69/71 (97.2%) P < 0.0001 
Tilmicosin 36/82 (43.9%) 55/71 (75.3%) P < 0.0001 
Sulfonamides 
Sulfadimethoxine 0/82 (0%) 35/71 (49.3%) P < 0.0001 
Trimethoprim + 
Sulfamethoxazole 
0/82 (0%) 0/71 (0%) NS, P = 1.0 
Trimethoprim 0/82 (0%) 0/71 (0%) NS, P = 1.0 
Fluoroquinolone 
Ciprofloxacin 19/82 (23.2%) 69/71 (97.2%) P < 0.0001 
Enrofloxacin 25/82 (30.5%) 69/71 (97.2%) P < 0.0001 
Levofloxacin 15/82 (18.3%) 69/71 (97.2%) P < 0.0001 
Moxifloxacin 18/82 (22.0%) 69/71 (97.2%) P < 0.0001 
Nitrofuran Nitrofurantoin 0/82 (0%) 0/71 (0%) NS, P = 1.0 
Lincosamide Clindamycin 39/82 (47.6%) 55/71 (77.5%) P = 0.0002 
Lipopeptide Daptomycin 0/82 (0%) 0/71 (0%) NS, P = 1.0 
Pleuromutilin Tiamulin 7/82 (8.5%) 1/71 (1.4%) NS, P = 0.0654 
Glycopeptide Vancomycin 0/82 (0%) 0/71 (0%) NS, P = 1.0 
Oxazolidinone Linezolid 0/82 (0%) 0/71 (0%) NS, P = 1.0 
a – Number resistant out of total isolates tested (percent resistant)  
b – Statistical significance designated at P < 0.05; NS = not significant 
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A)  
 
B)  
 
 
Figure 5.1: AMR index of isolates from MRSA ST5 from humans with no swine contact and swine 
associated LA-MRSA ST5. AMR index is defined as the proportion of the tested antibiotics to which an 
isolates is phenotypically resistant. (A) The AMR indexes determined for isolates from humans with no 
swine contact show a range of 0.21-0.59 with a median AMR index of 0.52. (B) The AMR indexes 
determined for swine associated LA-MRSA ST5 isolates. Swine associated isolates had AMR indexes with 
a wider range (0.14-0.66) and higher maximum AMR index; however, the median AMR index was 0.38, 
which was significantly less than that of humans with no swine contact (P < 0.0001).  
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In clinical MRSA ST5 isolates, fluoroquinolone resistance was associated with 
mutations in gyrA, parC, and/or parE, while resistance in swine associated isolates was 
primarily associated with mutations in both gyrA and parC (Table 5.2). Eight clinical 
isolates did not harbor any fluoroquinolone resistance determinants. This may be a result 
of gaps in the draft genome, novel mutations, or novel genes conferring fluoroquinolone 
resistance. Eight swine associated isolates also lacked a mutation or AMR gene 
conferring fluoroquinolone resistance. One of these isolates was from the farm harboring 
isolates with parC and gyrA mutations, indicating the mutations may be absent due to 
gaps in the draft genome sequence. Of the remaining seven isolates, six exhibited limited 
phenotypic resistance, being resistant only to enrofloxacin but susceptible to 
ciprofloxacin, levofloxacin, and moxifloxacin. These isolates also exhibited a lower 
enrofloxacin MIC (2.0 μg/mL) when compared to isolates with gyrA, parC, or parE 
mutations (MIC of >2.0 μg/mL). Other isolates from the same farms exhibited a range of 
MICs from <0.12-1.0 μg/mL and 21/33 (63.6%) of the non-resistant isolates from these 
farms were deemed of “intermediate” susceptibility.  
Table 5.2: Quinolone resistance mechanisms 
Mutant Genes Swine Associated 
LA-MRSA ST5 
MRSA ST5 from Humans 
with No Swine Contact 
gyrA 0/82 (0%) 10/71 (14.1%) 
parC 1/82 (1.2%) 11/71 (15.5%) 
parE 0/82 (0%) 3/71 (4.2%) 
gyrA + parC 16/82 (19.5%) 33/71 (46.5%) 
gyrA + parC + parE 0/82 (0%) 4/71 (5.6%) 
Unknown 8/82 (9.8%) 8/71 (11.3%) 
 
Tetracycline Resistance 
Phenotypic tetracycline resistance was seen exclusively in swine associated LA-
MRSA ST5 isolates (Table 5.1). Tetracycline resistance was observed on all but one farm 
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(7/8, 87.5%). Genetic analysis indicated swine associated LA-MRSA ST5 isolates 
harbored zero to two tetracycline resistance genes. The tetracycline resistance genes 
identified in LA-MRSA ST5 isolates were tetT (61/82, 74.4%) and tetL (62/82, 75.6%) 
(Table 5.3), and the majority (61/65, 93.8%) of tetracycline resistant isolates harbored 
both tetT, a ribosomal modification gene and tetL, a gene encoding antibiotic efflux. 
Further examination of the location of tetracycline resistance genes indicated they were 
encoded on a plasmid also harboring the aminoglycoside resistance gene aadD (Figure 
5.2). Consistent with the lack of phenotypic resistance, no tetracycline resistance genes 
were identified in the genomes of clinical MRSA ST5 isolates (0/71, 0%) (Table 5.3).  
Table 5.3: Tetracycline resistance genes 
Tetracycline 
Resistance Genes 
Swine Associated 
LA-MRSA ST5 
MRSA ST5 from Humans 
with No Swine Contact 
tetL 62/82 (75.6%)  0/71 (0%)  
tetT 61/82 (74.4%)  0/71 (0%)  
Unknown  3/82 (3.7%)  0/71 (0%)  
 
 
Figure 5.2: LA-MRSA ST5 tetracycline resistance plasmid. The tetracycline resistance genes tetT 
(magenta) and tetL (coral) were harbored on a 9,269bp multidrug resistance plasmid that also harbored the 
aminoglycoside resistance gene aadD (light blue). This plasmid was found in 62/82 (75.6%) of all swine 
associated LA-MRSA ST5 isolates and had a 95.4% (62/65) correlation with tetracycline resistance. 
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Macrolide, Lincosamide, and Streptogramin (MLS) Resistance 
Phenotypic resistance to macrolide (P < 0.0001) and lincosamide (P = 0.0002) 
antibiotics was significantly higher in clinical MRSA ST5 isolates than swine associated 
LA-MRSA ST5 isolates (Table 5.1). Genomic screening for determinants conferring 
resistance to MLS antibiotics revealed differences between isolate subsets. The majority 
of clinical MRSA ST5 isolates harbored the ermA gene (65/71, 91.5%) (Table 5.4). These 
isolates exhibited two distinct phenotypes: 14/65 (21.5%) were resistant to erythromycin 
and susceptible to tilmicosin and clindamycin and 51/65 (78.5%) were resistant to 
erythromycin, tilmicosin, and clindamycin. The ermA gene was identified within the type 
II SCCmec element in 65/69 (94.2%) of the erythromycin resistant isolates. The 
remaining four isolates also harbored a type II SCCmec element, indicating the ermA 
gene may be present but missing from the draft sequence. The remaining isolates (2/71, 
2.8%) were susceptible to tested MLS antibiotics and harbored a type IV SCCmec 
element, which did not harbor ermA.  
Clinical isolates also harbored several MLS resistance genes in addition to ermA 
(Table 5.4). Two isolates harbored lnuA, a gene that functions to inactivate lincosamide 
antibiotics. There were also 20 isolates (28.2%) that harbored mphC, a gene involved in 
macrolide antibiotic inactivation, and msrA, a streptogramin and macrolide efflux pump 
(Table 5.4). These genes (lnuA, mphC, and msrA) were found in isolates harboring ermA 
or isolates suspected to have ermA based on their SCCmec type. Due to the resistance 
profile of ermA harboring isolates, the contribution of lnuA, mphC, and msrA to 
macrolide resistance could not be determined.  
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Table 5.4: Genes conferring resistance to macrolide, lincosamide, or streptogramin (MLS) antibiotics 
Resistance Genes Swine Associated 
LA-MRSA ST5 
MRSA ST5 from Humans 
with No Swine Contact 
ermA 0/82 (0%)  65/71 (91.5%)  
ermC 36/82 (43.9%) 0/71 (0%)  
vgaA 78/82 (95.1 %)  0/71 (0%)  
vgaE 2/82 (2.4%) 0/71 (0%) 
mphC 0/82 (0%) 20/71 (28.2%) 
msrC 0/82 (0%) 20/71 (28.2%) 
lnuB 1/82 (1.2%)  0/71 (0%)  
lnuA 0/82 (0%) 2/71 (2.8%)  
Unknown  2/82 (2.4%)  4/71 (5.6%)  
 
Swine associated isolates with phenotypic resistance to MLS antibiotics harbored 
primarily ermC (36/82, 43.9%) (Table 5.4). These isolates displayed only one phenotype: 
resistance to erythromycin, tilmicosin, and clindamycin. Sequence analysis determined 
ermC was plasmid mediated. Two different plasmids were identified with the majority of 
ermC positive isolates (35/39, 89.7%) containing a 2.4 kbp plasmid encoding only ermC 
and a maintenance and replication protein (Figure 5.3). One swine associated isolate 
harbored lnuB, which functions to inactivate lincosamide antibiotics, and the isolate 
exhibited phenotypic lincosamide resistance.  
 
Figure 5.3: LA-MRSA ST5 plasmid containing ermC. MLS resistance in LA-MRSA ST5 was 
predominantly mediated by ermC (orange) in 92.3% (36/39) of isolates. This gene was found most 
commonly on a 2,432bp plasmid (35/36, 97.2%). Isolates carrying this plasmid were resistant to 
erythromycin, tilmicosin, and clindamycin. 
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The majority of swine associated LA-MRSA strains harbored AMR genes 
conferring resistance to streptogramin A. The most common streptogramin A resistance 
gene was vgaA (78/82, 95.1%), which functions as an efflux pump with activity toward 
streptogramin A and lincosamide antibiotics. Two isolates harbored vgaE along with 
vgaA. No correlation between phenotypic lincosamide resistance and the presence of 
vgaA or vgaE was detected. Streptogramin resistance genes were not found in any clinical 
MRSA ST5 isolates. 
Aminoglycoside Resistance 
Phenotypic aminoglycoside resistance (gentamicin, neomycin, or streptomycin) 
was not significantly different between swine associated and clinical MRSA ST5 isolates 
(Table 5.1). Neomycin resistance was widely distributed in LA-MRSA ST5 isolates and 
was present in isolates from all farms sampled (8/8, 100%). Phenotypic gentamicin and 
streptomycin resistance were limited in LA-MRSA ST5 isolates, with all gentamicin 
resistant isolates obtained from a single farm. Only one swine associated isolate exhibited 
streptomycin resistance. 
Genetic determinants conferring aminoglycoside resistance were more prevalent 
in clinical MRSA ST5 isolates (range 0-5, average 2.3, median 2) than isolates from 
swine associated sources (range 0-3, average 1.1, median 1) (p < 0.0001) (Table 5.5). The 
aminoglycoside resistance genes unique to clinical MRSA isolates were spc (ant(9)-Ia), 
aph(3’)-III, and ant(6)-Ia. Isolates from swine associated sources uniquely harbored aadE 
and str (aph(6)-Ia) (Table 5.5). Three resistance genes were shared between the two 
groups of isolates: aadD, aph(2”)-Ih, and aac(6’)-aph(2”) (Table 5.5). 
111 
 
Table 5.5: Aminoglycoside resistance genes 
Resistance Genes Swine Associated 
LA-MRSA ST5 
MRSA ST5 from Humans 
with No Swine Contact 
aadD (aka ant(4’)-Ia) 71/82 (86.6%) 62/71 (87.3%) 
aadE 1/82 (1.2%) 0/71 (0%) 
aph(2”)-Ih 2/82 (2.4%) 3/71 (4.2%) 
aac(6’)-aph(2”) 14/82 (17.1%) 9/71 (12.7%) 
spc (aka ant(9)-Ia) 0/82 (0%) 61/71 (85.9%) 
str (aka aph(6)-Ia) 1/82 0/71 (0%) 
aph(3’)-III 0/82 (0%) 15/71 (21.1%) 
ant(6)-Ia 0/82 (0%) 15/71 (21.1%) 
Unknown 3/82 (3.7%) 0/71 (0%) 
 
Neomycin resistance was distributed in both swine associated LA-MRSA ST5 
isolates (69/82, 84.1%) and clinical MRSA ST5 isolates (67/71, 94.4%) and correlated 
with the presence of aadD in both subsets of isolates. A strong association (100% in 
clinical isolates and 72.7% in swine associated isolates) between phenotypic resistance to 
gentamicin and the aminoglycoside resistance gene aac(6’)-aph(2”) or aph(2”)-Ih was 
also observed. Further genetic investigation indicated the gene identified as aph(2”)-Ih is 
likely a truncated version of aac(6’)-aph(2”) found at the end of the contig. A single 
swine associated isolate harbored the resistance gene str and was the only swine 
associated isolate to display phenotypic streptomycin resistance. The single clinical ST5 
isolate exhibiting phenotypic resistance to streptomycin did not harbor an identified 
streptomycin resistance determinant. 
The precise location of the shared aminoglycoside resistance genes was 
determined to detect potential transfer of AMR between the isolate subsets. The location 
of aadD varied among LA-MRSA ST5 isolates. The majority of isolates (62/71, 87.3%) 
harbored aadD on a multidrug resistance plasmid that also harbored the tetracycline 
resistance genes tetL and tetT (Figure 5.2). In the remaining nine LA-MRSA isolates, 
aadD was harbored on a different plasmid. Some of these plasmids contained other 
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antimicrobial resistance genes, such as the beta-lactamase, blaZ. In the majority (59/62, 
95.2%) of clinical MRSA ST5 isolates, aadD was identified within plasmid sequence that 
also contained a bleomycin resistance gene (Figure 5.4). Of the remaining isolates, two 
harbored aadD on a contig encoding a bacitracin ABC transporter permease; however, 
whether this contig was plasmid or chromosomal sequence could not be determined. 
Evaluation of the location of aac(6’)-aph(2”) indicated all isolates harbored a similar 
insertion sequence containing the gene (Figure 5.5). BLAST results indicated the 
insertion sequence was present in several plasmids, none of which were common 
between the subsets of isolates.  
 
 Figure 5.4: Small plasmid carrying aadD found in MRSA ST5 isolates from humans with no swine 
contact. The aadD gene (light blue) was harbored on a 5,370bp plasmid in the majority of MRSA ST5 
isolates from humans with no swine contact (60/62, 96.8%). The plasmid also harbored a bleomycin 
resistance protein (white), which confers resistance to belomycin a glycopeptide antibiotic used for 
chemotherapeutic treatment of cancer. 
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Figure 5.5: Transposon harboring aac(6’)-aph(2”). The gentamicin resistance gene aac(6’)-aph(2”) was 
harbored on the same transposon in both LA-MRSA ST5 isolates (14/82, 17.1%) and MRSA ST5 isolates 
from humans with no swine contact (9/71, 12.7%). The aminoglycoside resistance gene aph(2”)-Ih was 
found in LA-MRSA ST5 (2/82, 2.4%) and MRSA ST5 from humans with no swine contact (3/71, 4.2%). 
This gene was determined to be a truncated aac(6’)-aph(2”) due to its location at the end of a contig. This 
transposon was highly correlated with the presence of gentamicin resistance and was found in 72.7% 
(16/22) of gentamicin resistant LA-MRSA ST5 isolates and 100% (12/12) of isolates from humans with no 
swine contact that were phenotypically resistant to gentamicin. 
 
Phenicol Resistance 
Phenotypic resistance to phenicol class antibiotics differed between swine 
associated and clinical MRSA ST5 isolates (Table 5.1). Significantly more swine 
associated isolates exhibited phenotypic resistance to chloramphenicol (P = 0.02); while 
resistance to florfenicol was more prevalent in clinical ST5 isolates (P < 0.0001).  
All swine associated isolates exhibiting phenotypic chloramphenicol resistance 
(9/9, 100%) harbored the phenicol resistance gene fexA (Table 5.6). These isolates were 
also phenotypically resistant to florfenicol. The presence of fexA and chloramphenicol 
resistance was clustered in swine associated isolates and all fexA containing isolates were 
obtained from a single farm. No genetic determinants conferring chloramphenicol 
resistance were identified in the clinical isolate that exhibited phenotypic 
chloramphenicol resistance. All florfenicol resistant clinical ST5 isolates and the majority 
of florfenicol resistant swine associated isolates (21/30, 70%) did not harbor any 
recognized florfenicol resistance determinants. 
Table 5.6: Phenicol resistance genes 
Resistance Genes Swine Associated 
LA-MRSA ST5 
MRSA ST5 from Humans 
with No Swine Contact 
fexA 9/82 (11.0%) 0/71 (0%) 
Unknown 21/82 (25.6%) 54/71 (76.1%) 
 
114 
 
Discussion 
While previous studies have reported AMR prevalence among LA-MRSA ST398 
and ST9 isolates [330, 345, 446-449], little to no information exists regarding AMR 
prevalence among LA-MRSA ST5 isolates. Here, we found clinical ST5 isolates 
exhibited a higher AMR index than ST5 isolates obtained from swine associated sources. 
In contrast to this general trend, 13 (15.9%) LA-MRSA ST5 isolates displayed resistance 
to 15-19 of the antibiotics tested (AMR index of 0.52-0.66) (Figure 5.1). Nine of these 
isolates were from a single farm and one was obtained from a human with short-term 
swine contact on that farm. Multi-drug resistance patterns similar to that observed in this 
farm have also been reported in swine associated ST398 LA-MRSA isolates [330, 332, 
446, 450]. 
AMR distribution among swine associated MRSA ST5 isolates predominantly 
reflected patterns consistent with antimicrobial use in the swine industry. Tetracycline 
resistance was found in 79.3% of the LA-MRSA ST5 isolates and on 7 of the 8 farms 
sampled. Tetracycline resistance has been previously reported in LA-MRSA ST398 
isolates, where phenotypic resistance has approached 100% of isolates evaluated [330, 
331, 345, 450, 451]. This has been attributed to the long term use of chlortetracycline and 
oxytetracycline antibiotics in the swine industry. Similarly, the much lower prevalence of 
fluoroquinolone resistance in LA-MRSA ST5 is unsurprising given the relatively recent 
approval of fluoroquinolones for swine in the United States and the ban on extralabel 
fluoroquinolone use food animals under the Animal Medicinal Drug Use Clarification 
Act (AMDUCA) [452]. While the prevalence of chloramphenicol resistance in LA-
MRSA ST5 isolates was similar to that reported for LA-MRSA ST398 [331, 345], we 
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noted higher chloramphenicol resistance in swine associated LA-MRSA ST5 isolates 
compared to clinical ST5 isolates, despite the ban on chloramphenicol use in food 
animals in the USA under AMDUCA. The presence of chloramphenicol resistance 
among both LA-MRSA ST398 and ST5 may reflect coselection related to the use of 
florfenicol in the swine industry.   
Evaluation of the draft genome sequences indicated the AMR genes identified in 
the MRSA ST5 isolates were harbored on MGEs in all cases except for fluoroquinolone 
resistance. The AMR genes were found on plasmids (such as tetL, tetT, aadD, ermC, 
msrA, and mphC), transposable elements (such as aac(6’)-aph(2”), lnuB, aadE, and fexA), 
and within the SCCmec element (ermA and ant(9)-Ia). The presence of AMR genes 
detected in this study on MGEs underlies the potential for transfer of AMR genes among 
bacteria. S. aureus ST5 isolates are highly susceptible to transfer of MGEs [12], which 
may facilitate transmission of uncommon AMR genes to and from LA-MRSA ST5 
isolates. 
Notable differences in genetic determinants underlying AMR were identified in 
LA-MRSA ST5 isolates compared to clinical MRSA ST5 isolates. MLS resistance was 
mediated by the ermA gene in clinical isolates and the ermC gene in swine associated 
isolates. While a genetic determinant conferring resistance to phenicol class antibiotics 
was unidentified in the majority of florfenicol resistant isolates, fexA was harbored by a 
portion of LA-MRSA ST5 isolates expressing phenicol resistance (9/30, 30%) yet absent 
from all phenicol resistant clinical MRSA ST5 isolates. There were two shared AMR 
genes between swine associated and clinical MRSA ST5 isolates: aadD and aac(6’)-
aph(2”). For these genes, although sequence analysis showed high sequence identity for 
116 
 
both genes (>90% across all isolates), the genes were harbored on different plasmids in 
the two groups of isolates, indicating it is unlikely the presence of these genes in clinical 
MRSA ST5 isolates was associated with transfer from LA-MRSA ST5 isolates. 
Similarly, separate and distinct sets of AMR genes harbored by human isolates compared 
to livestock associated isolates were previously reported for Salmonella Typhmurium 
DT104 and in comparisons between LA-MRSA and HA-MRSA isolates in the same 
location [330, 453]. 
LA-MRSA ST5 isolates harbored a different complement of AMR genes than 
previously identified in LA-MRSA ST398 isolates. For example, tetracycline 
modification genes and tetracycline efflux genes were widespread in the LA-MRSA ST5 
isolates tested here and in LA-MRSA ST398 [323, 330, 331, 345]. While both sequence 
types can harbor tetL, tetracycline resistance genes (tetM and tetK) previously identified 
in LA-MRSA ST398 were not found in our LA-MRSA ST5 isolates. Similarly, MLS 
resistance genes in LA-MRSA ST398 have been more diverse than those in LA-MRSA 
ST5 [330, 331, 345]. The prevalence of ermC ranged from 16-40% in previous reports of 
LA-MRSA ST398 isolates [330, 331, 345], in which ermA (0-34% of isolates) and ermB 
(10-38% of isolates) also occurred. However, only ermC was detected in the LA-MRSA 
ST5 isolates tested here. The prevalence of fexA in LA-MRSA ST5 was similar to that 
reported among LA-MRSA ST398 isolates, where 2-13% of isolates harbored fexA [331, 
345]; however, these studies also identified the multidrug resistance gene cfr in 1-3% of 
ST398 isolates screened [330, 331, 345], but cfr was not found in the LA-MRSA ST5 
isolates tested here.  
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The identified differences in the repertoire of AMR genes harbored by ST5 
isolates compared to LA-MRSA ST398 isolates could reflect differences in the specific 
study populations or may represent lineage specific adaptions. Lineage specific adaptions 
have been previously identified for disinfectants in HA-MRSA isolates and zinc 
resistance in LA-MRSA isolates [397]. In the present study, LA-MRSA ST5 isolates 
harbored tetL and tetT on an extrachromosomal plasmid. In contrast, the tetM gene is 
integrated into the chromosome of LA-MRSA ST398 isolates and reports indicate it is 
widespread in isolates from livestock [323, 330, 331, 345, 454]. This may be an adaption 
specific to the ST398 lineage, while ST5 isolates harbor plasmid encoded tetracycline 
resistance. Differences in study populations may also play a role, as most studies 
investigating LA-MRSA ST398 have evaluated European isolates, which are 
geographically distinct and may be under different selection pressures than isolates in the 
U.S. We observed substantial between-farm and within-farm variation in both phenotypic 
resistance and antimicrobial resistance genes. Variation between farms may be associated 
with differences in on-farm selection pressures, in the case of mobile genetic elements 
encoding resistance, or the genetic background of isolates prior to introduction, such as 
isolates with parC and gyrA mutations. Within farm variation of resistance phenotypes 
and resistance elements was also seen in LA-MRSA ST5 isolates. For example, ISU839 
expressed phenotypic resistance to tetracycline antibiotics, clindamycin, and 
streptomycin; while ISU837 and ISU842 were isolated from the same farm and 
susceptible to these antibiotics. ISU839 harbored the tetracycline resistance plasmid 
(Figure 5.2) and the insertion sequence ISSsu5, discovered in Streptococcus suis, 
containing the lincosamide resistance gene lnuB and the aminoglycoside resistance gene 
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aadE,[455] which was absent in other isolates from the farm. Overall, this indicates 
isolates gain and/or lose MGEs encoding AMR genes and supports concerns regarding 
the capacity of these isolates to potentially disseminate AMR beyond the agricultural 
setting. 
To begin addressing the public health concerns over the potential for LA-MRSA 
isolates to disseminate AMR beyond the agricultural setting, we specifically selected 
clinical isolates from a geographically distinct population in an urban environment to 
ensure the clinical isolates were from humans with no swine contact. We found swine 
associated LA-MRSA ST5 isolates exhibited resistance to fewer antibiotics than clinical 
MRSA ST5 isolates. More importantly, we identified separate and distinct genetic 
determinants of AMR harbored by clinical ST5 isolates compared to swine associated 
LA-MRSA ST5 isolates. Collectively, our data suggest that the swine reservoir of ST5 
MRSA in the USA is unlikely to serve as a source for AMR determinants in human 
clinical MRSA ST5 isolates. To fully evaluate the contribution of LA-MRSA ST5 
isolates to the risk of human MRSA infections and antimicrobial resistance in human 
MRSA isolates, follow up studies including human clinical isolates obtained from regions 
of swine production are warranted.  
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Abstract 
Staphylococcus aureus is part of the nasal microbiome of many humans and has 
become a significant public health burden due to infections with antibiotic resistant 
strains, including methicillin resistant S. aureus (MRSA). Several lineages of S. aureus 
including MRSA are found in livestock species and can be acquired by humans through 
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contact with animals. These livestock associated MRSA (LA-MRSA) isolates raise 
public health concerns because of the potential for livestock to act as reservoirs for 
MRSA outside of the hospital setting. In the United States, swine harbor a mixed 
population of LA-MRSA isolates with the sequence type (ST) 398, ST9, and ST5 
lineages being detected. LA-MRSA ST5 isolates are particularly concerning to the public 
health community because, unlike ST398 and ST9 lineages, the ST5 lineage is a 
significant cause of human disease in both the hospital and community setting globally. 
The ability of swine associated LA-MRSA ST5 isolates to adhere to human keratinocytes 
in vitro was investigated and adherence genes harbored by these isolates were evaluated 
and compared to clinical MRSA ST5 isolates from humans with no swine contact. The 
two subsets of isolates adhered equivalently to human keratinocytes in vitro and 
contained an indistinguishable complement of adherence genes that possessed a high 
degree of sequence identity. Collectively our data indicate that, unlike LA-MRSA ST398 
isolates, LA-MRSA ST5 isolates did not exhibit a reduced genotypic or phenotypic 
capacity to adhere to human keratinocytes. 
Importance 
Our data indicate swine associated livestock-associated methicillin resistant 
Staphylococcus aureus (LA-MRSA) ST5 isolates are equally capable of adhering to 
human skin and have the same genetic potential to adhere as clinical MRSA ST5 isolates 
from humans. This suggests humans in contact with livestock have the potential to 
become colonized with LA-MRSA ST5 isolates; however, genes that contribute to 
persistence of S. aureus on human skin were absent in LA-MRSA ST5 isolates. The data 
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presented here is important evidence in evaluating potential risks LA-MRSA ST5 isolates 
pose to humans with livestock contact. 
Introduction 
Humans and several other mammals harbor Staphylococcus aureus as a 
component of their nasal and skin microbiome. Although this organism is a commensal in 
25-33% of humans in developed countries [403], it can cause opportunistic infections that 
range in severity from mild skin infections to severe systemic infections [8, 58]. 
Treatment of these infections is challenging due to the rapid acquisition of antimicrobial 
resistance genes, including the SCCmec element that encodes the mecA gene conferring 
methicillin resistance [247, 254]. These isolates, deemed methicillin resistant S. aureus 
(MRSA), have become a significant public health burden in the United States causing 
thousands of infections annually, which result in significant healthcare costs and losses in 
productivity [404, 456].  
MRSA isolates are classified by the source from which they are acquired to form 
the following categories: hospital acquired (HA-MRSA), community acquired (CA-
MRSA), and livestock associated (LA-MRSA) [22]. These subsets of isolates possess 
unique characteristics that allow them to thrive in each environment. For example, HA-
MRSA isolates tend to possess a large number of antimicrobial resistance genes that 
enable them to survive in a hospital setting where the use of antimicrobial agents is more 
common [182]. Alternatively, CA-MRSA isolates more commonly possess the arginine 
catabolic mobile element (ACME), which improves their survival on the skin of healthy 
humans through the degradation of polyamines and pH modulation at the skin surface 
[457]. Finally, LA-MRSA isolates are thought to have adapted to colonizing livestock 
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species through the loss of human specific virulence factors and, in some cases, gain of 
virulence factors specific to their livestock host species [251, 323, 325]. 
With the discovery of LA-MRSA sequence type (ST) 398 in swine [248], 
significant concerns arose due to the potential that livestock species can be reservoirs for 
MRSA, and LA-MRSA may contribute to the risk for human infections in the 
community. This precipitated research investigating the prevalence of LA-MRSA and the 
associated infection risk. Studies found, while ST398 was the predominant lineage in 
Europe [312], outside of Europe other lineages were more prevalent. In Asian swine, LA-
MRSA ST9 was the most common lineage. North America harbored a more diverse 
population of LA-MRSA, with isolates of the ST398, ST9, and ST5 lineages being found 
[335, 357]. Evidence indicates the ST398 and ST9 lineages are animal adapted and less 
able to colonize and cause disease in humans [251, 323, 344]. This has not been shown 
for the ST5 lineage, which is a globally disseminated and highly successful S. aureus 
clone in humans [12].  
Nasal colonization with S. aureus contributes to S. aureus infections in the host, 
especially within the hospital setting [54, 458]. This becomes important for humans with 
livestock contact, as these individuals are significantly more likely to carry MRSA than 
their counterparts with no livestock contact [248, 353]. Persistent colonization is a 
complex interaction between host tissues and the microbiota of the nasal cavity or skin. 
While the impact of few genes has been experimentally verified [76-78], many genes are 
thought to contribute to adherence and colonization of S. aureus through their interaction 
with host proteins, such as fibrinogen and fibronectin [97, 101]. Furthermore, there are 
many genes suspected to function in adherence based on identified motifs consistent with 
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other adherence genes [91], although their specific ligand has yet to be identified. Genetic 
investigation examining known and suspected adherence genes indicates variability in the 
presence or absence of these genes in different lineages, such as the sdr genes that are not 
uniformly present in all lineages [69]. Additional genes, such as the arginine catabolic 
mobile element (ACME) and speG, are found on mobile genetic elements (MGEs) and 
are thought to promote bacterial survival on the skin and contribute to long term 
colonization with S. aureus [176, 182, 457].  
Reports indicate LA-MRSA ST398 isolates have a reduced ability to adhere to 
human keratinocytes, seem to colonize humans more transiently than other lineages, and 
seem to be less transmissible between humans than their HA-MRSA counterparts [334, 
338, 339, 344]. These LA-MRSA ST398 isolates possess genetic differences, such as 
truncation of the adherence genes clfA, clfB, and fnbB and the absence of sdrE [344], 
which are thought to contribute to the reduced capacity of LA-MRSA ST398 to colonize 
and cause disease in humans. The adherence properties and genetic factors contributing 
to adherence have not been investigated for LA-MRSA ST5 isolates. In this study, we 
present a comparison of the in vitro adherence capability of LA-MRSA ST5 isolates and 
MRSA ST5 isolates from humans with no swine contact and compare identified and 
suspected adherence genes in these populations of S. aureus. 
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Materials and methods 
Isolate acquisition and selection 
S. aureus isolates were acquired from Iowa State University (n = 73), University 
of Minnesota (n = 9), University of California Irvine (n = 64) and University of 
California San Francisco (n = 8) [335, 375]. These isolates included 82 LA-MRSA ST5 
isolates from swine associated sources including pigs (n = 38), the environment within 
swine buildings (n = 26), veterinary students with short term swine contact were sampled 
after a one time visit to a swine farm (n = 9) and swine veterinarians with long term, 
occupational swine exposure (n = 9). Seventy-one clinical MRSA ST5 isolates and one 
clinical methicillin susceptible S. aureus ST5 isolate were included from humans residing 
in urban areas with no known swine contact (n = 72). All isolates were confirmed to be 
ST5 by MLST and spa typed prior to acquisition (Appendix A). Staphylococcus aureus 
Mu3 (ATCC #700698, ATCC, Manassas, VA) was used for comparison during analysis 
of the adherence assays and as a reference genome for adherence factor gene analysis.  
Isolates were purposively selected from swine associated sources to represent the 
potential diversity among the isolates during adherence assays. Ten swine associated LA-
MRSA isolates were selected from the 82 total isolates. They were selected such that 
each farm was represented in the adherence assay by an environmental (n = 3) or swine 
isolate (n = 4) or represented by an isolate from a human after visiting the farm (n = 1). 
Two isolates were from humans with long term swine contact were also selected for 
phenotypic screening. Nine isolates from humans with no known swine contact were 
randomly selected for inclusion in the adherence assay. Name and source information for 
isolates included in adherence assays can be found in Table 6.1.  
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Table 6.1: Isolates selected for adherence assays  
Isolate Name Isolate Source 
ISU837 Environment (Farm 10) 
ISU876 Pig (Farm 24) 
ISU936 Pig (Farm 39) 
ISU949 Pig (Farm 42) 
ISU960 Environment (Farm 38) 
ISU978 Pig (Farm 39) 
ISU980 Environment (Farm 41) 
ISU1007 Human – short term contact 
UMN4 Human – long term contact 
UMN38 Human – long term contact 
UCI08 Human clinical isolate 
UCI15 Human clinical isolate 
UCI22 Human clinical isolate 
UCI27 Human clinical isolate 
UCI30 Human clinical isolate 
UCI45 Human clinical isolate 
UCI52 Human clinical isolate 
UCI64 Human clinical isolate 
UCSF13938 Human clinical isolate 
 
Genome sequencing 
Draft genome sequences were generated using the protocol previously described 
[376-381]. In short, isolates were grown in Trypticase Soy Broth (TSB) (BD Biosciences, 
Sparks, MD) and genomic DNA was extracted using the High Pure PCR Template 
Preparation Kit (Roche Applied Science, Indianapolis, IN). The Nextera XT DNA sample 
preparation and index kit (Illumina, San Diego, CA) was used to generate DNA libraries 
that were sequenced using the MiSeq v2 500 Cycle reagent kit (Illumina, San Diego, CA) 
on an Illumina MiSeq instrument. Sequence reads were assembled using MIRA v. 4.0.2 
(http://mira-assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html) and resulting 
sequences can be found in GenBank with the accession numbers listed in Supplemental 
Table 1. The whole genome sequence for Mu3 was obtained from NCBI (GenBank 
Sequence #AP009324.1) to use for adherence gene comparisons. 
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Gene comparisons 
The adherence genes analyzed can be found in Table 6.2 and Table 6.3. For each 
gene, the percent nucleotide sequence identity as compared to that gene in the reference 
genome Mu3 was determined using multiple sequence alignments in Geneious 9.0.5 
(Biomatters Ltd., Auckland, New Zealand). Percent identities relative to Mu3 were then 
used to generate heatmaps using R [459]. For sasG, the gene was designated as present or 
absent due to the gene structure including “B repeats”, 384 nucleotide repeats, which 
prevented adequate alignment of the entire gene. The genes composing ACME, cna, and 
sasX were also a present or absent designation as these genes are not found in Mu3.  
Accessory gene regulator (agr) typing 
The agr type of the isolates was determined by screening the draft genome 
sequences in silico with Geneious 9.0.5 for type specific regions using the following 
primer sets: agrI (5′-GTC ACA AGT ACT ATA AGC TGC GAT-3′), agrII (5′-TAT 
TAC TAA TTG AAA AGT GGC CAT AGC-3′), agrIII (5′-GTA ATG TAA TAG CTT 
GTA TAA TAA TAC CCA G-3′), and agrIV (5′-CGA TAA TGC CGT AAT ACC CG-
3′) (as described previously [460]). 
Human epidermal keratinocyte adherence assay 
Human epidermal keratinocytes (HEKs) (ATCC #PCS-200-010, ATCC, 
Manassas, VA) were obtained to screen isolates for in vitro adherence to human 
keratinocytes. These cells were grown in Dermal Cell Basal Medium (DCBM) (ATCC, 
Manassas, VA) supplemented with the Keratinocyte Growth Kit (ATCC, Manassas, VA). 
For the assay, HEKs of passage 5 or lower were plated into 24-well plates (Becton, 
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Dickinson and Company, Franklin Lakes, NJ) at 5000 cells/cm2 and allowed to grow to 
confluence. 
An overnight MRSA culture grown in TSB was used to inoculate 5mL of TSB 
and was incubated at 37ºC until logarithmic growth. The bacterial culture was diluted to 
an optical density at 600nm (OD600) ranging from 0.50-0.59 and 60μL was inoculated 
into 10mL of supplemented DCBM to reach an average inoculum concentration 3.96x106 
colony forming units (CFU)/mL. Wells of HEKs were inoculated with 750 µl of diluted 
culture from each isolate (n = 3) resulting in an average multiplicity of infection (MOI) of 
45, with an uninoculated DCBM control on each plate (n = 3). The plate was centrifuged 
at 400 x g for five minutes followed by a one hour incubation at 37ºC with 5% CO2. After 
incubating, each well was washed gently eight times with phosphate buffered saline 
(PBS). Each well was then treated with 200μL of 0.1% trypsin to dislodge cells and 
adherent bacteria. The trypsin was collected and combined with 800μL of PBS.  
Serial dilutions of the inoculum and the recovered contents from each well were 
generated and plated onto Trypticase Soy Agar (BD Biosciences, Sparks, MD) plates and 
incubated for 24 hours at 37ºC. Three non-treated control wells from each plate were 
collected in the same manner as the test wells and a Scepter 2.0 cell counter (Millipore, 
Billerica, MA) was used to calculate the average keratinocytes/well in the plate. Each 
isolate was screened with three biological replicates generated from the average of three 
technical replicates. For each biological replicate, the CFU per HEK was calculated for 
comparison. 
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Swine skin biopsy adherence assay 
The external epidermis of the pinna and the base of the ear was cleaned of visible 
surface debris, scrubbed with gauze soaked in 7.5% povidone-iodine surgical scrub 
(Purdue Pharma L.P., Stamford, CT), and rinsed with gauze soaked in 95% ethanol three 
times. A section of scrubbed skin was excised and washed in Gibco EpiLife cell culture 
media (Thermo Fisher Scientific Inc., Oakwood Village, OH) supplemented with Gibco 
Human Keratinocyte Growth Supplement (Thermo Fisher Scientific Inc., Oakwood 
Village, OH) containing 100 IU/mL Penicillin G, 100μg/mL Streptomycin, 50μg/mL 
Gentamycin sulfate and 1.0μg/mL Amphotericin B. The skin segment was moved to 
supplemented EpiLife media containing 100 IU/mL Penicillin G and incubated for 2 
hours at 37ºC. Skin was then transferred to supplemented EpiLife media without 
antibiotic and incubated for 30 minutes at 37ºC. The hypodermis was removed and punch 
biopsies were generated using Militex sterile disposable 8mm punch biopsy tool (Thermo 
Fisher Scientific Inc., Oakwood Village, OH). Biopsies were placed into 48-well plates 
(Corning Inc., Corning, NY) with the epidermis exposed. From each skin section, one 
biopsy was used for each isolate screened and one biopsy treated with uninoculated 
EpiLife medium and used as a control to detect contamination.  
For each isolate, an overnight culture in TSB was used to inoculate 5mL of TSB 
and grown to logarithmic growth phase. The cultures were diluted to an OD600 ranging 
from 0.50-0.59 and 500μL was inoculated into 4.5mL of supplemented EpiLife media 
generating an average MRSA inoculum concentrations of 4.18x106 CFU/mL. The 
cultures were mixed well and 25μL was inoculated onto each skin biopsy resulting in an 
average inoculum distribution of 8.32x104 MRSA/mm2. After each skin biopsy in the 
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plate was inoculated, the plate was incubated for 1 hour at 37ºC with 5% CO2. The skin 
biopsies were then washed four times with PBS to remove non-adherent bacteria and 
50μL of trypsin 0.1% was added to each skin biopsy and they were incubated for 15 
minutes at 37ºC to dislodge adhered bacteria. After trypsinization, the skin biopsies were 
moved to centrifuge tubes with 950μL of supplemented EpiLife media and vortexed to 
suspend the bacteria.  
Serial dilutions were made of the inoculum and the bacteria retrieved from the 
skin biopsies after trypsinization. Dilutions were plated onto Trypticase Soy Agar plates 
containing 1μg/mL oxacillin. Plates were incubated for 48 hours at 37ºC, colonies were 
counted and used to determine CFU/mL for the inoculum and skin biopsies. Each isolate 
was tested with at least three biological replicates consisting of the average of three 
technical replicates. For each biological replicate, the CFU/mm2 surface area of the skin 
biopsy was calculated. 
Statistical analysis  
All statistics were completed using GraphPad Prism 7.01 (GraphPad Software, 
Inc., La Jolla, CA). Mann Whitney tests were used to compare the CFU per HEK and the 
CFU per mm2 between LA-MRSA ST5 isolates and clinical MRSA ST5 isolates from 
humans with no swine contact. Fisher’s exact tests were used to compare the prevalence 
of individual genes between the subsets of isolates. 
Accession Numbers 
The draft genome sequences for all isolates were deposited in 
DDBJ/ENA/GenBank with the following accession numbers: LKVI00000000-
LKWJ00000000, LKWY00000000-LKYQ00000000, LKYS00000000-LLBD00000000, 
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LLBG00000000-LLBI00000000, and LLBK00000000-LLBW00000000. Individual 
isolate accession numbers are listed in Appendix A [376-381]. 
Results 
Adherence to human epidermal keratinocytes 
Adherence assays were used to determine the capacity of swine associated LA-
MRSA ST5 and MRSA ST5 from humans with no swine contact to colonize human skin. 
LA-MRSA ST5 isolates and MRSA ST5 isolates from humans with no swine contact 
adhered to the HEK cell line equivalently (Figure 6.1). There was no significant 
difference in the CFU adhered per HEK (P = 0.74) when isolates were compared as 
subsets (Figure 6.1-A). There was considerable varaibilityin the ability of individual 
isolates to adhere to HEK cells (Figure 6.2-A). For example, the average CFU per HEK 
for UCI27 was higher than the average CFU per HEK adhered for ISU980 (Figure 6.2-
A). In some cases, there were also wide ranges in the CFU per HEK adhered between 
biological replicates of an individual isolate, such as that seen for ISU978 (Figure 6.2-A). 
Adherence to swine skin biopsy 
To assess the capacity of the selected isolates to colonize swine epithelial tissue, 
adherence assays were completed using swine skin biopsies. Swine associated LA-
MRSA ST5 isolates adhered in greater CFU per mm2 than MRSA ST5 isolates from 
humans with no swine contact (P < 0.0001) (Figure 6.1-B). Similar to adherence patterns 
for the HEK cells, differences were noted in the adherence capacity for individual isolates 
as well as variation between biological replicate (Figure 6.2-B). 
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Figure 6.1: Adherence capacity of swine associated LA-MRSA ST5 isolates and clinical MRSA ST5 
isolate from humans with no swine contact to human keratinocytes and swine skin biopsies. Figure 
1A represents the CFU adhered per HEK for LA-MRSA ST5 isolates and clinical MRSA ST5 isolates with 
each point representing the average of three technical replicates. Figure 1B represents the MRSA CFU 
adhered per mm2 of the swine skin biopsies for LA-MRSA ST5 and clinical MRSA ST5 isolates. (*) 
denotes statistical significance of P < 0.05. 
 
Comparison of adherence genes 
To examine genomic differences that may influence how MRSA ST5 isolates 
interact with their host and environment, we compared the nucleotide sequences of 22 
genes encoding factors associated with adherence and skin colonization [69]. The percent 
identity for each of the adherence-associated genes in LA-MRSA ST5 and MRSA ST5 
isolates from humans with no swine contact was determined for each isolate relative to 
Mu3 (Figure 6.3 and Figure 6.4). This analysis indicated the adherence genes harbored by 
both subsets of isolates showed a high degree of nucleotide identity. Specifically, a 
nucleotide percent identity greater than 90 relative to the reference isolate Mu3 was 
observed for all evaluated genes (Table 6.2). The gene displaying the greatest sequence 
divergence was  
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Figure 6.2: Adherence patterns of individual isolates to HEKs and swine skin biopsies. Differential 
adherence patterns were noted between individual isolates in adherence to HEKs (A) and swine skin 
biopsies (B). There were also differences noted in the adherence pattern between biological replicates of an 
individual isolate, such as CFU per HEK for ISU978 (A) or CFU per mm2 for UMN38 (B).  
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clfA (Figure 6.3 and Figure 6.4); however, it was intact in all the isolates and variation 
was associated with single nucleotide polymorphisms, insertions, and deletions that did 
not result in a premature stop codon or removal of large segments of the clfA gene. The 
greatest variation in clfA was present in LA-MRSA ST5 isolates and was due to an 
insertion of 162 bp at position 2,125 and a deletion of 24 bp at position 2,799 detected in 
the clfA gene of 19 of isolates (Figure 6.5). There were isolates that lacked sequence 
associated with specific adherence genes (Figure 6.3 and Figure 6.4 indicated in black). 
This may be associated with gaps in the draft genome sequence rather than a true absence 
of the gene of interest. 
 
Figure 6.3: Percent identity of adherence associated genes for isolates evaluated with phenotypic 
assay. Genes were compared to the gene in the reference isolate, Mu3. The percent identity of all screened 
genes was greater than 90%. The greatest variation was seen in the clfA gene. This was true for both LA-
MRSA ST5 isolates and clinical MRSA ST5 isolates; however, a subset of LA-MRSA ST5 isolates 
(ISU876, ISU949, ISU978, and ISU980) showed added variation due to nucleotide insertions and deletions. 
Genes not found in the draft genomes are depicted in black. 
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Figure 6.4: Percent identity of adherence associated genes in 82 LA-MRSA ST5 isolates and 71 clinical MRSA ST5 isolates. Percent identity of adherence 
genes as compared to the reference isolate Mu3 is depicted. All screened genes showed a high percent identity (greater than 90%) to the reference gene. Similar 
to that noted in the phenotypically screened isolates, the clfA gene had the greatest variation. Genes depicted in black were absent from the draft genome 
sequence. 
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Figure 6.5: Representative image of clfA alignment from 19 LA-MRSA ST5 and Mu3. There were 19 
LA-MRSA ST5 isolates in which the clfA gene showed a reduced percent nucleotide identity to Mu3. The 
clfA genes in LA-MRSA ST5 isolates with a reduced identity possessed an insertion of 162 bp at position 
2,125 and a deletion of 24 bp at 2,799. The insertion and deletion did not result in a frameshift mutation 
and the clfA gene in these isolates remained intact. 
 
Table 6.2: Percent nucleotide identity for adherence factors in LA-MRSA ST5 isolates and MRSA 
ST5 isolates from humans with no swine contact as compared to MRSA ST5 Mu3 
Adherence Factor LA-MRSA ST5 a,b MRSA ST5 from Humans 
with No Swine Contact a,c 
clfA 90-100 (97) 93-100 (96) 
clfB 93-100 (99) 91-100 (97) 
sdrC 97-100 (99) 96-100 (98) 
sdrD 99-100 (100) 97-100 (99) 
sdrE 98-100 (100) 99-100 (100) 
eap 100-100 (100) 100-100 (100) 
ebhA 100-100 (100) 99-100 (100) 
ebhB 100-100 (100) 100-100 (100) 
ebpS 100-100 (100) 100-100 (100) 
fnbpA 98-100 (100) 97-100 (100) 
fnbpB 100-100 (100) 95-100 (100) 
isbA 100-100 (100) 100-100 (100) 
isdA 99-100 (100) 97-100 (99) 
isdB 100-100 (100) 100-100 (100) 
isdH 100-100 (100) 100-100 (100) 
sasB 98-100 (100) 100-100 (100) 
sasC 100-100 (100) 100-100 (100) 
sasD 100-100 (100) 100-100 (100) 
sasF 99-100 (100) 100-100 (100) 
sasH 100-100 (100) 100-100 (100) 
sasK 100-100 (100) 100-100 (100) 
sraP 99-100 (100) 100-100 (100) 
a minimum identity-maximum identity (average identity) 
b includes 82 swine associated LA-MRSA ST5 isolates 
c includes 72 human clinical S. aureus ST5 isolates from humans with no swine contact  
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Several adherence genes were not conducive to sequence identity analysis due to 
variable repeat regions (sasG) or the absence of the gene in the reference genome 
(ACME and speG). Therefore isolate subsets were compared based on the presence or 
absence of these adherence genes (Table 6.3). The adherence gene sasG was found in 
equal prevalence in both subsets of isolates (P = 0.26). There were significantly more 
MRSA ST5 isolates from humans with no swine contact harboring the ACME arc gene 
cluster as well as speG (P = 0.02 and P < 0.0001). The adherence-associated genes cna 
and sasX were not found in ST5 isolates obtained from swine-associated sources or from 
humans with no known swine contact. 
Table 6.3: Prevalence of adherence genes in LA-MRSA ST5 isolates and MRSA ST5 isolates from 
humans with no swine contact 
Adherence Factor LA-MRSA ST5 MRSA ST5 from Humans 
with No Swine Contact  
sasG 67/82 (81.7%) 64/72 (88.9%) 
ACME – arc gene cluster 0/82 (0%) 5/72 (6.9%)* 
ACME – speG 0/82 (0%) 14/72 (19.4%)* 
cna 0/82 (0%) 0/72 (0%) 
sasX 0/82 (0%) 0/72 (0%) 
* denotes significance of P < 0.05 as compared to LA-MRSA ST5 
 
The agr genes encode a two-component sensor system that functions as a global 
regulator and a pivotal regulator of virulence factors and adherence genes [461, 462]. 
Swine associated LA-MRSA ST5 and MRSA ST5 from humans with no swine contact 
were evaluated for agr type. All isolates with detectable agr genes harbored a type II agr, 
including 78/82 of LA-MRSA ST5 isolates (95.1%) and 70/72 of clinical MRSA ST5 
isolates (97.2%). No difference in in agr type was observed between isolate subsets. The 
isolates in which an agr system was not identified are likely missing the agr type due to 
gaps in the draft genome sequences. 
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Discussion 
Reports of the colonization capacity of LA-MRSA ST398 indicate these isolates 
possess a reduced capacity for adherence to human epithelium [344], which results in 
transient colonization with ST398 isolates and reduced transmissibility of these isolates 
between humans in both the hospital and community settings [336, 338-342]. The 
reduction in adherence to human keratinocytes is suspected to be due to the absence of 
genes known to be involved in adherence, such as sdrE, and mutations and truncations in 
adherence genes, such as those noted in clfA and clfB [344]. These changes are 
hypothesized to contribute to the adaption of LA-MRSA ST398 isolates to livestock 
species [344]. Although adherence capacity and transmissibility has been reported for 
LA-MRSA ST398 isolates, there are no reports to date addressing these concerns in LA-
MRSA ST5 isolates.  
In this study, we investigated the ability of LA-MRSA ST5 isolates and human 
clinical MRSA ST5 to adhere to human keratinocytes and swine skin biopsies to better 
understand the potential for these isolates to colonize humans and pigs. We found no 
difference between the human keratinocyte adherence capacity of LA-MRSA ST5 
isolates and MRSA ST5 isolates from humans with no swine contact. We further 
determined the keratinocytes adherence patterns exhibited by both subsets of isolates 
were consistent with the adherence-related genes the isolates harbored. Notably, 
adherence genes reported to be absent or truncated in LA-MRSA ST398 were present and 
intact in LA-MRSA ST5 isolates, including clfA, clfB, sdrC, sdrE, and fnbB [344]. In the 
case of LA-MRSA ST5 isolates, there was a high proportion of nucleotide identity with 
the specific gene in reference genome (Mu3), which was also seen for the human clinical 
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MRSA ST5 isolates (Table 6.2, Figure 6.3, and Figure 6.4). This indicates an equivalent 
genetic capacity for adherence that was confirmed with in vitro testing. Although 
adherence to human keratinocytes was equivalent, the LA-MRSA ST5 isolates did show 
significantly greater adherence to swine epithelium in vitro (Figure 6.1-B). This 
difference may reflect the adaptation of swine associated LA-MRSA ST5 isolates to 
colonizing swine epithelium through unidentified mechanisms. 
Evaluation of multiple isolates of LA-MRSA ST5 and MRSA ST5 from humans 
with no swine contact indicated that there is a large amount of individual isolate variation 
as well as variation between test replicates for an individual isolate (Figure 6.2). 
Variability was anticipated between different isolates; however, the large variability 
between test replicates for the same isolate was not expected. The variation in replicates 
may be associated with differences in adherence gene expression during an individual test 
and is controlled for by screening in vivo adherence for each isolate multiple times.  
Overall, we conclude that, unlike LA-MRSA ST398 isolates, LA-MRSA ST5 
isolates do not have a reduced capacity to adhere to human keratinocytes. This was seen 
both in vitro and through in silico analysis of adherence genes, which showed greater 
than 90% identity in all isolates. While the adherence capacity of LA-MRSA ST5 isolates 
was not different from MRSA ST5 isolates from humans with no swine contact, this does 
not directly indicate their ability to colonize and cause disease. Colonization is a complex 
interaction between the host, the bacterium, and the microbiota, which is difficult to 
replicate in an in vitro setting. It is also important to note that adhesion alone is not 
sufficient to cause disease and many virulence factors that contribute to colonization and 
mediate disease in S. aureus were not found in LA-MRSA ST5 isolates [398]. This 
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includes ACME, which was found only in clinical MRSA ST5 isolates in this study and 
contribute to the persistence of S. aureus on the skin of hosts. We have also previously 
shown immune evasion genes, such as those found in the β-hemolysin converting 
bacteriophage, are absent in the LA-MRSA ST5 isolates evaluated in this study [398]. 
Collectively, this study indicates that LA-MRSA ST5 isolates are able to adhere to 
human keratinocytes equivalently to clinical MRSA ST5 isolates. This may result in 
humans that contact livestock harboring LA-MRSA ST5 isolates becoming colonized 
with those isolates; however, LA-MRSA ST5 isolates are suspected to be less virulent 
than clinical MRSA ST5 isolates and less capable of causing disease in humans. 
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CHAPTER 7. SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
Summary and Conclusions 
The association of LA-MRSA and swine has drawn concerns within the public 
health community surrounding the risk of LA-MRSA dissemination outside of the 
agricultural setting and the potential for livestock species to serve as the largest source of 
MRSA outside of the hospital setting [333]. The prototypical and most prevalent 
European lineage of LA-MRSA is ST398 [312], which has been shown to lack human 
specific virulence factors and a reduced capacity to colonize humans [12, 323, 330, 340-
342, 344]. Outside of Europe, LA-MRSA shows regional diversity with Asian swine 
being colonized with predominantly ST9 isolates and swine in the United States 
harboring ST398, ST9, and ST5 isolates [335, 354, 357, 360-362]. Public health concerns 
elevated with the discovery of LA-MRSA ST5, because unlike MRSA ST398 and MRSA 
ST9, which are considered animal adapted [12, 251, 323, 370, 417], the MRSA ST5 
lineage is a widespread and successful MRSA lineage [12]. While LA-MRSA ST398 
isolates have been well studied, there have been no investigations addressing the 
concerns surrounding LA-MRSA ST5 isolates. The body of work presented in this 
dissertation addresses the concerns associated with LA-MRSA ST5 isolates obtained 
from swine associated sources.  
The primary objective of this dissertation was to evaluate the genetic relatedness 
and pathogenic potential of LA-MRSA ST5 isolates as compared to human clinical 
MRSA ST5 isolates from humans with no swine contact. This was accomplished with the 
generation of draft genomes using the Illumina MiSeq platform and sequence analysis 
comparing chromosomal genes and mobile genetic elements. This began with SNP 
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detection and phylogenetic analysis of the core genomes, which were presented in 
Chapter 2. This study revealed LA-MRSA ST5 isolates are distinct from human clinical 
MRSA ST5 isolates. The degree of genetic relatedness among LA-MRSA ST5 isolates 
and the clonality of isolates from individual farms or production systems indicates there 
have been limited introductions of MRSA ST5 into the U.S. swine population. The 
clonality within farms was also sufficient to allow the traceback of isolates in humans 
with recent swine contact to the farm of origin.  
Phylogenetic analysis was then paired with screening of mobile genetic elements 
(MGEs) to detect potential transfer of virulence factors or antimicrobial resistance genes 
between LA-MRSA ST5 isolates and human clinical MRSA ST5 isolates from humans 
with no swine contact. The prevalence of the immune evasion genes harbored by the β-
hemolysin converting bacteriophage were evaluated in Chapter 3. The sak, chp, scn, and 
sep genes were found only in human clinical MRSA ST5 isolates and function to thwart 
the host immune response. The loss of immune evasion genes harbored by the β-
hemolysin converting bacteriophage may represent an adaption of LA-MRSA ST5 
isolates to colonizing swine, because sak, chp, and scn have been shown to have a high 
degree of specificity for human proteins and minimal reactivity in other mammalian 
species [165, 168, 408].  
Additionally, the analyses found in Chapter 4 and 5 evaluate the distribution of 
antimicrobial resistance genes and the contribution of selective pressures to the 
development and acquisition of antimicrobial resistance in LA-MRSA ST5 and 
humanclinical MRSA ST5 isolates. In Chapter 4, the prevalence of czrC and zinc-
chloride resistance was presented. While czrC and zinc resistance is widespread in LA-
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MRSA ST398 and is thought to have had a significant contribution to the dissemination 
of LA-MRSA ST398 [348, 349, 426, 463], it was absent from LA-MRSA ST5 isolates. 
The absence of czrC in LA-MRSA ST5 isolates indicates that there may be a lineage 
association that enabled LA-MRSA ST398 isolates to acquire czrC and benefit from this 
acquisition, while czrC was not an essential gene for LA-MRSA ST5 isolates to become 
prevalent in United States swine herds. The report in Chapter 4 also evaluated the 
SCCmec type of LA-MRSA ST5 and human clinical MRSA ST5 isolates, which revealed 
LA-MRSA ST5 isolates harbored types III, IV, and untypable SCCmec elements and 
human clinical MRSA ST5 isolates harbored predominantly type II SCCmec elements. 
The difference in SCCmec elements may represent selection pressures in swine 
associated isolates against the larger SCCmec elements (type I-III) [183, 432]. It also 
identified that the SCCmec elements are different between the two subsets, which argues 
against the transfer of this resistance cassette between the subsets of isolates evaluated 
here.  
In Chapter 5, LA-MRSA ST5 and human clinical MRSA ST5 isolates were 
evaluated for genes conferring antibiotic resistance and phenotypic resistance patterns. 
Antibiotic resistance profiles and genes conferring antibiotic resistance were found to 
differ between LA-MRSA ST5 and human clinical MRSA ST5 isolates. The antibiotic 
resistance harbored by each subset of isolates tended to represent selective pressures 
found in the environment from which the isolate was obtained, such that LA-MRSA ST5 
isolates possessed resistance to antibiotics heavily used in animal agriculture (tetracycline 
antibiotics) and human clinical MRSA ST5 isolates possessed resistance to antibiotics 
widely used in a hospital setting (fluoroquinolone antibiotics). The differences noted in 
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antibiotic resistance elements, similar to the difference in SCCmec elements, provides 
further evidence against the transfer of mobile genetic elements harboring antibiotic 
resistance genes between LA-MRSA ST5 isolates and human clinical MRSA ST5 
isolates. 
Finally, to address the potential of LA-MRSA ST5 isolates to colonize human 
skin, Chapter 6 provides a genetic analysis of adherence factors in LA-MRSA ST5 
isolates and human clinical MRSA ST5 isolates and phenotypic screening of a subset of 
LA-MRSA ST5 isolates and human clinical MRSA ST5 isolates for the capacity to 
adhere to human keratinocytes. The adherence factors harbored by LA-MRSA ST5 and 
human clinical MRSA ST5 isolates had a high percent identity to the reference gene in 
Mu3 and adhered equivalently to human keratinocytes in vitro. Human clinical MRSA 
ST5 were noted to harbor the arginine catabolic mobile element and speG, genes 
harbored on MGEs that are involved in survival and persistence on human skin, which 
were absent in LA-MRSA ST5 isolates. The absence of the arginine catabolic mobile 
element and speG is further support indicating a reduced virulence of LA-MRSA ST5 
isolates as compared to their clinical counterparts and contributes additional evidence that 
transfer of MGEs between LA-MRSA ST5 and human clinical MRSA ST5 isolates is not 
occurring. 
Overall, the work contained herein indicates that the LA-MRSA ST5 isolates 
screened in this study are genetically distinct from the human clinical MRSA ST5 
isolates screened. This distinction was evident from the phylogenetic analysis conducted 
using identified SNPs and confirmed through the screening of MGEs. MGE analysis 
revealed few shared genes harbored by both subsets of isolates, which indicates MRSA 
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ST5 isolates may be adapting to their environment and their host species through the 
acquisition or loss of host specific virulence factors and acquiring antibiotic resistance 
genes that contribute to their fitness in the agricultural or clinical setting. The major 
pitfall to this investigation is that the human clinical MRSA ST5 isolates were obtained 
from university hospitals in urban areas of California. The hospitals selected for this 
analysis were chosen due to the availability of isolates and the ability to ensure the 
selected isolates were obtained from humans with no swine contact. The concern with the 
clinical isolates used in this study is due to the geographic isolation of the populations 
harboring the LA-MRSA ST5 and the human clinical MRSA ST5 isolates, which makes 
contact between the subsets of isolates unlikely and limits the physical interaction 
required for transfer of MGEs.  
Future directions 
As discussed, the experimental design of this study ensured that no clinical 
isolates were obtained from humans with swine contact and also caused the geographic 
separation of the LA-MRSA ST5 and human clinical MRSA ST5 isolates analyzed here. 
The results of this study indicate there are genetic differences between LA-MRSA ST5 
isolates and human clinical MRSA ST5 isolates; however, because of the study design, 
these differences have the potential to represent regional variation in MRSA ST5 isolates 
rather than a difference in clinical and agricultural ST5 isolates. To better address this, 
future research should investigate human clinical MRSA ST5 isolates from regions of 
swine production and determine their genetic relationship with the isolates investigated 
here. If human clinical MRSA ST5 isolates from regions of swine production are more 
closely related to the clinical MRSA ST5 isolates from humans with no swine contact, it 
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indicates a difference in the capacity of LA-MRSA ST5 and human clinical MRSA ST5 
to cause disease and provides evidence that LA-MRSA ST5 isolates have adapted to 
colonizing swine. Alternatively, if human clinical MRSA ST5 isolates from regions of 
swine production are more genetically similar to LA-MRSA ST5 isolates, it may indicate 
several conclusions: there are regional differences in MRSA ST5 populations, there may 
be transmission of LA-MRSA ST5 isolates outside of the livestock setting, or humans in 
regions of swine production are acting as a source of MRSA ST5 isolates in pigs. The 
information obtained from an analysis of human clinical MRSA ST5 isolates from 
regions of swine production when paired with patient history will be able to provide 
information on the capacity of these isolates to cause disease. 
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APPENDIX A. ISOLATE INFORMATION 
Isolate Name Isolate Source 
GenBank 
Accession 
Number 
Spa 
Type 
SCCmec 
Type 
β-Hemolysin 
Converting 
Bacteriophage 
czrC 
gene 
Tetracycline 
Resistance 
Genes 
erm 
Resistance 
Gene 
ACME genes 
ISU837 Environment LKVQ00000000 t002 IV Absent Absent Absent Absent Absent 
ISU839 Environment LKVR00000000 t002 IV Absent Absent Absent Absent Absent 
ISU842 Environment LKVS00000000 t002 IV Absent Absent Absent Absent Absent 
ISU871 Pig LKVT00000000 t002 III Absent Absent Absent ermC Absent 
ISU872 Pig LKVU00000000 t002 III Absent Absent Absent ermC Absent 
ISU873 Pig LKVV00000000 t002 III Absent Absent Absent ermC Absent 
ISU874 Pig LKVW00000000 t002 III Absent Absent tetL, tetT ermC Absent 
ISU875 Pig LKVX00000000 t002 III Absent Absent tetL, tetT ermC Absent 
ISU876 Pig LKVY00000000 t002 III Absent Absent tetL, tetT ermC Absent 
ISU877 Pig LKVZ00000000 t002 III Absent Absent Absent ermC Absent 
ISU878 Pig LKWA00000000 t002 III Absent Absent tetL, tetT ermC Absent 
ISU879 Pig LKWB00000000 t002 III Absent Absent Absent ermC Absent 
ISU880 Pig LKWC00000000 t002 III Absent Absent tetL, tetT ermC Absent 
ISU881 Pig LKWD00000000 t002 III Absent Absent tetL, tetT ermC Absent 
ISU882 Pig LKWE00000000 t002 III Absent Absent Absent ermC Absent 
ISU883 Environment LKWF00000000 t002 III Absent Absent tetL, tetT ermC Absent 
ISU886 Human - ST LKWG00000000 t002 III Absent Absent Absent ermC Absent 
ISU887 Human - ST LKWH00000000 t002 III Absent Absent Absent ermC Absent 
ISU888 Human - ST LKWI00000000 t002 III Absent Absent Absent ermC Absent 
ISU889 Human - ST LKWJ00000000 t002 III Absent Absent Absent ermC Absent 
ISU928 Human - ST LKWY00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU930 Human - ST LKWZ00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU931 Human - ST LKXA00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU933 Pig LKXB00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU934 Pig LKXC00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU935 Pig LKXD00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU936 Pig LKXE00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU939 Pig LKXF00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU940 Environment LKXG00000000 t002 IV Absent Absent Absent Absent Absent 
1
9
4
 
195 
 
Appendix A Continued 
Isolate Name Isolate Source 
GenBank 
Accession 
Number 
Spa 
Type 
SCCmec 
Type 
β-Hemolysin 
Converting 
Bacteriophage 
czrC 
gene 
Tetracycline 
Resistance 
Genes 
erm 
Resistance 
Gene 
ACME genes 
ISU941 Pig LKXH00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU943 Environment LKXI00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU944 Environment LKXJ00000000 t002 IV Absent Absent tetL Absent Absent 
ISU946 Environment LKXK00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU947 Environment LKXL00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU948 Environment LKXM00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU949 Pig LKXN00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU951 Pig LKXO00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU952 Pig LKXP00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU953 Pig LKXQ00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU954 Pig LKXR00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU956 Pig LKXS00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU960 Environment LKXT00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU961 Environment LKXU00000000 t002 IV Absent Absent Absent Absent Absent 
ISU962 Environment LKXV00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU963 Environment LKXW00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU964 Environment LKXX00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU968 Pig LKXY00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU969 Pig LKXZ00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU970 Pig LKYA00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU971 Pig LKYB00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU972 Environment LKYC00000000 t002 IV Absent Absent Absent Absent Absent 
ISU973 Environment LKYD00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU976 Pig LKYE00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU978 Pig LKYF00000000 t002 IV Absent Absent tetL, tetT ermC Absent 
ISU979 Pig LKYG00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU980 Environment LKYH00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU981 Environment LKYI00000000 t002 IV Absent Absent Absent Absent Absent 
ISU982 Environment LKYJ00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU983 Environment LKYK00000000 t002 IV Absent Absent tetL, tetT Absent Absent 
ISU992 Pig LKYL00000000 t548 untypable Absent Absent tetL, tetT ermC Absent 
ISU993 Environment LKYM00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
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Appendix A Continued 
Isolate Name Isolate Source 
GenBank 
Accession 
Number 
Spa 
Type 
SCCmec 
Type 
β-Hemolysin 
Converting 
Bacteriophage 
czrC 
gene 
Tetracycline 
Resistance 
Genes 
erm 
Resistance 
Gene 
ACME genes 
ISU994 Environment LKYN00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
ISU995 Environment LKYO00000000 t002 untypable Absent Absent tetL, tetT Absent Absent 
ISU996 Environment LKYP00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
ISU998 Environment LKYQ00000000 t002 untypable Absent Absent tetL, tetT Absent Absent 
ISU1000 Pig LKVI00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
ISU1001 Pig LKVJ00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
ISU1002 Pig LKVK00000000 t548 untypable Absent Absent tetL, tetT ermC Absent 
ISU1004 Human - ST LKVL00000000 t548 untypable Absent Absent tetL, tetT ermC Absent 
ISU1007 Human - ST LKVM00000000 t1107 untypable Absent Absent tetL, tetT ermC Absent 
ISU1008 Pig LKVN00000000 t548 untypable Absent Absent tetL, tetT ermC Absent 
ISU1009 Pig LKVO00000000 t002 untypable Absent Absent tetL, tetT Absent Absent 
ISU1010 Pig LKVP00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
UMN1 Human - LT LLBO00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
UMN2 Human - LT LLBP00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
UMN3 Human - LT LLBQ00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
UMN4 Human - LT LLBS00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
UMN5 Human - LT LLBT00000000 t002 untypable Absent Absent tetL, tetT ermC Absent 
UMN6 Human - LT LLBV00000000 t002 untypable Absent Absent Absent Absent Absent 
UMN7 Human - LT LLBW00000000 t002 untypable Absent Absent Absent Absent Absent 
UMN38 Human - LT LLBR00000000 t242 untypable Absent Absent Absent ermC Absent 
UMN50 Human - LT LLBU00000000 t2049 untypable Absent Absent tetL, tetT ermC Absent 
UCSF 13502 Human - NSC LLBG00000000 t002 II Present Absent Absent ermA Absent 
UCSF 13582 Human - NSC LLBH00000000 t845 II Present Absent Absent ermA Absent 
UCSF 13938 Human - NSC LLBI00000000 t002 II Present Absent Absent ermA Absent 
UCSF 14054 Human - NSC LLBJ00000000 t14590 n/a Present Absent Absent Absent Absent 
UCSF 14262 Human - NSC LLBK00000000 t002 II Present Absent Absent ermA Absent 
UCSF 14436 Human - NSC LLBL00000000 t002 IV Present Absent Absent Absent Absent 
UCSF 14655 Human - NSC LLBM00000000 t002 II Present Absent Absent ermA Absent 
UCSF 14811 Human - NSC LLBN00000000 t002 II Present Absent Absent ermA Absent 
UCI 01 Human - NSC LKYS00000000 t045 II Present Absent Absent ermA Absent 
UCI 02 Human - NSC LKYT00000000 t045 II Present Absent Absent ermA Absent 
UCI 03 Human - NSC LKYU00000000 t002 II Present Present Absent Absent speG 
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Appendix A Continued 
Isolate Name Isolate Source 
GenBank 
Accession 
Number 
Spa 
Type 
SCCmec 
Type 
β-Hemolysin 
Converting 
Bacteriophage 
czrC 
gene 
Tetracycline 
Resistance 
Genes 
erm 
Resistance 
Gene 
ACME genes 
UCI 04 Human - NSC LKYV00000000 t242 II Present Absent Absent ermA Absent 
UCI 05 Human - NSC LKYW00000000 t242 II Present Absent Absent ermA Absent 
UCI 06 Human - NSC LKYX00000000 t002 IV Present Absent Absent Absent Absent 
UCI 07 Human - NSC LKYY00000000 t002 II Present Absent Absent ermA Absent 
UCI 08 Human - NSC LKYZ00000000 t045 II Present Absent Absent ermA Absent 
UCI 09 Human - NSC LKZA00000000 t045 II Present Present Absent ermA speG 
UCI 10 Human - NSC LKZB00000000 t002 II Present Absent Absent ermA Absent 
UCI 11 Human - NSC LKZC00000000 t242 II Present Present Absent ermA speG, arc genes 
UCI 12 Human - NSC LKZD00000000 t242 II intact Absent Absent ermA Absent 
UCI 13 Human - NSC LKZE00000000 t242 II Present Absent Absent ermA Absent 
UCI 14 Human - NSC LKZF00000000 t002 II Present Absent Absent ermA Absent 
UCI 15 Human - NSC LKZG00000000 t242 II Absent Absent Absent ermA Absent 
UCI 16 Human - NSC LKZH00000000 t242 II Present Absent Absent ermA Absent 
UCI 17 Human - NSC LKZI00000000 t242 II Present Absent Absent ermA Absent 
UCI 18 Human - NSC LKZJ00000000 t002 II Present Absent Absent Absent Absent 
UCI 19 Human - NSC LKZK00000000 t002 II Present Present Absent ermA speG 
UCI 20 Human - NSC LKZL00000000 t002 II Present Absent Absent ermA Absent 
UCI 21 Human - NSC LKZM00000000 t002 II Present Present Absent ermA speG 
UCI 22 Human - NSC LKZN00000000 t002 II Present Absent Absent ermA Absent 
UCI 23 Human - NSC LKZO00000000 t002 II Absent Absent Absent ermA Absent 
UCI 24 Human - NSC LKZP00000000 t002 II Present Present Absent Absent speG 
UCI 25 Human - NSC LKZQ00000000 t045 II Present Absent Absent ermA Absent 
UCI 26 Human - NSC LKZR00000000 t242 II Present Absent Absent ermA Absent 
UCI 27 Human - NSC LKZS00000000 t242 II Present Present Absent ermA speG, arc genes 
UCI 28 Human - NSC LKZT00000000 t242 II Present Present Absent ermA speG 
UCI 29 Human - NSC LKZU00000000 t002 II Present Absent Absent Absent Absent 
UCI 30 Human - NSC LKZV00000000 t002 II Present Absent Absent ermA Absent 
UCI 31 Human - NSC LKZW00000000 t242 II Present Absent Absent ermA Absent 
UCI 32 Human - NSC LKZX00000000 t242 II Present Absent Absent ermA Absent 
UCI 33 Human - NSC LKZY00000000 t002 II Present Absent Absent ermA Absent 
UCI 34 Human - NSC LKZZ00000000 t242 II Present Absent Absent ermA Absent 
UCI 35 Human - NSC LLAA00000000 t045 II Present Absent Absent ermA Absent 
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Appendix A Continued 
Isolate Name Isolate Source 
GenBank 
Accession 
Number 
Spa 
Type 
SCCmec 
Type 
β-Hemolysin 
Converting 
Bacteriophage 
czrC 
gene 
Tetracycline 
Resistance 
Genes 
erm 
Resistance 
Gene 
ACME genes 
UCI 36 Human - NSC LLAB00000000 t002 II Present Absent Absent ermA Absent 
UCI 37 Human - NSC LLAC00000000 t002 II Present Absent Absent ermA Absent 
UCI 38 Human - NSC LLAD00000000 t002 II Present Absent Absent ermA Absent 
UCI 39 Human - NSC LLAE00000000 t242 II Present Absent Absent ermA Absent 
UCI 40 Human - NSC LLAF00000000 t002 II Present Absent Absent ermA Absent 
UCI 41 Human - NSC LLAG00000000 t002 II Absent Absent Absent ermA Absent 
UCI 42 Human - NSC LLAH00000000 t002 II Present Absent Absent ermA Absent 
UCI 43 Human - NSC LLAI00000000 t242 II Present Present Absent ermA speG 
UCI 44 Human - NSC LLAJ00000000 t242 II Present Absent Absent ermA Absent 
UCI 45 Human - NSC LLAK00000000 t242 II Present Present Absent ermA speG 
UCI 46 Human - NSC LLAL00000000 t242 II Present Present Absent ermA Absent 
UCI 47 Human - NSC LLAM00000000 t045 II Absent Absent Absent ermA Absent 
UCI 48 Human - NSC LLAN00000000 t242 II Present Present Absent ermA speG, arc genes 
UCI 49 Human - NSC LLAO00000000 t002 II Present Absent Absent ermA Absent 
UCI 50 Human - NSC LLAP00000000 t045 II Present Absent Absent ermA Absent 
UCI 51 Human - NSC LLAQ00000000 t002 II Present Absent Absent ermA Absent 
UCI52 Human - NSC LLAR00000000 t002 II Present Present Absent ermA speG 
UCI53 Human - NSC LLAS00000000 t002 II Present Absent Absent ermA Absent 
UCI54 Human - NSC LLAT00000000 t242 II Present Absent Absent ermA Absent 
UCI55 Human - NSC LLAU00000000 t045 II Absent Absent Absent ermA Absent 
UCI56 Human - NSC LLAV00000000 t242 II Present Present Absent ermA Absent 
UCI57 Human - NSC LLAW00000000 t002 II Present Absent Absent ermA Absent 
UCI58 Human - NSC LLAX00000000 t242 II Present Absent Absent ermA Absent 
UCI59 Human - NSC LLAY00000000 t242 II Present Absent Absent ermA Absent 
UCI60 Human - NSC LLAZ00000000 t242 II Present Absent Absent ermA Absent 
UCI61 Human - NSC LLBA00000000 t002 II Present Absent Absent ermA Absent 
UCI62 Human - NSC LLBB00000000 t242 II Present Present Absent ermA speG, arc genes 
UCI63 Human - NSC LLBC00000000 t045 II Absent Absent Absent ermA Absent 
UCI64 Human - NSC LLBD00000000 t242 II Present Present Absent ermA speG, arc genes 
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APPENDIX B. COMPLETE GENOME SEQUENCES OF TWO 
STAPHYLOCOCCUS AUREUS SEQUENCE TYPE 5 ISOLATES FROM 
CALIFORNIA, USA 
 
Modified from a paper published in Genome Announcements  
 
Samantha J. Hau1, Darrell O. Bayles2, David P. Alt2, Tracy L. Nicholson2 
 
1Department of Veterinary Diagnostic and Production Animal Medicine, College of 
Veterinary Medicine, Iowa State University, Ames, Iowa 
2National Animal Disease Center, Agricultural Research Service, United States 
Department of Agriculture, Ames, Iowa 
 
Abstract 
Staphylococcus aureus causes a variety of human diseases ranging in severity. 
The pathogenicity of S. aureus can be partially attributed to the acquisition of mobile 
genetic elements. In this report, we provide two complete genome sequences from human 
clinical S. aureus isolates. 
Genome Announcement 
Staphylococcus aureus is a commensal of the skin and nasopharynx of various 
animals, including humans. It is also pathogenic in humans, causing disease that ranges in 
severity from mild skin infections to severe invasive infections [464]. Methicillin-
resistant S. aureus (MRSA) isolates are categorized epidemiologically into three 
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categories: hospital-acquired MRSA (HA-MRSA), community-acquired MRSA (CA-
MRSA), or livestock-associated MRSA (LA-MRSA). They are further characterized 
through multilocus sequence typing into sequence types (STs), which indicate the genetic 
lineage and characteristics of the isolates. ST5 isolates are widely distributed and known 
to readily acquire mobile genetic elements containing virulence factors or antibiotic 
resistance elements [12].  
We sequenced two clinical ST5 isolates from the University of California, Irvine 
(UCI28 and UCI62) [375]. They were obtained from patients with MRSA-related disease 
who had no known exposure to livestock. Because a full patient history was not obtained, 
HA- and CA-MRSA could not be differentiated. Each isolate was grown in Trypticase 
soy broth (BD Biosciences, Sparks, MD), and total genomic DNA was extracted using 
the High Pure PCR template preparation kit (Roche Applied Science, Indianapolis, IN).  
Whole-genome sequencing was performed on both the PacBio and Illumina 
MiSeq platforms. Library preparation for PacBio sequencing was performed according to 
the PacBio 10-kb insert library preparation protocol available at 
http://www.pacb.com/wp-content/uploads/2015/09/Procedure-Checklist-10-kb-Template-
Preparation-and-Sequencing.pdf. The 10-kb library was sequenced using the PacBio RSII 
platform, with one single-molecule real-time (SMRT) cell for each isolate. Indexed 
libraries for the MiSeq protocol were generated with the Nextera XT DNA sample 
preparation and index kits (Illumina, San Diego, CA), pooled, and sequenced using the 
MiSeq version 2 500-cycle reagent kit, yielding 2 × 250-bp paired-end reads on the 
Illumina MiSeq platform (Illumina).  
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Whole-genome assemblies were generated using PacBio SMRT Analysis version 
2.3.0 and the CANU version 1.3 software. The average PacBio coverages for the 
assembled genomes were 306× for UCI28 and 297× for UCI62. After assembling the 
PacBio data, any overlapping sequence was trimmed and the genomes oriented to start at 
the dnaA gene. The genomes were polished and error corrected using the Broad 
Institute’s Pilon program version 1.18, with Illumina data at 75× and 112× average 
coverage for UCI28 and UCI62, respectively.  
Accession numbers 
The whole-genome sequences for these isolates were deposited in 
DDBJ/ENA/GenBank with the accession numbers CP018768 and CP018769 for UCI28 
and CP018766 and CP018767 for UCI62. 
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Abstract  
Staphylococcus aureus is part of the human epithelial microbiota; however, it is 
also a pathogen. The acquisition of mobile genetic elements plays a role in the virulence 
of S. aureus isolates and contributes to treatment failures. This report details the draft 
genome sequences of 14 clinical S. aureus isolates. 
Genome Announcement 
Staphylococcus aureus is part of the microbiota found on the skin of humans and 
other animals. It is also a known pathogen that causes mild to severe infections, as well as 
toxin-mediated diseases [464]. Methicillin-resistant S. aureus (MRSA) is a growing 
concern in the health industry, and MRSA isolates are categorized based on each isolate’s 
source as either hospital-acquired MRSA (HA-MRSA), community-acquired MRSA 
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(CA-MRSA), or livestock-associated MRSA (LA-MRSA). Multilocus sequence typing is 
employed to determine an isolate’s sequence type (ST), which indicates the genetic 
background and denotes the characteristics of the isolate common to the group. The ST5 
lineage is globally distributed and well known for acquisition of virulence factors and 
antibiotic resistance genes contained on mobile genetic elements [12].  
We sequenced 14 ST5 isolates from patients with clinical disease caused by 
MRSA. These isolates were obtained from the University of California, Irvine (UCI3, 
UCI9, UCI11, UCI19, UCI21, UCI24, UCI27, UCI43, UCI45, UCI46, UCI48, UCI52, 
UCI56, and UCI64) [375]. The patients had no known livestock exposure; however, 
because full patient histories were not provided, it could not be determined whether the 
isolates were HA- or CA-MRSA. Isolates were grown in Trypticase soy broth (BD 
Biosciences, Sparks, MD), and total genomic DNA was extracted using the High Pure 
PCR template preparation kit (Roche Applied Science, Indianapolis, IN).  
Draft genome sequences were generated using an Illumina MiSeq instrument. 
Nextera XT DNA sample preparation and index kits (Illumina, San Diego, CA) were 
used to generate indexed libraries. Libraries were pooled and sequenced using the MiSeq 
version 2 500-cycle reagent kit, yielding 2 × 250-bp paired-end reads (Illumina).  
Draft genome assemblies were generated using MIRA version 4.0.2 (http://mira-
assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html), resulting in the average 
coverages indicated here for each isolate: UCI3, 56×; UCI9, 82×; UCI11, 72×; UCI19, 
47×; UCI21, 66×; UCI24, 62×; UCI27, 40×; UCI43, 46×; UCI45, 53×; UCI46, 73×; 
UCI48, 46×; UCI52, 33×; UCI56, 36×; and UCI64, 52×. Following assembly, only 
contigs >1,500 bp in length having a coverage of >66% of the average genome coverage 
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were retained. Additionally, when the assembly tool indicated that a contig was part of a 
potentially repetitive element, the contig was required to be >2,000 bp for inclusion in the 
assembly.  
Accession numbers 
The draft genome sequences obtained for these isolates were entered into 
DDBJ/ENA/GenBank with accession numbers as follows: UCI3, LKYU00000000; 
UCI9, LKZA00000000; UCI11, LKZC00000000; UCI19, LKZK00000000; UCI21, 
LKZM00000000; UCI24, LKZP00000000; UCI27, LKZS00000000; UCI43, 
LLAI00000000; UCI45, LLAK00000000; UCI46, LLAL00000000; UCI48, 
LLAN00000000; UCI52, LLAR00000000; UCI56, LLAV00000000; and UCI64, 
LLBD00000000.  
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Abstract 
Methicillin resistant Staphylococcus aureus (MRSA) can be a commensal or 
pathogen in humans. Pathogenicity and disease are related to the acquisition of mobile 
genetic elements encoding virulence and antimicrobial resistance genes. Here, we report 
draft genome sequences for 50 clinical MRSA isolates from humans with MRSA related 
disease. 
Genome Announcement 
Methicillin resistant Staphylococcus aureus (MRSA) was first isolated in 1961 
[246]. MRSA rapidly became widespread in the hospital setting and remained contained 
there until the late 1990s, when isolates began infecting patients with no known risk 
factors for hospital acquired MRSA (HA-MRSA) [370]. This subset of MRSA isolates 
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was termed community acquired MRSA (CA-MRSA). The third group of isolates are 
acquired by contact with livestock species and are called livestock associated MRSA 
(LA-MRSA). Specific lineages of S. aureus predominate within each subset and these 
lineages are defined by their multi-locus sequence type (ST). S. aureus lineages are 
defined by differing characteristics that allow them to possess distinct niches. The ST5 
lineage, specifically, is a widespread and successful lineage of HA-MRSA [12]. This is 
primarily attributed to the capacity of this lineage to acquire mobile genetic elements 
encoding virulence factors and antimicrobial resistance genes [12]. 
Here, we report the generation of 48 draft genome sequences from MRSA ST5 
isolates obtained from the hospital at the University of California, Irvine [375]. Isolates 
sequenced, listed in Table 1, were from patients who had MRSA related disease and no 
known livestock exposure. Minimal patient history was available, including source 
information, making HA- and CA-MRSA indistinguishable. The isolates were grown in 
Trypticase Soy Broth (BD Biosciences, Sparks, MD) and the High Pure Template 
Preparation Kit (Roche Applied Science, Indianapolis, IN) was used to isolate total 
genomic DNA. 
Draft genome sequences were produced using the Illumina MiSeq platform. 
Indexed libraries were produced with the Nextera XT DNA sample preparation and index 
kit (Illumina, San Diego, CA). Sequencing employed the MiSeq v2 500 Cycle reagent kit 
(Illumina, San Diego, CA) and generated 2 × 250-bp paired-end reads. 
Sequence reads were assembled into draft genomes using MIRA v.4.0.2 
(http://mira-assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html). The average 
coverage for each isolate is listed in Table 1. For retention in the assembly, the contigs 
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were required to be >1500bp and have a coverage with at least 2/3 the average coverage 
of the genome. When repetitive elements were identified during assembly, the contig was 
required to be >2000bp to be included in the assembly. 
Accession numbers 
The assembled draft genome sequences obtained from this project were deposited 
into DDBJ/ENA/GenBank with the accession numbers listed in Table C.1. 
Table C.1. Isolate name and genome information for 50 clinical MRSA ST5 isolates. 
Isolate 
Name 
Average 
Coverage 
Number of 
Contigs 
NCBI Accession 
Number 
UCI 1 73.13× 89 LKYS00000000 
UCI 2 51.15× 162 LKYT00000000 
UCI 4 69.93× 137 LKYV00000000 
UCI 5 83.47× 105 LKYW00000000 
UCI 6 59.19× 111 LKYX00000000 
UCI 7 51.04× 158 LKYY00000000 
UCI 8 53.59× 120 LKYZ00000000 
UCI 10 50.26× 125 LKZB00000000 
UCI 12 61.68× 167 LKZD00000000 
UCI 13 46.01× 144 LKZE00000000 
UCI 14 43.15× 183 LKZF00000000 
UCI 15 46.20× 123 LKZG00000000 
UCI 16 83.09× 117 LKZH00000000 
UCI 17 83.32× 140 LKZI00000000 
UCI 18 55.44× 205 LKZJ00000000 
UCI 20 55.04× 201 LKZL00000000 
UCI 22 59.19× 148 LKZN00000000 
UCI 23 38.77× 311 LKZO00000000 
UCI 25 80.63× 125 LKZQ00000000 
UCI 26 71.95× 114 LKZR00000000 
UCI 28 48.98× 145 LKZT00000000 
UCI 29 65.78× 247 LKZU00000000 
UCI 30 66.07× 148 LKZV00000000 
UCI 31 56.88× 219 LKZW00000000 
UCI 32 43.65× 269 LKZX00000000 
UCI 33 43.35× 242 LKZY00000000 
UCI 34 49.12× 224 LKZZ00000000 
UCI 35 46.42× 111 LLAA00000000 
UCI 36 46.00× 246 LLAB00000000 
UCI 37 37.53× 264 LLAC00000000 
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Table C.1 continued 
Isolate 
Name 
Average 
Coverage 
Number of 
Contigs 
NCBI Accession 
Number 
UCI 38 53.12× 227 LLAD00000000 
UCI 39 83.79× 107 LLAE00000000 
UCI 40 44.79× 171 LLAF00000000 
UCI 41 50.09× 175 LLAG00000000 
UCI 42 54.66× 160 LLAH00000000 
UCI 44 60.57× 140 LLAJ00000000 
UCI 47 65.17× 191 LLAM00000000 
UCI 49 57.85× 237 LLAO00000000 
UCI 50 50.05× 174 LLAP00000000 
UCI 51 41.44× 184 LLAQ00000000 
UCI 53 69.80× 97 LLAS00000000 
UCI 54 49.38× 138 LLAT00000000 
UCI 55 80.91× 156 LLAU00000000 
UCI 57 80.99× 87 LLAW00000000 
UCI 58 79.17× 112 LLAX00000000 
UCI 59 82.31× 132 LLAY00000000 
UCI 60 49.91× 231 LLAZ00000000 
UCI 61 66.52× 178 LLBA00000000 
UCI 62 61.44× 131 LLBB00000000 
UCI 63 54.37× 96 LLBC00000000 
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Abstract 
Staphylococcus aureus is a commensal of humans that can cause a spectrum of 
diseases. An isolate’s capacity to cause disease is partially attributed to the acquisition of 
novel mobile genetic elements. This report provides the draft genome sequence of one 
methicillin susceptible and seven methicillin resistant clinical human S. aureus isolates. 
Genome Announcement 
Staphylococcus aureus is a component of the microbiota of normal humans but is 
also able to cause a wide range of diseases, from mild skin and soft tissue infections to 
systemic or toxin mediated disease. In 1961, the first isolates of methicillin resistant S. 
aureus (MRSA) were reported in the hospital setting [246]. More recently, MRSA 
isolates have been found outside of the hospital setting and isolates are now classified 
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based on epidemiologic characteristics into the following categories: hospital acquired 
(HA-MRSA), community acquired (CA-MRSA), and livestock associated (LA-MRSA). 
Multi-locus sequence typing is used to define lineages of S. aureus into sequence types 
(ST). Isolates within a given ST possess attributes specific to that group that cause them 
to behave similarly. For example, MRSA ST5 as well as methicillin sensitive (MSSA) 
isolates compose a lineage that is widespread and highly pathogenic [12]. These isolates 
are readily able to acquire virulence genes and antimicrobial resistance genes by 
horizontal gene transfer [12], which allows them to cause more severe disease and 
treatment failures. 
In this report, we present draft genome sequences for one methicillin sensitive S. 
aureus ST5 (BD14054) and seven MRSA ST5 isolates (BD13502, BD13582, BD13938, 
BD14262, BD14436, BD14655, and BD14811). The isolates were obtained from the 
University of California San Francisco where they were isolated from patients with S. 
aureus related disease. Full patient histories were not available, so we were unable to 
determine whether isolates were HA- or CA- in origin; however, the urban location of the 
hospital ruled out LA-MRSA. Isolates were grown in Trypticase Soy Broth (BD 
Biosciences, Sparks, MD) and total genomic DNA was isolated with the High Pure 
Template Preparation Kit (Roche Applied Science, Indianapolis, IN). 
The draft genome sequences were generated with the Illumina MiSeq platform. 
The Nextera XT DNA sample preparation and index kit (Illumina, San Diego, CA) was 
used to generate indexed libraries that were pooled and sequenced with the MiSeq v2 500 
Cycle reagent kit (Illumina, San Diego, CA). This generated 2 × 250-bp paired-end reads 
that were assembled into draft genomes using MIRA v.4.0.2 (http://mira-
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assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html). Average coverage for 
each isolate was the following: BD13502 (74.95×), BD13582 (58.07×), BD13938 
(47.09×), BD14054 (42.02×), BD14262 (79.08×), BD14436 (55.28×), BD14655 
(57.68×), and BD14811 (73.00×). To be retained in the assembly, contigs had to be 
>1500bp and have a coverage at least 2/3 the average coverage of the genome. When the 
assembly tool identified repetitive elements, it required the contig to be >2000bp for 
inclusion. 
Accession number(s). 
The draft genome assemblies generated in this project can be found in 
DDBJ/ENA/GenBank with the accession numbers as follows: BD13502 
(LLBG00000000), BD13582 (LLBH00000000), BD13938 (LLBI00000000), BD14054 
(LLBJ00000000), BD14262 (LLBK00000000), BD14436 (LLBL00000000), BD14655 
(LLBM00000000), and BD14811 (LLBN00000000). 
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Abstract 
Methicillin resistant Staphylococcus aureus colonizes humans and other animals 
such as swine. LA-MRSA sequence type (ST) 5 isolates are a public concern due to their 
pathogenicity and ability to acquire mobile genetic elements. This report presents draft 
genome sequences for 64 LA-MRSA ST5 isolates in the US. 
Genome Announcement 
Livestock associated methicillin resistant Staphylococcus aureus (LA-MRSA) 
was first isolated in association with the swine industry in 2004 [248]. Healthy pigs were 
found to harbor LA-MRSA as a component of their normal microbiota, although there are 
reports of swine disease attributed to LA-MRSA [251, 465, 466]. The most prevalent 
multi-locus sequence type (ST) of LA-MRSA in swine varies based on geography, with 
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ST398 and ST9 predominant in Europe and Asia, respectively [312, 357]. In the United 
States, LA-MRSA isolates are more diverse with ST398, ST9, and ST5 being found 
[335]. Although ST398 and ST9 are considered to be livestock adapted lineages, ST5 
isolates comprise a widespread and highly pathogenic lineage [12]. This has been 
attributed to the capacity of these isolates to acquire mobile genetic elements containing 
antimicrobial resistance genes or virulence factors [12]. LA-MRSA ST5 isolates raise 
concerns due to their potential to cause disease or disseminate antimicrobial resistance 
elements, which can be further investigated through genome sequence analysis.  
In this report, we present the draft genome sequences of 64 LA-MRSA ST5 
isolates obtained by an Iowa State University study evaluating the presence and 
prevalence of LA-MRSA in the US swine herd [335]. Swabs were taken from healthy 
pigs and the environment of eight high density livestock operations. All isolates and 
related information are listed in Table 1. Each isolate was grown in Trypticase Soy Broth 
(BD Biosciences, Sparks, MD) and total genomic DNA was extracted using the High 
Pure Template Preparation Kit (Roche Applied Science, Indianapolis, IN). 
Draft genome sequence data was produced using an Illumina MiSeq platform 
(Illumina, San Diego, CA). An indexed library was generated for each isolate using the 
Nextera XT DNA sample preparation and index kit (Illumina, San Diego, CA). They 
were then sequenced using MiSeq v2 500 Cycle reagent kit to generate 2 × 250-bp 
paired-end reads (Illumina, San Diego, CA).  
Assemblies were generated using MIRA v.4.0.2, http://mira-
assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html. Average coverage for 
each isolate is listed in Table 1. Contigs were retained in the assembly if they were 
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>1500bp in length and had a coverage of >66% of the average coverage for the genome. 
Repetitive elements identified by the assembly tool were required to be >2000bp for 
inclusion in the assembly. 
Accession numbers 
The draft genome sequences generated in this study were deposited into 
DDBJ/ENA/GenBank with the accession numbers listed in Table E.1. 
Table E.1. Isolate name, source, and genome information for 64 swine associated LA-MRSA ST5 
isolates 
Isolate 
Name 
Isolate 
Source 
Farm 
Number 
Average 
Coverage 
Number of 
Contigs 
NCBI Accession 
Number 
ISU 837 Environment 10 52.86× 60 LKVQ00000000 
ISU 839 Environment 10 40.15× 138 LKVR00000000 
ISU 842 Environment 10 77.53× 115 LKVS00000000 
ISU 871 Pig 24 62.61× 137 LKVT00000000 
ISU 872 Pig 24 64.16× 107 LKVU00000000 
ISU 873 Pig 24 57.95× 110 LKVV00000000 
ISU 874 Pig 24 58.50× 175 LKVW00000000 
ISU 875 Pig 24 50.01× 107 LKVX00000000 
ISU 876 Pig 24 35.52× 198 LKVY00000000 
ISU 877 Pig 24 25.39× 168 LKVZ00000000 
ISU 878 Pig 24 28.30× 142 LKWA00000000 
ISU 879 Pig 24 59.75× 174 LKWB00000000 
ISU 880 Pig 24 50.06× 173 LKWC00000000 
ISU 881 Pig 24 26.98× 141 LKWD00000000 
ISU 882 Pig 24 59.74× 102 LKWE00000000 
ISU 883 Environment 24 21.31× 231 LKWF00000000 
ISU 933 Pig 38 43.18× 163 LKXB00000000 
ISU 934 Pig 38 26.69× 140 LKXC00000000 
ISU 935 Pig 38 18.71× 192 LKXD00000000 
ISU 936 Pig 39 33.15× 105 LKXE00000000 
ISU 939 Pig 41 31.89× 154 LKXF00000000 
ISU 940 Environment 41 52.49× 98 LKXG00000000 
ISU 941 Pig 39 63.97× 134 LKXH00000000 
ISU 943 Environment 40 54.66× 145 LKXI00000000 
ISU 944 Environment 42 14.52× 264 LKXJ00000000 
ISU 946 Environment 41 36.83× 80 LKXK00000000 
ISU 947 Environment 42 39.23× 164 LKXL00000000 
ISU 948 Environment 42 18.98× 172 LKXM00000000 
ISU 949 Pig 42 52.56× 126 LKXN00000000 
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Table E.1 Continued 
Isolate 
Name 
Isolate 
Source 
Farm 
Number 
Average 
Coverage 
Number of 
Contigs 
NCBI Accession 
Number 
ISU 951 Pig 42 35.47× 131 LKXO00000000 
ISU 952 Pig 42 34.31× 153 LKXP00000000 
ISU 953 Pig 42 27.51× 115 LKXQ00000000 
ISU 954 Pig 42 31.65× 114 LKXR00000000 
ISU 956 Pig 42 27.32× 198 LKXS00000000 
ISU 960 Environment 38 22.56× 160 LKXT00000000 
ISU 961 Environment 38 12.46× 392 LKXU00000000 
ISU 962 Environment 39 40.02× 122 LKXV00000000 
ISU 963 Environment 39 44.82× 118 LKXW00000000 
ISU 964 Environment 39 36.13× 125 LKXX00000000 
ISU 968 Pig 41 48.31× 155 LKXY00000000 
ISU 969 Pig 41 18.26× 172 LKXZ00000000 
ISU 970 Pig 41 30.09× 91 LKYA00000000 
ISU 971 Pig 39 21.67× 187 LKYB00000000 
ISU 972 Environment 42 17.93× 91 LKYC00000000 
ISU 973 Environment 42 52.18× 200 LKYD00000000 
ISU 976 Pig 39 16.94× 261 LKYE00000000 
ISU 978 Pig 39 53.16× 188 LKYF00000000 
ISU 979 Pig 41 51.52× 176 LKYG00000000 
ISU 980 Environment 41 68.97× 126 LKYH00000000 
ISU 981 Environment 39 78.78× 142 LKYI00000000 
ISU 982 Environment 42 46.30× 272 LKYJ00000000 
ISU 983 Environment 42 49.20× 85 LKYK00000000 
ISU 992 Pig 46 32.47× 259 LKYL00000000 
ISU 993 Environment 46 38.92× 221 LKYM00000000 
ISU 994 Environment 46 20.49× 199 LKYN00000000 
ISU 995 Environment 46 43.37× 149 LKYO00000000 
ISU 996 Environment 46 17.77× 185 LKYP00000000 
ISU 998 Environment 46 51.18× 102 LKYQ00000000 
ISU 1000 Pig 46 31.07× 243 LKVI00000000 
ISU 1001 Pig 46 22.23× 157 LKVJ00000000 
ISU 1002 Pig 46 29.08× 157 LKVK00000000 
ISU 1008 Pig 46 25.44× 111 LKVN00000000 
ISU 1009 Pig 46 55.49× 69 LKVO00000000 
ISU 1010 Pig 46 54.23× 91 LKVP00000000 
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Abstract 
Livestock associated methicillin resistant Staphylococcus aureus (LA-MRSA) 
sequence type 5 have raised concerns surrounding the potential for these isolates to 
colonize or cause disease in humans with swine contact. Here, we report draft genome 
sequences for 9 LA-MRSA ST5 isolates obtained from humans after short term swine 
contact. 
Genome Announcement 
Methicillin resistant Staphylococcus aureus (MRSA) was first isolated in 1961 
[246]. Isolates have since been categorized based on epidemiologic characteristics into 
hospital acquired (HA-MRSA), community acquired (CA-MRSA), and livestock 
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associated (LA-MRSA). Humans can be colonized by all categories of MRSA isolates; 
however, LA-MRSA isolates have been considered less pathogenic and livestock adapted 
when compared to HA- and CA-MRSA isolates [369, 370]. The predominant multi-locus 
sequence type (ST) found in European swine is ST398, while Asian swine harbor ST9 
[312, 357]. In the United States, swine carry a more diverse population of isolates 
including ST398, ST9, and ST5 isolates [335]. LA-MRSA ST5 isolates are concerning 
due to the widespread and pathogenic nature of MRSA ST5 isolates in the hospital and 
community setting [12]. This has been attributed to the ability of this lineage to acquire 
mobile genetic elements encoding virulence factors and antimicrobial resistance genes 
[12], which are found rarely in LA-MRSA ST398 and ST9 isolates. Genome sequence 
data can be used to further evaluate the capacity of LA-MRSA ST5 to colonize and cause 
disease in humans. 
Here, we report the draft genome sequences of 9 LA-MRSA ST5 isolates 
obtained from humans after short term contact with swine (ISU 886, ISU 887, ISU 888, 
ISU 889, ISU 928, ISU 930, ISU 931, ISU 1004, and ISU 1007). Each isolate was 
obtained by Iowa State University from nasal swabs taken from veterinary students after 
visiting high density swine operations [335]. To obtain genomic DNA, isolates were 
grown in Trypticase Soy Broth (BD Biosciences, Sparks, MD) and total genomic DNA 
was extracted utilizing the High Pure PCR Template Preparation Kit (Roche Applied 
Science, Indianapolis, IN).  
The Illumina MiSeq platform (Illumina, San Diego, CA) was employed to 
generate draft genome data. Indexed libraries were produced using the Nextera XT DNA 
sample preparation and index kits (Illumina, San Diego, CA), pooled, and sequenced 
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using the MiSeq v2 500 Cycle reagent kit (Illumina, San Diego, CA) to generate 2 × 250-
bp paired-end reads. The data was then assembled using MIRA v. 4.0.2 software 
(http://mira-assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html) leading to 
the following average coverage: ISU 886 (82.26×), ISU 887 (41.07×), ISU 888 (42.62×), 
ISU 889 (39.08×), ISU 928 (29.49×), ISU 930 (37.43×), ISU931 (36.54×), ISU 1004 
(31.37×), and ISU 1007 (54.60×). For inclusion in the assembly, contigs were filtered 
allowing only those with a length greater than 1500bp and coverage over 2/3 the average 
coverage of the genome. When potentially repetitive elements were identified, the contig 
was required to be greater than 2000bp for inclusion in the assembly. 
Accession numbers 
The draft genome sequences produced in this study were deposited into 
DDBJ/ENA/GenBank with the following accession numbers: ISU 886 
(LKWG00000000), ISU 887 (LKWH00000000), ISU 888 (LKWI00000000), ISU 889 
(LKWJ00000000), ISU 928 (LKWY00000000), ISU 930 (LKWZ00000000), ISU 931 
(LKXA00000000), ISU 1004 (LKVL00000000), and ISU 1007 (LKVM00000000). 
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Abstract 
Humans have been found to harbor livestock associated methicillin resistant 
Staphylococcus aureus (LA-MRSA) isolates. LA-MRSA are considered adapted to 
colonizing livestock and less pathogenic in humans than their hospital- and community-
acquired counterparts. Here, we present 9 LA-MRSA ST5 isolates from veterinarians 
with long-term swine contact.  
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Genome Announcement 
Methicillin resistant Staphylococcus aureus (MRSA) is found as a component of 
the nasal microbiota of 1.5% of the U.S. population [42], and colonization can be 
transient or persistent [339]. MRSA isolates are classified based on source into hospital 
acquired (HA-MRSA), community acquired (CA-MRSA), and livestock associated (LA-
MRSA). LA-MRSA isolates are considered less pathogenic than HA- or CA-MRSA 
isolates and are thought to be adapted to colonize livestock species [369]; however, LA-
MRSA has been isolated from humans with swine contact and there are reports of disease 
associated with multi-locus sequence type (ST) 398 isolates [441]. Although ST398 
MRSA is the most prevalent genotype in European swine [312], the ST5 and ST9 
genotypes also occur in swine in the United States [335]. Potential animal reservoirs of 
LA-MRSA ST5 raise particular concerns due to the prominence and pathogenicity of this 
lineage among hospital and community acquired infections globally [12]. The clinical 
significance of MRSA ST5 is primarily attributed to the capacity of these isolates to 
acquire mobile genetic elements encoding virulence factors and resistance to antibiotics 
[12]. The evaluation of genome sequence data from LA-MRSA ST5 isolates obtained 
from humans is important to determining the capacity of LA-MRSA ST5 isolates to 
colonize and cause disease in people. 
This report presents the draft genome sequence of 9 LA-MRSA ST5 isolates 
obtained from the University of Minnesota (MN 1, MN 2, MN 3, MN 4, MN 5, MN 6, 
MN 7, MN 38, and MN 50). They were isolated from swine veterinarians who had long-
term contact with pigs. Total genomic DNA was extracted with the High Pure Template 
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Preparation Kit (Roche Applied Science, Indianapolis, IN) after overnight growth in 
Trypticase Soy Broth (BD Biosciences, Sparks, MD). 
DNA sequencing was performed on the Illumina MiSeq platform (Illumina, San 
Diego, CA). Indexed libraries were produced using the Nextera XT DNA sample 
preparation and index kits (Illumina, San Diego, CA). The libraries were pooled and the 
MiSeq v2 500 Cycle reagent kit was used with an Illumina MiSeq instrument (Illumina, 
San Diego, CA) generating 2 × 250-bp paired-end reads. 
Assembly was completed with the software MIRA v. 4.0.2 (http://mira-
assembler.sourceforge.net/docs/DefinitiveGuideToMIRA.html). This resulted in the 
average coverage for each isolate as follows: MN 1 (27.44×), MN 2 (47.54×), MN 3 
(57.94×), MN 4 (21.15×), MN 5 (37.41×), MN 6 (64.26×), MN 7 (59.56×), MN 38 
(28.24×), and MN 50 (24.95×). For contigs to be included in the assembly, they had to be 
>1500bp in length and the coverage had to be >2/3 the average coverage of the genome. 
Repetitive elements identified by the assembler were only included in the assembly if the 
contig was >2000bp in length. 
Accession numbers 
Draft genome sequences data from this study has been deposited into 
DDBJ/ENA/GenBank with the following accession numbers: MN 1 (LLBO00000000), 
MN 2 (LLBP00000000), MN 3 (LLBQ00000000), MN 4 (LLBS00000000), MN 5 
(LLBT00000000), MN 6 (LLBV00000000), MN 7 (LLBW00000000), MN 38 
(LLBR00000000), and MN 50 (LLBU00000000). 
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